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1.1 A HISTORICAL OVERVIEW
In 1970, Janet Baum of Ann Arbor submitted a paper to the Journal of the American Medical 
Association suggesting, on the basis of 3 cases, that oral contraceptives might be implicated 
in the development of benign hepatic tumours in young women. To her annoyance, the edi-
tors rejected the paper with the comment that her suggestion was ridiculous. The ﬁrst two 
published reports of hepatocellular adenoma in women using oral contraceptives appeared 
in 1971 and 19721,2. However, in neither case did the author speculate on a possible etiologi-
cal relationship between oral contraceptives and hepatic tumours, so that the credit must go 
to Baum and her colleagues for drawing attention to this possibility in their report of seven 
cases which appeared in Lancet in 19733. This paper excited great interest and touched oﬀ an 
avalanche of similar reports.
After that, Dr. Gerald Klatskin presented a paper at a meeting held at Kurume University in 
Japan in 1977, where he outlined the possible relationship of hepatic tumours to the use of 
oral contraceptives, and expressed his concern that “…hepatic tumours may prove to be an 
even more serious problem than thromboembolic disease as a complication of oral contra-
ceptives”4. At this meeting, he gave an overview of the clinical course of benign liver lesions in 
a group of patients with prolonged follow-up. Once one reads this paper it is remarkable that 
most insights on nature and clinical course of these benign lesions did, in fact, not change. 
Nowadays, there is still little evidence on aetiology, pathogenesis, and treatment of these 
benign tumours. And still, we are confronted with serious complications as haemorrhage and 
malignant transformation.
The large and confusing terminology that has been used to identify diﬀerent hepatic le-
sions, such as hepatic adenoma, hepatoma, adenomatosis, nodular transformation, multiple 
nodular hyperplasia and focal nodular hyperplasia, has led to an International Working Party 
on nodular diseases of the liver5. The working party was raised and sponsored by the World 
Congress of Gastroenterology 1994 in order to standardise the terminology applied to dis-
eases of the liver.
Having reached the stage of diagnosis and treatment, there are a lot of controversies in the 
literature. The increased availability and routine use of highly advanced radiological modali-
ties improved the detection of small hepatic lesions. As a consequence, there is an increased 
incidence of incidentalomas of the liver that are more often benign than malignant6,7. How-
ever, an accurate characterisation of these incidentalomas may be impossible with a single 
imaging modality, especially because of the limited phases due to the routine nature and 
radiation hazards of the investigation8. On the other hand, a lot of nuclear and radiologi-
cal modalities have been described to discriminate benign and malignant tumours and to 
obtain a diﬀerential diagnosis. The various entities that must be considered in the diﬀerential 
diagnosis creates the need for a clear management strategy.
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With concern to treatment of benign liver lesions, one should realise that there is no high 
level of evidence in the literature. Diﬀerent treatment or management guidelines have been 
proposed based on observational reports and personal experiences. This stresses the need 
for a critical review of these reports and to deﬁne criteria for observation, surgery, or other 
interventional techniques in the management of benign liver lesions. Furthermore, it should 
be questioned if a world-wide well-organised data-base can be implemented to collect data 
and experience with benign liver tumors in order to handle with more evidence.
The following personal communication we had with a hepatobiliary surgeon clearly illustrates 
the low level of evidence concerning a management aspect of hepatocellular adenoma.
“Considering your wide experience with the management of liver tumors, we would like 
to ask your opinion about a challenge we encountered in our clinic about hepatocellular 
adenomas. We are wondering what would be your advice to a young female patient who 
has been operated on a hepatocellular adenoma and wants to use oral contraceptives again. 
In the literature we could not ﬁnd any clarifying evidence or case reports that answers this 
problem. Dou you think it is reasonable that a general sensitivity to steroid hormones do 
exist in the whole liver?”
“In brief, my colleagues and myself would unequivocally dissuade your young patient from 
any further use of oral contraceptives. Clearly, even though the incidence of hepatocellular 
adenomas has been reduced with the current dose of estrogens used, we still believe the risk 
of recurrence is signiﬁcant in those women who have developed hepatocellular adenomas 
on oral contraceptives. Moreover, there is a slight increase in risk of hepatocellular carcinoma 
with the long-term use of oral contraceptives again, though diminished with current dos-
ages used. Given the nearly equally eﬀective alternatives to contraception compared to oral 
contraceptives, we would recommend alternative prevention methods. I concur that once 
present, the sensitivity of that liver to subsequent adenomas is increased. I do not have 
speciﬁc references that I can cite at this time, however, this recommendation is the current 
recommendation at our Clinic.” D.M. Nagorney. Mayo Clinic, Rochester, Minnesota, USA.
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1.2 OUTLINE OF THE THESIS
In chapter 2, a review of the literature concerning diagnosis and treatment of the most com-
mon benign liver lesions is performed. In part 2.1, we describe the epidemiology, aetiology, 
histological and imaging characteristics of these lesions. Furthermore, we discuss the role of 
state-of-the-art MR imaging versus the role of needle biopsy during diﬀerential diagnosis, 
and formulate the indications for surgery based on recent literature and our own experience 
(part 2.2).
Chapter 3 of this thesis deals with the management of giant haemangioma. Lesion size and 
the potential for complications, such as rupture and a consumptive coagulopathy, are still 
reasons for a surgical treatment of hepatic haemangioma, even when the lesion is an inci-
dental ﬁnding. In this part, we report on a study of giant haemangiomas with a long-term 
follow-up, either after a surgical or conservative treatment.
In chapter 4, some speciﬁc aspects of hepatocellular adenoma are discussed. In part 4.1, 
we describe a case of hepatocellular adenoma detected during pregnancy and consider 
the reasons for surgical therapy. In part 4.2, we report our own experience with ruptured 
hepatocellular adenoma, and formulate an algorithm for management of this emergency 
situation. Another challenge that may be encountered during diﬀerential diagnosis of a focal 
liver lesion is the distinction between a hepatocellular adenoma and a well-diﬀerentiated 
hepatocellular carcinoma, which we line out in part 4.3.
In chapter 5, focal nodular hyperplasia of the liver is studied in detail. In part 5.1, we describe 
the spectrum of typical and atypical features of focal nodular hyperplasia at state-of-the-art 
MR imaging, ultrasonography, computed tomography, and histopathology. In part 5.2, we 
performed a prospective cohort study, in which we studied lesion characteristics of focal 
nodular hyperplasia at state-of-the-art MR imaging including dynamic Gadolinium-enhanced 
and a tissue speciﬁc contrast agent (superparamagnetic iron-oxide). Finally, we report on a 
treatment modality of focal nodular hyperplasia with transcatheter arterial embolisation in 
part 5.3.

Chapter 2
Benign liver tumors: a general review
2.1
Diagnosis and treatment of benign focal liver lesions. 
T Terkivatan, SM Hussain, RA de Man, JNM IJzermans. 
Accepted for publication in Scandinavian Journal of Gastroenterology.
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DIAGNOSIS AND TREATMENT OF BENIGN FOCAL LIVER LESIONS
ABSTRACT
Background: With the routine use of improved imaging modalities more benign liver le-
sions are detected nowadays. An accurate characterisation of these incidental lesions may 
be a challenge, and frequently a biopsy or even unnecessary surgery is being performed. 
However, these interventions are not always to the beneﬁt of the patient.
Methods: A Medline search of studies relevant to imaging diagnosis and management of 
the most common, benign, solid and non-solid liver lesions was undertaken. References from 
identiﬁed articles were handsearched for further relevant articles. The authors’ own experi-
ence with benign liver lesions was also taken into account.
Results: Although atypical imaging features are the exception rather than the rule, it is some-
times diﬃcult to diﬀerentiate between benign and malignant lesions and knowledge of their 
imaging features is essential to avoid unnecessary work-up. The use of tissue speciﬁc contrast 
media, which has clearly improved the accuracy of highly advanced radiological techniques, 
may be helpful during diﬀerential diagnosis. Once having established an accurate diagnosis, 
it is rarely indicated to perform surgery for a benign liver lesion, because of its asymptomatic 
nature.
Conclusion: Knowledge of imaging features and a clear management strategy during di-
agnostic work-up, emphasising the indications for surgery will minimalise the number of 
patients who have to undergo biopsy or unnecessary surgery.
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INTRODUCTION
Solitary focal liver lesions in a noncirrhotic liver often present as incidental ﬁnding during 
routine abdominal imaging as part of a general check-up, or during work-up in case of a 
known malignancy1,2. Only in some cases, liver tumours may be symptomatic3,4.
The most important diagnostic challenge involves diﬀerentiating benign tumours from 
pre-malignant or malignant lesions. Especially during work-up of a known malignancy a 
correct diagnosis of a liver lesion is essential for an adequate staging, thereby preventing 
an over-, or undertreatment of malignant disease. However, there are still patients who do 
undergo unnecessary biopsy or surgery because of a presumed malignancy or because of 
uncertainty in the diagnosis despite an extensive work-up5-7. Even after having diagnosed a 
benign lesion, the most appropriate treatment still may remain controversial, as in case of a 
hepatocellular adenoma.
For these reasons, a clinical review of benign liver tumours that emphasises diagnostic 
work-up and the indications for surgery is warranted. A Medline search of studies relevant to 
epidemiology, pathogenesis, diagnosis and management of benign solid and non-solid liver 
lesions was undertaken. References from identiﬁed articles were handsearched for further 
relevant articles.
SOLID LESIONS
Hepatocellular adenoma
One of the problems that a hepatobiliary surgeon may be confronted with is the presence of 
a centrally located liver lesion in a healthy young woman, suspected of being a hepatocel-
lular adenoma.
Hepatocellular adenoma is a benign liver tumour that occur more frequently in women 
in their third and fourth decades8,9. Following the introduction of oral contraceptives in the 
1960s, reports began to emerge about the association of oral contraceptives and hepato-
cellular adenoma10. Epidemiological studies reported that the relative risk of hepatocellular 
adenoma was 25.0 for women who used oral contraceptives for more than 9 years compared 
with those who used oral contraceptives for less than one year11,12. An incidence has been 
calculated of 3 to 4/100,000 in long-term users of oral contraceptives. Recent data do not 
reveal an increased risk for women using modern low-dose oral contraceptives13. Although 
rare, hepatocellular adenomas are known to occur in patients without a history of hormone 
use2,14,15. Spontaneous development has also been observed in patients with glycogen stor-
age disease, in that case often a precursor of hepatocellular carcinoma16,17. The tumour is 
uncommon in men, but may be associated with the use of anabolic steroids18,19. The female:
male ratio ranges from 3.9:1 to 11:19.
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The pathogenesis is speculative but a consensus indicates that this is an end consequence 
of general vascular ectasia caused by oral contraceptives and related synthetic steroids, which 
leads to a benign clonal proliferation of hepatocytes20. In patients who have been advised to 
discontinue oral contraception, regression of hepatocellular adenoma has been described 
within months21. However, persistent growth of the tumour after cessation of steroids can 
occur as well22.
Especially large hepatocellular adenomas (> 5 cm) do have a potential for spontaneous 
rupture and bleeding, causing haemoperitoneum and shock2,23. Spontaneous rupture occurs 
more often in steroid users than in nonusers, and is the mode of presentation in 50-65 per 
cent of patients taking oral contraceptives24,25. Especially during pregnancy, and durante- or 
post-partum there is an increased risk for haemorrhage due to the high levels of sex steroids 
and increased vascularity of the liver25.
Foster and Berman have focussed attention on the potential of hepatocellular adenoma 
for malignant transformation26. It might be argued that this malignant transformation merely 
reﬂects the incorrect diagnosis of hepatocellular adenoma in cases of well-diﬀerentiated 
hepatocellular carcinoma. However, Tao suggested that hepatocellular adenoma itself is not 
a premalignant lesion and may undergo reversible changes after withdrawal of causative 
agents, whereas foci or areas of liver cell dysplasia arising within adenomas are irreversible, 
premalignant changes and eventually progress to hepatocellular carcinoma27.
Histology
Grossly, hepatocellular adenoma are very well circumscribed and possess a pseudocapsule 
that is formed from compressed and collapsed surrounding hepatic parenchyma28. There may 
be focal areas of haemorrhage and degeneration. On histological examination the hepato-
cytes in the lesion are identical to those in the surrounding liver, but contain a large amount 
of fat and glycogen, which contribute to the imaging appearance. The hepatic plate may 
be two or more cells thick, and rosettes may be seen, which suggest increased hepatocyte 
proliferation in the lesion. The absence of bile ducts and portal triads makes this lesion a pure 
growth of hepatocytes.
Diﬀerentiation of hepatocellular adenoma from a well-diﬀerentiated carcinoma may be 
diﬃcult, or even impossible. Modern cytopathological techniques such as cytophotomet-
ric analysis of DNA content underline the correlation of aneuploidy with the presence and 
grade of diﬀerentiation of hepatocellular carcinoma29. Analysis of cytogenetic aberrations in 
hepatocellular carcinoma may also provide a potential solution to problematic histological 
queries. Comparative genomic hybridisation and ﬂuorescence in situ hybridisation revealed 
typical aberration patterns not only in moderate or poorly diﬀerentiated hepatocellular car-
cinoma but also in well-diﬀerentiated samples30,31. These aberrations were strikingly diﬀerent 
from the low number of aberrations detected in hepatocellular adenoma30. Although these 
techniques may reduce the uncertainty of distinguishing benign lesions from well-diﬀerenti-
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ated carcinoma, they are based on an elaborate and time consuming procedures of full tissue 
samples making it diﬃcult to apply in small biopsies in daily routine.
Radiology
Hepatic adenomas lack predictable diagnostic features on ultrasonography (US), which as 
a sensitivity of about 30%2. Although hepatic adenomas are mostly isodense to the sur-
rounding liver on plain computed tomography (CT), they may show variable densities. These 
smooth well-deﬁned lesions often show a subtle homogeneous blush during arterial phase 
fastly fading to nearly isodensity during portal or delayed phases32. Hepatic adenomas may 
show intralesional hypo or hyperdensities, depending on the presence or absence of necro-
sis or haemorrhage. On magnetic resonance (MR) imaging hepatic adenomas have mildly 
low to moderately high signal intensity on T1-weighted images, and mildly high signal in-
tensity T2-weighted images. A characteristic feature is that of decreased signal intensity on 
out-of-phase T1-weighted (or fat suppressed) images because of their fat content33,34. They 
may contain areas with high signal intensity on both T1-weighted and T2-weighted images 
because of intra-tumoural haemorrhage. The typical enhancement features are, according 
to the hypervascular nature of the lesion, uniform, moderately intense enhancement on im-
mediate post-gadolinium images, and relatively rapid fading to isointensity on subsequent 
images. It is sometimes diﬃcult to distinguish adenomas from hepatocellular carcinomas, 
based on the MR imaging features. Clinical history, and the availability of tissue speciﬁc MR 
contrast media targeting either the Kupﬀer’s cells or hepatocytes will improve the speciﬁcity 
of MR imaging33,35,36.
This same principle was used in nuclear imaging in the past. Hepatic adenomas may lack 
Kupﬀer’s cells which concentrate colloid used in nuclear HIDA scanning37. Consequently, with 
colloid imaging, 80% of lesions are cold defects3,38,39. In case of uptake (20%), excretion of the 
agent does not occur because hepatic adenomas lack bile ductules for normal excretion.
Treatment
Since the two clinical concerns in a patient with hepatocellular adenoma are bleeding and 
progression to hepatocellular carcinoma, the discovery of a hepatocellular adenoma is a rea-
son for resection for most surgeons1,14,40. In our clinic, we perform surgery for hepatocellular 
adenomas with a diameter greater than 5 cm, since lesion size may be an important indicator 
of malignancy and potential for rupture (Figure 1)2,23. A conservative approach by a radiologi-
cal follow-up (e.g. 6 monthly) may be justiﬁed with smaller hepatocellular adenomas, even 
in case of bleeding.
Patients have to be advised to stop steroid use and to avoid pregnancy. Ruptured hepa-
tocellular adenoma during pregnancy is associated with a high foetal as well as maternal 
mortality rate (50-60%)41,42. This might be caused by a serious delay in diagnosis because of 
confusion with other pregnancy related diseases, like preeclampsia or pulmonary embolism, 
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which leads to a poor general condition prior to surgery. Large hepatocellular adenomas 
that are detected during pregnancy should be resected because of the high risk of rupture42. 
A surgical procedure can be performed during the second trimester when surgical risks are 
minimal for both the mother and the foetus43.
Arterial embolisation should be considered as an alternative to surgical treatment in case 
of a large and centrally located lesion with a considerable risk of surgery, especially when 
there is a desire for pregnancy.
Focal nodular hyperplasia
Focal nodular hyperplasia (FNH) is one of the least controversial benign liver lesions for the 
clinician, and typically is an incidental ﬁnding in women during their reproductive years. 
Cases have been reported in men and children44. The female:male ratio ranges between 6:1 
to 8:145. Although considered as a rare neoplasm, FNH is the second most common benign 
liver tumour after haemangioma and has a reported frequency of 3% in adults46.
There are two theories regarding the pathogenesis of FNH. Congenital vascular malfor-
mations as teleangiectasies and arteriovenous malformations, or vascular injury has been 
suggested as the underlying mechanism for a hyperplastic response of liver parenchyma47,48. 
Figure 1. Algorithm for management of solid benign liver lesions.
BENIGN LIVER LESION*
Adenoma FNH or other lesion
Bleeding
YesNo
Diameter > 5 cm
ResectionStop steroid use
Observation
Complaints
YesNo
SurgeryConservativeHemodynamic
Stabilization
YesNo
IncreaseDecrease
Figure 1. Algorithm for management of solid benign liver lesions.
* There is no sign of liver cirhosis
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There is some evidence, however, that FNH is a proliferative lesion with a clonal nature49. 
These data suggest that the cells in the lesion may arise from one pluripotent progenitor cell 
capable of diﬀerentiating into hepatocytes and biliary epithelial cells. Although the relation-
ship between the occurrence of FNH and the use of oral contraceptives has been discussed 
a long time, this association with steroids has been denied more recently50. Compared with 
hepatocellular adenoma, which was quite uncommon before the introduction of oral con-
traceptives in 1960, FNH has been frequently described in autopsy series published before 
196051,52.
Histology
On gross examination, FNH tends to be lobulated and usually has a central stellate scar radi-
ating into nodules of normal hepatocytes, which is histopathologically detected in as many 
as 83%3. The lesion is sharply demarcated from the surrounding liver, but does not have a 
tumour capsule53,54. A pseudocapsule may be prominent as a result of compression of the 
surrounding liver parenchyma by the tumour, and inﬂammatory reaction. Microscopically, 
there are some characteristic features of FNH53. First, the central scar contains ﬁbrous con-
nective tissue with inﬂammatory cells and large tortuous arteries with its sources from the 
branches of the hepatic artery that provides excellent arterial blood supply in the form of a 
capillary network to the individual nodules of the lesion. Second, the nodules lack normal 
lobular architecture and are devoid of portal triads. Within the nodules, relatively large veins 
drain blood from the sinusoids toward the main hepatic vein. There is no direct connection 
between the abnormal arteries and the veins54. The proliferating cells are practically identical 
to the surrounding hepatocytes, and Kupﬀer’s cells are identiﬁed in the sinusoidal spaces. 
Third, there are areas of dense bile duct proliferation that do not connect to the biliary tree.
Radiology
On US, FNH is often isoechoic to normal liver and therefore, it may be diﬃcult to detect. 
The lesion is mostly homogenous (60%) and a large or prominent central scar, which is so-
nographically detected in 19-40%, is considered as a characteristic feature55. As in case of 
hepatic adenomas, the sensitivity of US is also low for FNH2. Most lesions are isodense or 
slightly hypodense to the liver on unenhanced CT56,57. The typical contrast enhancement pat-
tern of FNH, being a hypervascular lesion with its vascularity from the hepatic arterial system, 
is immediate homogeneous hyperdense enhancement on early phases (arterial and early 
portal venous) becoming isodense to the liver on late portal venous and delayed images. 
An enlarged central feeding artery is present in 60%58. The absence of contrast retention on 
late phases is one of the most important characteristics of FNH. The central scar, which is 
hypodense on unenhanced images, shows a gradual enhancement on portal venous and de-
layed images58,59. This delayed enhancement is caused by the presence of abundant ﬁbrous 
stroma in the scar. Especially, the presence of a characteristic central scar (20%-65%)32,58, 
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which is radiating in a spoke-wheel pattern from the periphery to the centre of the tumour 
is highly supportive of FNH58. However, a central scar may be seen in other lesions such as 
giant haemangioma, large hepatocellular carcinomas, and ﬁbrolamellar carcinoma60. On MR 
imaging, FNH usually presents as a homogeneous, iso- or hypointense lesion on T1-weighted 
images, and a slightly hyper- or isointense lesion on T2-weighted images (94-100%)33,61. The 
central scar typically has a low signal intensity on T1-weighted images and a high signal in-
tensity on T2-weighted images. FNH shows an intense uniform enhancement on immediate 
postgadolinium images and fades rapidly to near isointensity. The central scar, being hypoin-
tense on early MR images, shows enhancement on delayed phases. A central scar is visible 
in up to 85% on T2-weighted images, while contrast enhanced CT scans may detect it in 
65% of the lesions32,56. The development of tissue-speciﬁc contrast agents like mangafodipir 
trisodium and reticuloendothelial agents such as ferumoxides provide new possibilities for 
lesion characterisation on the basis of its cellular composition and function rather than its 
vascularity and diﬀusion within its extracellular space33,35. High accuracy rates of MR imaging 
has been reported for characterisation of FNH and for diﬀerentiation from other focal liver 
lesions, especially from hepatic adenoma and ﬁbrolamellar carcinoma62,63.
The ability to show Kupﬀer’s cell activity in FNH has historically made technetium-99m 
sulphur colloid scintigraphy a diagnostic modality for this lesion64. In addition to the Kupﬀer’s 
cell activity, the vascular supply of the tumour may additionally contribute to its uptake of the 
sulphur colloid56. Overall, 50% of tumours show uptake similar or greater to that of normal 
liver, and 50% show less uptake than normal liver3. Unfortunately, other hepatocellular neo-
plasms that may contain Kupﬀer’s cells, such as hepatocellular adenoma and hepatocellular 
carcinoma, can also show sulphur colloid uptake3,60. Thus, the uptake of sulphur colloid can 
suggest the diagnosis of FNH, but is not pathognomonic. At our clinic, we rely on T1- and T2-
weighted gadolinium enhanced MR imaging with or without tissue speciﬁc contrast agents.
Treatment
When the diagnosis of FNH is certain, treatment is rarely indicated (Figure 1). A conservative 
approach for asymptomatic lesions is well established because there is no predisposition 
to haemorrhage or malignant transformation and symptoms may resolve during follow-
up9,14,15,40,46.
Some authors have expressed concern about the progression of FNH during pregnancy. 
Two recent reports by Weimann et al and Mathieu et al failed to demonstrate any increase in 
tumour size and any other complications as bleeding during pregnancy50,65.
Nevertheless, large lesions (>5 cm) may be responsible for abdominal complaints, espe-
cially if located in the left liver lobe. In case of a symptomatic lesion, a surgical intervention 
can be considered.
Transcatheter arterial embolisation has been increasingly useful as a less invasive percuta-
neous tumour ablation technique in a variety of liver lesions66,67. As it has been suggested that 
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FNH is a hyperplastic response of hepatic parenchyma to a congenital arterial malformation, 
embolisation appears to be a logical treatment option68. Besides, the presence of a central 
feeding artery makes this method more feasible69. Transcatheter arterial embolisation should 
be considered as a safe and eﬀective alternative to a surgical treatment of symptomatic FNH, 
especially those with a considerable risk for surgery because of localisation70.
Angiomyolipoma
Angiomyolipoma of the liver is a rare benign mesenchymal tumour morphologically similar 
to the more common angiomyolipoma of the kidney. Although the association of renal an-
giomyolipoma in patients with tuberous sclerosis has been reported in 40-50% of cases71, this 
association is less common in case of hepatic angiomyolipomas72.
There is speculation that all the components of angiomyolipoma may arise from a com-
mon precursor cell in the perivascular space, the pericyte; the various morphologic cell types 
noted in the tumour may, therefore, represent diﬀerent developmental stages of this precur-
sor cell73.
Symptoms attributed to a liver mass may be noted in the larger tumours72,74.
Histology
Grossly, angiomyolipomas are circumscribed, soft masses. Its histological composition, which 
is characterised by an admixture of mature fat cells, blood vessels, and smooth muscle cells 
with a large variety in the proportions of the various components in diﬀerent parts of indi-
vidual tumours and from case to case, largely determines its radiological appearance.
Radiology
Ultrasonographic examination of the lesion usually shows a hyperechoic mass75. On plain CT 
the lesion commonly appears as a well-deﬁned, heterogeneous hypoattenuating mass. After 
contrast administration a marked early and prolonged enhancement is usually seen74,75. On 
MR imaging, angiomyolipomas often show high signal intensity on both T1- and T2-weighted 
images, and a low signal intensity on fat-suppressed images, reﬂecting their high fat con-
tent33. They may show diﬀuse and heterogeneous enhancement on immediate postgado-
linium spoiled gradient echo (GRE) images. Common to most reports in the literature is the 
initial misdiagnosis of this lesion by radiological and histopathological examination, most 
probably because of the infrequency with which this tumour is encountered72,76. The most 
common errors in diagnosis are other fat-containing liver lesions as lipoma, hepatocellular 
carcinoma, adenoma, liposarcoma or focal fatty inﬁltration reﬂecting the heterogeneity and 
varying proportions of cell types encountered in the lesion.
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Treatment
Surgical resection is not necessary unless there is associated pain, which occasionally results 
from intratumoural haemorrhage74. No malignant counterpart, malignant transformation, or 
extrahepatic metastases of angiomyolipoma has been reported, although several cases of 
malignant counterparts of this tumour in the kidney have been reported. Therefore, a con-
servative approach by follow-up of the lesion is suﬃcient if the diagnosis of angiomyolipoma 
is established (Figure 1).
NON-SOLID LESIONS
Simple hepatic cysts
Simple hepatic cysts may be solitary or multiple. They usually are asymptomatic lesions that 
are detected incidentally, and do not have a clinical signiﬁcance. However, at the same time, 
small hepatic cysts are lesions that most commonly cause clinical concern during work-up of 
an extra-hepatic malignancy.
Epidemiological studies report a prevalence of 0.17-5%, which clearly increases with age77. 
The female:male ratio is approximately 4:145.
The pathogenesis of simple hepatic cysts is poorly understood and may be related to con-
genital lymphatic obstruction, to faulty development or fusion of intrahepatic bile ducts, or 
to stenosis and obstruction of aberrant bile ducts78.
Isolated hepatic cysts grow very slowly. Hence, they usually do not cause symptoms in pa-
tients younger than 40 years79. Solitary hepatic cysts that become symptomatic typically have 
diameters larger than 5 cm and present as a dull, vague right upper-quadrant discomfort or 
fullness. Rarely, hepatic cysts present with acute symptoms due to intracystic haemorrhage, 
or superinfection of the cyst80,81.
Histology
Hepatic cysts contain various amounts of ﬂuid, which may be clear, mucoid, bloody, or bile 
stained. Histologically, they are generally lined with ﬂattened cuboidal or columnar epithe-
lium that resembles bile duct epithelium and have a basement membrane surrounded by a 
ﬁbrous layer.
Radiology
A simple hepatic cyst has to be diﬀerentiated from infectious cysts (echinococcal cysts, ab-
scesses), from pre-malignant or malignant cysts as cystadenomas and cystadenocarcinomas, 
and from metastases of extra-hepatic cancer. On US, the cyst is usually hypoechoic and 
thin walled with sharp, smooth margins and shows increased transmission of ultrasound 
through the lesion, resulting in posterior acoustic enhancement82. On CT, cysts can be seen 
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as sharp, smooth-walled, hypodense lesions of homogeneous density that do not enhance 
after intravenous injection of contrast. Acute intracystic haemorrhage may produce a higher 
density, whereas older haemorrhage lacks this characteristic feature62,83. For small (<1 cm) 
and complicated cysts MR imaging is superior to CT63. On MR imaging, all uncomplicated 
hepatic cysts, even those with a few millimetres in diameter, have a low intensity on the T1-
weighted scans and high signal intensity on the T2-weighted scans84. Cysts with intracystic 
haemorrhage may show high signal intensity on T1-weighted images. At MR imaging cysts 
are well-circumscribed lesions that do not show enhancement after contrast administration. 
Therefore, delayed postgadolinium images are useful to diﬀerentiate cysts from poorly vas-
cularised metastases, such as mucinous type colorectal metastases, that show gradual, or 
only septal enhancement33.
Treatment
Asymptomatic simple hepatic cysts are best managed conservatively (Figure 2). The preferred 
treatment of isolated symptomatic cysts is US- or CT-guided percutaneous cyst aspiration 
followed by alcohol (or doxycycline) sclerotherapy, prohibited that the cyst content does not 
contain bilirubin85. This approach is more than 90% eﬀective in controlling symptoms and 
ablating the cyst cavity45. If the radiologically guided, percutaneous approach is ineﬀective 
or unavailable, treatment may include either laparoscopic or open surgical cyst fenestra-
tion86,87.
Biliary cystadenoma
Biliary cystadenoma typically are large, bulky masses in middle-aged women (more than 75 
per cent) and tend to present as a discomfort in the right upper quadrant of the abdomen88.
Figure 2. Algorithm for management of non-solid benign liver lesions.
Benign liver tumors: a general review 27
The aetiology of biliary cystadenoma remains largely unknown. One of the proposed theo-
ries is that it develops from ectopic remnants of primitive foregut sequestered within the liver89. 
Another theory suggests an origin from ectopic rests of embryonic gall bladder tissue90. Malig-
nant degeneration of cystadenoma has been described in as many as 25% of cases91,92.
Histology
On gross examination, the thick walls, cystic components, and septations within the lesion 
are remarkable. Microscopically, the tumour is characterised by three layers of tissue: an inner 
epithelial component, a middle mesenchymal layer with ﬁbroblasts, smooth muscle, adipose 
tissue, and capillaries, and an outer layer of collagen and mixed connective tissue.
The histological diﬀerentiation of benign cystadenoma from cystadenocarcinoma may be 
diﬃcult. One study suggests that these two lesions can be diﬀerentiated by cytokeratin pat-
tern and in situ hybridisation of albumin mRNA93.
Radiology
US and CT scanning show the cystadenoma as a multiseptal cystic mass that frequently has 
mural nodules at the periphery94. At CT, after contrast administration, enhancement of the 
septa and mural nodules can be seen. Mural or septal nodules, discrete soft tissue masses and 
possibly thick or coarse calciﬁcations increase the likelihood of a cystadenocarcinoma92. The MR 
imaging descriptions of biliary cystadenoma or cystadenocarcinoma are limited38,95,96. They ap-
pear hyperintense on T2- and hypointense on T1-weighted images. Focal areas of haemorrhage 
or mucinous contents within the locules may have areas of relatively higher signal intensity on 
T1 weighting than those with purely bilious ﬂuid content. On T2-weighted images, the septa-
tions are evident as low signal intensity bands separating the high signal intensity locules38,95.
Treatment
Malignant degeneration of cystadenoma has been described in as many as 25% of cases, and 
a reliable pre-operative diagnosis on aspiration of cyst content or biopsy of the cyst wall is 
not possible91,92. Hence, once a cystadenoma is suspected, the lesion should be completely 
excised even in the absence of symptoms (Figure 2)78,97. If the lesion appears to be malignant, 
which can be assessed by frozen section during surgery, a wider excision should be obtained. 
These tumours have a relatively low-grade malignant potential and infrequently recur if ad-
equately excised78.
Biliary Hamartoma
Biliary hamartomas, also called Von Meyenburg complexes, are benign biliary malforma-
tions98,99. The prevalence of biliary hamartomas has not been precisely established, but they 
are currently estimated to be present in about 3% of autopsy patients99. Biliary hamartomas 
are typically multiple, small (usually <1 cm), well-circumscribed focal lesions that are scat-
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tered throughout both lobes of the liver95. They originate from ductal plate malformations of 
the small interlobular ducts100.
Biliary hamartomas are generally without clinical manifestation and are usually encountered 
as an incidental ﬁnding at laparotomy or autopsy, more than on imaging studies. They can be 
mistaken for metastatic lesions, particularly in patients with underlying malignancy95,99.
Histology
Biliary hamartomas are usually noted as subcapsular white or green nodules. At pathologic 
analysis, they consist of small irregular, disorderly, sometimes dilated, ducts that do not com-
municate with the biliary tree and are embedded in an extensive ﬁbrous stroma.
Radiology
On imaging, biliary hamartomas are usually depicted as non-speciﬁc hypoechoic and hy-
podense small foci on US and CT, respectively101. Although homogeneous enhancement of 
the lesions have been noted, they have been described mostly as non-enhancing structures 
on contrast-enhanced CT101. This might be caused by a detection problem of former CT 
techniques, since enhancement is detected on gadolinium-enhanced MR imaging33,99. On 
MR imaging, biliary hamartomas are typically hypointense on T1- and hyperintense on T2-
weighted images, reﬂecting their high ﬂuid content. Although this appearance resembles 
that of simple cysts, biliary hamartomas show a thin rim of enhancement that represents 
compressed hepatic parenchyma, or an inﬂammatory reaction surrounding the lesion33,99. It 
may be diﬃcult to distinguish biliary hamartomas from metastatic lesions because of the 
presence of this rim enhancement. Rim enhancement does not spread centrally, whereas 
enhancement in metastases most often is irregular and spreads centrally. Biliary hamartomas 
are usually smaller in size, and are very bright at MR imaging, as opposed to most metastases. 
These imaging features may help to distinguish biliary hamartomas from metastatic lesions.
Treatment
The signiﬁcance of these lesions lies in their possibility of their being mistaken on gross 
examination or on imaging studies for malignant lesions, such as cholangiocarcinoma or 
metastatic disease. There is no risk of malignant degeneration, and hepatic resection is not 
indicated (Figure 2)45.
Cavernous haemangioma
Cavernous haemangioma is the most common benign tumour of the liver, with an estimated 
prevalence of 5-7 per cent9. Cavernous haemangiomas occur in all age groups but are more 
frequently encountered in patients in the third, fourth and ﬁfth decades of life. Published 
series indicate a female preponderance, with female:male gender ratios up to 6:138,102.
Benign liver tumors: a general review 29
The aetiology of liver haemangiomas is still a matter of speculation. It is suggested that 
haemangioma is probably a congenital abnormality and not a neoplasm102. The possibility of 
a role of female sex hormones in the development of hepatic haemangioma and the eﬀects 
of pregnancy on growth has been described in the literature103-105 but these data are most 
inconsistent.
Although often small, they are capable of reaching enormous size. Traditionally, lesions 
greater than 4 cm in diameter have been referred to as giant haemangiomas106. They are 
usually solitary, but two or more tumours occur in 10% of patients45.
The most common clinical presentation of cavernous haemangioma is an incidental ﬁnd-
ing on hepatic imaging. The lesion is typically small (<5 cm in diameter)4. Large cavernous 
haemangiomas may present with symptoms of abdominal pain or discomfort due to capsu-
lar stretch, partial infarction, intralesional haemorrhage, or pressure on surrounding tissues. 
More rarely, giant haemangiomas may rupture spontaneously or traumatic, be associated 
with a consumptive coagulopathy with low platelet count and hypoﬁbrinogenaemia (Kasa-
bach-Merritt syndrome), a high output cardiac failure or abscess formation107-110.
Histology
Cavernous haemangiomas have a dark colour and are readily recognised on gross exami-
nation. The cystic spaces are engorged with blood and palpation of the lesion indicates a 
compressibility that is practically restricted to vascular lesions. Microscopically, cavernous 
haemangiomas consist of cystically dilated vascular spaces that are lined by a single layer of 
endothelial cells. These spaces contain either ﬁbrin thrombi or aggregates of red blood cells 
separated from one another by ﬁbrous tissue.
Radiology
The usual ultrasonographic appearance is a lobulated, predominantly hyperechoic, and 
sharply marginated lesion in the liver, which is not pathognomonic. The echogenicity of 
haemangiomas can be variable secondary to internal ﬁbrosis, thrombosis, haemorrhage, and 
occasionally calciﬁcations111. Because primary and metastatic liver tumours may also have a 
hyperechoic appearance, the diagnosis is usually made in conjunction with other imaging 
modalities. The sensitivity of US for the diagnosis of cavernous haemangioma ranges from 
60% to 70%, and speciﬁcity ranges from 60% to 80%45. At CT, cavernous haemangiomas 
have a typical appearance showing a low density without contrast medium112. Following 
intravenous injection of contrast, small haemangiomas may show an hyperdense and ho-
mogeneous appearance. Larger lesions (> 3 or 4 cm) show characteristic peripheral nodular 
enhancement that may or may not progress towards the centre of the lesion. Over time, the 
lesions usually become more homogeneously enhanced with a density equal to or greater 
than the surrounding liver parenchyma. Very large haemangiomas with extensive ﬁbrosis or 
bleeding may show persistent areas of nonenhancement, centrally113. A ﬁnding of peripheral 
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nodular, or globular enhancement, or areas of pooling of contrast within the lesion is a sign 
that has been identiﬁed as an enabling distinction of haemangioma from hepatic metasta-
ses113,114. The overall sensitivity of dynamic CT scans ranges from 75% to 85%, and speciﬁcity 
from 75% to 100%45. At MR imaging, haemangiomas are typically very bright on T2-weighted 
images, and have moderately low signal intensity on T1-weighted images with a homoge-
neous pattern33,84. Large haemangiomas (> 5 cm) tend to have mildly complex signal inten-
sity on T2-weighted images with the frequent presence of low signal strands, which reﬂects 
their internal network of ﬁbrous stroma. Haemangiomas typically show peripheral nodular 
enhancement on immediate postgadolinium images with slow, orderly, complete or nearly 
complete spread of enhancement to involve the entire lesion. Occasionally, small haeman-
giomas may show a homogeneous intense enhancement during early phases of the dynamic 
study, though, haemangiomas, unlike malignant lesions, retain contrast material and stay 
hyperintense on delayed contrast-enhanced images33,115. The overall accuracy of MR imaging 
for detection and characterisation of haemangioma has been reported to be the highest of 
all imaging modalities with a sensitivity of 85 % to 95%63,116, and speciﬁcity of 90-100%, espe-
cially when T2- weighted MR images with short and long echo-times are combined with the 
multiphasic dynamic contrast-enhanced images, and delayed contrast-enhanced images.
Scintigraphic imaging with technetium (99mTc)-labelled red blood cells (RBCs), which is 
reported to be a highly sensitive and speciﬁc method for the diagnosis of hepatic haeman-
gioma because of its blood-ﬁlled nature, reveals a focal photopenic defect on early phase 
imaging that ﬁlls in centripetally with delayed imaging over a 30- to 50-minute time inter-
val117-119. Lesions less than one cm cannot be detected because they are beyond the limit of 
spatial resolution of the gamma camera117. Although the use of this scintigraphic imaging 
with Tc-99m-pertechnatate-labeled RBCs has been accepted and widely used for diagnosis 
of haemangioma14,15, we rely on the state-of-the-art MR imaging, especially, if other imaging 
modalities, such as US or CT, are non-conclusive, in order to gain a more accurate diﬀerential 
diagnosis (Figure 2)2,120.
Treatment
Treatment is not indicated for small asymptomatic haemangiomas. Although follow-up with 
annual ultrasonography has been advised, recent data suggest that this may not be neces-
sary for lesions that appear typical with diagnostic imaging121.
In case of a large symptomatic lesion surgery can be considered122. Indications for excision 
have been the presence of symptoms, or even a perceived risk of complications as mentioned 
above. However, the risks of liver surgery in case of a hypervascular lesion must be carefully 
balanced against the beneﬁt that might be expected from a surgical procedure123,124. In a 
substantial proportion of patients (15-30 per cent) symptoms persist after resection, prob-
ably as a consequence of another undiagnosed problem4,125. The potential for complications 
during a conservative approach is minimal and symptoms may even resolve14,120. Any risk of 
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morbidity and mortality must be considered unacceptable, taking into account the benign 
nature and high prevalence of the tumour. Based on our experience we advocate surgery for 
cavernous liver haemangioma only in patients with incapacitating symptoms (Figure 2). Size 
of the lesion, per se, is not a criterion for resection.
Surgical options include enucleation or resection126,127. Embolisation should be reserved 
for tumours with extensive hilar involvement that have favourable vascular anatomy, for pa-
tients who require haemodynamic stabilisation before surgery, or to reduce blood loss at the 
time of surgery128,129. Transplantation is indicated for large, unresectable or multiple tumours, 
or when neither surgical resection nor embolisation is feasible130,131. Ligation of the hepatic 
artery132 and hepatic irradiation133 have been used in rare cases when surgical resection or 
transplantation was not feasible.
DISCUSSION
Due to the increased use of imaging modalities as US, CT and MR imaging more incidental 
liver lesions are discovered that are benign54,134. Problems may arise in obtaining a deﬁnite 
diagnosis in case of a solid hepatic tumour in a non-cirrhotic liver. Clinical evidence of malig-
nant disease or a known extrahepatic malignancy in medical history may be helpful during 
diﬀerentiation between benign and malignant tumours. When there is no such evidence, 
serum tumour markers are normal, and markers for chronic viral infection (hepatitis B or C 
serology tests) are negative, a benign lesion must be considered in diﬀerential diagnosis.
Routine laboratory tests do not contribute to the diﬀerential diagnosis in case of a fo-
cal liver lesion in a non-cirrhotic liver. Some cases of giant haemangioma complicated by 
focal thrombosis or haemorrhage within the tumour may show evidence of disseminated 
intravascular coagulation (Kasabach-Merritt syndrome), such as thrombocytopenia and hy-
poﬁbrinogenaemia. The only serum tumour markers that are clinically used during work-up 
of an isolated focal liver lesion, such as alpha-fetoprotein (AFP) carcinoembryonic antigen 
(CEA) and carbohydrate antigen (CA19-9) may contribute to the diﬀerential diagnosis of the 
tumour135.
After detection of a focal liver lesion and its segmental extent, characterisation of the le-
sion will permit an accurate treatment after evaluation. Although atypical imaging features 
are the exception rather than the rule, it is sometimes diﬃcult to diﬀerentiate between be-
nign and malignant lesions, and knowledge of their imaging features is essential to avoid 
unnecessary work-up.
US is frequently used because of its non-invasive nature and its wide accessibility. With US, 
mass lesions of the liver can be classiﬁed as solid or non-solid lesions. The broad availability 
of CT as well as the recent development of the faster multirow detector machines makes this 
modality an excellent technique for detection and characterisation of focal liver tumours. 
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Currently, the multirow detector CT does allow multiphasic dynamic contrast enhanced im-
aging in relatively shorter scanning times. The shorter scanning times allow the capture of 
distinct phases, including the unenhanced phase, arterial phase, portal phase, and venous 
phase that provide important information for characterisation of a focal liver lesion. In clini-
cal practice however, the number of phases is limited and often kept to a minimum, mainly 
due to the radiation hazard. At the same time, helical scanning and thinner collimation are 
used, more often. As a consequence, more smaller hepatic lesions are detected that can-
not be characterised with CT scanning after monophasic injection of contrast material134. MR 
imaging, however, may be the most reliable way of detection and characterisation of benign 
and malignant liver tumours62,136,137. The superiority of MR imaging is due to diﬀerences in 
techniques of data acquisition and contrast medium administration, in addition to inherently 
greater tissue contrast with MR imaging. Although nuclear imaging has been advocated for 
determination of a liver lesion56,118,119, the recent availability of tissue speciﬁc contrast media 
such as manganese chelates and reticuloendothelial agents, e.g. ferumoxides targeting ei-
ther hepatocytes or Kupﬀer cells, improved the speciﬁcity of MR imaging, and its utility above 
the less speciﬁc scintigraphic techniques138,139.
The role of needle biopsy or aspiration of focal liver lesions remains much debated. Al-
though histological examination is still considered to be the gold standard in the diagnosis 
of benign and malignant liver tumours, the availability of highly advanced radiological tech-
niques provides a non-invasive diagnostic tool that is being used frequently. It is remarkable 
that histology and radiological examination almost share the same accuracy rate, and in some 
Figure 3. Algorithm for diagnostic work-up in case of a solitary focal liver lesion.
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studies even a higher accuracy has been reported for MR imaging137,140,141. In addition, small 
hepatic lesions deemed too small to characterise, are more frequently benign than malig-
nant, even in patients with extrahepatic cancer134,142. This may have consequences for the role 
of histology during work-up of a focal liver lesion, which has its own diagnostic pitfalls. The 
morphology and immunohistochemical phenotype of liver tumours may overlap, while sam-
pling error and needle-tract tumour seeding can provide another diagnostic problem143,144.
In our clinic, we recommend to do only a liver biopsy in patients where radiological diagnosis 
remains unclear and if patients are not eligible for surgery, due to general condition or locali-
sation of the tumour (Figure 3)2.
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INDICATIONS AND LONG-TERM OUTCOME OF TREATMENT FOR BENIGN 
HEPATIC TUMOURS: A CRITICAL APPRAISAL
ABSTRACT
Background: Haemangioma, focal nodular hyperplasia (FNH) and hepatocellular adenoma 
are benign hepatic tumours that continue to pose diagnostic and therapeutic dilemmas. Till 
now, the most appropriate treatment for these liver tumours remains undeﬁned and often 
a primary surgical treatment is being performed. However, the natural history and clinical 
behaviour of benign hepatic tumours during long-term follow-up may not justify a primary 
surgical treatment.
Methods: Two hundred and eight patients were diagnosed with a benign liver tumour be-
tween January 1979 and December 1999. The medical records were analysed and symptoms 
and complications were assessed during management and long-term follow-up.
Results: Hepatic surgery was performed in 74 patients, and 134 were managed conser-
vatively by radiological follow-up. In the surgically treated population the liver lesion was 
symptomatic in 64% and an incidental ﬁnding in 36%. Operative morbidity and mortality was 
27% and 3%, respectively. Overall, 80% of patients with complaints were asymptomatic after 
surgery. During observation of the tumour in the conservatively managed group, 39 out of 
45 patients (87%) who presented with complaints are currently asymptomatic during a mean 
follow-up of 45 months; 6 patients have mild abdominal pain considered to be unrelated to 
the tumour.
Conclusions: A conservative management of solid benign liver lesions as FNH and haeman-
gioma can be performed safely, irrespective of their size. We only advise surgery for liver le-
sions when there is an inability to exclude malignancy or in case of severe complaints related 
to the tumour. Resection is always advocated in case of a large hepatocellular adenoma (>5 
cm) to reduce the risk of rupture and malignant degeneration.
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INTRODUCTION
In contrast with haemangioma, focal nodular hyperplasia (FNH) and hepatocellular adenoma 
are uncommon benign liver tumours that are detected more frequently nowadays because 
of improvements in radiological modalities and the widespread use of ultrasound1,2. They 
are often recognised as incidental hepatic masses during imaging for nonspeciﬁc abdominal 
symptoms. It is important to establish the diagnosis of an indeterminate hepatic mass to 
apply either surgical or conservative treatment. During management, it is essential to decide 
whether the mass is the cause of the patient’s symptoms, since simple observation might 
aﬀord the best clinical approach in the case of a benign liver lesion. In addition, the beneﬁt of 
resection should be carefully balanced against the risk inherent to liver surgery.
Several reports have documented the cause, diﬀerential diagnosis and treatment of FNH, 
adenoma and haemangioma of the liver1,3-8. Although ﬁndings in these studies provide a 
framework for the management of benign hepatic tumours, the most appropriate treatment 
remains controversial9-11. Especially in the case of a hepatocellular adenoma, many prefer sur-
gery to conservative treatment because of the risk of rupture and potential malignancy5,6,9.
We summarise a single-centre experience with the diagnosis and management of benign 
hepatic tumours. This study reviews the indications for surgery and the outcome of long-
term follow-up in treatment of these tumours.
PATIENTS AND METHODS
A total of 208 patients with a benign liver tumour were analysed between January 1, 1979, and 
December 31, 1999. A total of 74 patients underwent surgery and 134 were observed in our clinic 
(Table 1). The medical records of these 208 patients were reviewed to document clinical presenta-
tion, imaging studies, surgical or conservative treatment, complications, and follow-up.
The male-female ratio for FNH was 1:7.5; for hepatocellular adenoma, 1:7.3; and for hae-
mangioma, 1:2.8 (Table 1). Seventy-ﬁve percent (45/60) of women with FNH used oral contra-
ceptives for a mean±SD of 137 ± 44 months, and 93% of those with a hepatocellular adenoma 
used oral contraceptives for a mean±SD of 144 ± 84 months.
Mainly since 1990, laboratory analyses included hepatitis B and C serology tests (hepatitis 
B surface antigen, anti-hepatitis B core [antigen], and anti-hepatitis C virus) and levels of α-
fetoprotein as surrogate markers for malignancy.
The radiological investigation consisted of US, computed tomography (CT), magnetic reso-
nance imaging (MRI), angiography, technetium Tc 99m liver scintigraphy, and cholescintig-
raphy with the diisopropyl iminodiacetic acid hepatobiliary agent. The tumour was classiﬁed 
using predeﬁned criteria as FNH, hepatocellular adenoma, haemangioma or undetermined 
(Table 2)12-14. Angiography had an additive value for diagnosis when a central feeding artery 
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was visible. At scintigraphy, a normal or increased uptake within a lesion is typical for FNH 
because of the presence of Kupﬀer cells and allows diﬀerentiation from a hepatocellular ad-
enoma, which is associated with a focal defect.
The ﬁndings of diagnostic imaging were compared with the outcome of the histological 
examination of the resected specimen; the latter was taken as the gold standard for conﬁr-
mation of the diagnosis.
Hepatic surgery consisted of hemihepatectomy or a segmental or local resection. In the 
case of multiple tumours, resection was performed for the largest tumour, unless all tumours 
were located in the same segment or lobe. When surgical morbidity was calculated, all com-
plications requiring treatment were included in the analysis.
Table 1. Benign liver tumours and patients’ characteristics (n = 208)
Tumour Sex, M/F Age, y*
Patients Who 
Underwent 
Surgery
Pateints Who
Underwent 
Observation
Total no.
Focal nodular 
hyperplasia
8/60 36 (24-61) 26 42 68
Hepatocellular 
adenoma
4/29 34 (15-49) 19 14 33
Haemangioma 27/76 48 (30-77) 25 78 103
Cyst adenoma 1/0 - 1 0 1
Angiomyolipoma 0/2 - 2 0 2
Rhabdomyoma 1/0 - 1 0 1
Total 41/167 74 134 208
*Data are given as the mean (range).
Table 2. Lesion characteristics for each imaging modality*
Type of Lesion US CT Scanning MRI
Haemangioma 90 % Hyperechoic, a well-
deﬁned spherical or lobulated 
lesion; in 68% homogeneous 
signal
Low density on unenhanced 
CT; after delivery of contrast 
media peripheral nodular 
enhancement; ﬁll-in of the lesion 
over time (5-10 min)
Round or lobulated mass, low SI 
on T1 and high SI on T2; typical 
peripheral nodular enhancement 
after the administration of Gd
FNH Hypoechoic and a well-deﬁned 
lesion with a smooth border
Unenhanced well-deﬁned 
hypodense or isodense lesion; 
after delivery of contrast media 
homogeneous increase in 
density; 
50% of the lesions may show a 
central scar
Slightly lower SI on T1 and 
slightly higher SI on T2, 
homogeneous enhancement 
after the administration of Gd; 
may show a central scar
Hepatocellular 
adenoma
Hypoechoic, mostly localised 
at the periphery of the liver 
parenchyma; a well-deﬁned 
lesion with a smooth border
Well-deﬁned hypodense lesion, 
rapid transient enhancement 
on dynamic CT; may show 
haemorrhage
Isointense SI on both T1 and T2 
and transient enhancement after 
the administration of Gd
*US indicates ultrasonography; CT, computed tomographic; MRI, magnetic resonance imaging; SI, signal intensity; T1, T1-weighted image; T2, 
T2-weighted image; Gd, gadolinium; and FNH, focal nodular hyperplasia.
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RESULTS
Surgical treatment
In the case of an incidentally detected tumour (32%, or 24 of 74 patients), the inability to dif-
ferentiate between FNH, hepatocellular adenoma, or carcinoma was an indication for surgery 
(Table 3). Small tumours that allowed simple surgery during laparotomy for other reasons 
were also resected. Abdominal symptoms were the reason for resection in 47 (64%) of the 74 
patients, even when there was a clear diagnosis of FNH or haemangioma. The tumour diam-
eter was signiﬁcantly greater in patients with abdominal pain than in those with an incidental 
ﬁnding (median [range], 8.0 [4.0-21.0] vs 5.5 [2.5-19.0] cm; P=.01). Rupture of the tumour was 
observed in 8 (42%) of the 19 patients with hepatocellular adenoma.
Table 3. Clinical presentation in 74 patients with a benign liver tumour, treated surgically*
Focal Nodular Hyperplasia Hepatocellular Adenoma Haemangioma
Clinical presentation (n = 26) (n = 19) (n = 25)
Incidental 12 (46) 4 (21) 3 (12)
Suspected metastases 1 (4) 0 4 (16)
Abdominal pain 10 (38) 6 (32) 15 (56)
Nonspeciﬁc complaints 2 (8) 1 (5) 1 (4)
Palpable mass 1 (4) 0 2 (8)
Bleeding 0 8 (42) 0
*Data are given as the number (percentage) of patients. Four patients with cystadenoma, angiomyolipoma, and rhabdomyoma had abdominal 
complaints.
Routine laboratory analyses did not contribute to the diagnosis. α-fetoprotein levels were 
determined in 129 (62%) of all 208 patients and were found to be normal. Hepatitis B and C 
serologic tests (hepatitis B surface antigen, anti-hepatitis B core [antigen], and anti-hepatitis 
C virus) were performed in 135 (65%) of the 208 patients, and the results were negative in all 
samples.
The diagnostic work-up usually included US and contrast-enhanced CT (Table 4). Comput-
ed tomographic scanning led to the imaging diagnosis in 37% of patients with FNH, in 56% 
of those with hepatocellular adenoma, and in 70% of those with haemangioma. The most 
important diagnostic diﬃculty was in diﬀerentiating FNH from hepatocellular adenoma and 
in some cases from carcinoma. It is remarkable that the sensitivity rate of US and CT scanning 
for FNH has increased signiﬁcantly between the ﬁrst 10-year period (1979-1989) (14% and 
33%, respectively) and the last 10 years (46% and 39%, respectively) (P=.04). In addition, MRI 
was used in 11 patients; in all 4 patients with a haemangioma, the diagnosis was established 
unequivocally.
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Table 4. Imaging modality and sensitivity rates for FNH, Hepatocellular adenoma and Haemangioma*
Imaging Modality FNH Hepatocellular Adenoma Haemangioma
US 6/18 (33) 6/18 (33) 12/24 (50)
CT scanning 7/19 (37) 9/16 (56) 16/23 (70)
MRI 1/4 (25) 1/3 (33) 4/4 (100)
Angiography 2/8 (25) 2/3 (67) 4/6 (67)
Liver scintigraphy 2/7 (29) 0/2 1/4 (25)
Cholescintigraphy 1/6 (17) 1/1 (100) 0/2
*Data are given as the number of patients in whom the speciﬁc imaging modality led to the diagnosis/the total number of patients in that group 
(percentage). FNH indicates focal nodular hyperplasia; US, ultrasonography; CT, computed tomographic; and MRI, magnetic resonance imaging.
Table 5. Surgical procedure in 74 patients*
Procedure Focal Nodular Hyperplasia 
(n = 26)
Hepatocellular 
Adenoma (n = 19)
Haemangioma
(n = 25)
Other (n = 4)
Right hemihepatectomy 2 5 5 1
Right extended 
hemihepatectomy
0 0 1 0
Left hemihepatectomy 1 0 2 0
Segmental resection 13 11 7 1
Nonanatomic resection 10 3 10 2
*Data are given as the number of patients.
The results of a pre-operative needle biopsy, performed in 38 patients, were conﬁrmatory, 
with the histopathological diagnosis of the resected tumour in 8 (50%) of the 16 patients 
with FNH, in 8 (67%) of the 12 with a hepatocellular adenoma, and in 10 (100%) of the 10 with 
a haemangioma.
In the surgically treated population, 5 patients with FNH and 9 patients with haemangioma 
had 2 or more tumours in the liver. Hepatocellular adenoma was solitary in all patients. Ma-
jor hepatic resections were performed in 17 patients (23%) including right (extended) and 
left hemihepatectomies. Nonanatomic resection (enucleation or wedge resection) was per-
formed in 25, and a (bi)segmental resection was performed in 32 cases (Table 5).
The mean±SD greatest diameter of the resected tumour was 8.3 ± 4.1 cm (median, 7.5 cm; 
range, 3.0-19.0 cm) for FNH, 10.3 ± 3.4 cm (median, 9.0 cm; range, 7.0-20.0 cm) for hepatocel-
lular adenoma, and 9.0 ± 5.3 cm (median, 7.0 cm; range 2.5-21.0 cm) for haemangioma.
During the postoperative hospital stay (median, 11days; range, 2-33 days), overall morbidity, 
including all minor complications, was 27% (20 of 74 patients) (Table 6). Two patients (3%) died 
of continued bleeding and a severe consumptive coagulopathy after liver surgery for a large 
and symptomatic tumour (14 and 15 cm). One of these tumours, located centrally in the liver, 
compressed the duodenum from outside and caused gastric outlet obstruction, which necessi-
tated surgical treatment. Six patients required additional surgical intervention during the same 
period of hospitalisation, 5 patients with secondary bleeding for control of haemorrhage and 1 
with thrombosis of the inferior caval vein for thrombectomy. All complications were randomly 
distributed during the period of study and were not related to surgical experience.
48
C
ha
pt
er
 2
.2
The mean follow-up was 39 months (median, 11 months; range, 1-182 months). Of 27 pa-
tients who were asymptomatic at presentation, 6 (22%) had complaints related to surgery 
and 21 (78%) remained asymptomatic. The long-term morbidity related to surgery is shown 
in Table 7.
Of the patients who presented with complaints (n=35), symptoms resolved in 28 after sur-
gery. However, in 7 patients (3 with FNH and 4 with haemangioma), symptoms persisted. All 
women with previous hepatocellular adenoma stopped using oral contraceptives. Tumour 
recurrence was not detected during radiological follow-up of all patients.
Conservative treatment
A total of 134 patients (42 with FNH, 14 with hepatocellular adenoma, and 78 with haeman-
gioma) were managed by observation. In 43% of the patients with FNH, in 43% with a he-
patocellular adenoma, and in 78% with a haemangioma the tumour was found incidentally 
during abdominal imaging or laparotomy for other indications (Table 8). Abdominal pain was 
noted in 33%, 14%, and 12% of those with FNH, a hepatocellular adenoma and a haeman-
gioma, respectively. Four patients presented with a ruptured hepatocellular adenoma and 
Table 6. Surgical morbidity*
Complication
Focal Nodular 
Hyperplasia (n = 26)
Hepatocellular 
Adenoma (n = 19)
Haemangioma  
(n = 25)
Other (n = 4)
Pneumonia 2 0 0 0
Pleural eﬀusion 0 0 2 0
Pulmonary embolism 0 0 1 0
Urinary tract infection 0 0 1 0
Wound infection 2 1 0 0
Venous thrombosis 0 2 0 0
Secondary bleeding 3 1 1 0
Perihepatic abscess 0 0 1 1
Ascites 2 0 0 0
Total, No. (%) 9 (35) 4 (21) 6 (24) 1 (25)
*Data are given as the number of patients.
Table 7. Long-term morbidity related to surgery*
Complaint No. of Patients
(n = 72)**
Abdominal pain 5
Incisional pain 3
Incisional hernia 2
Fatigue 3
Total, No. (%) 13 (18)
*Data are given as the number of patients.
**Two patients who are died are excluded. 
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were managed conservatively by haemodynamic stabilisation and control of coagulation 
disorders. When the tumour was an incidental ﬁnding during laparotomy, the diagnosis was 
conﬁrmed by incisional biopsy peroperatively. In all other patients, imaging methods led to 
the diagnosis. In case of doubt, needle biopsy was performed (in 25 patients with FNH, in 16 
with a hepatocellular adenoma, and in 15 with a haemangioma).
Patients were observed for a mean of 45 months (range, 24-72 months). Of the 42 patients 
with FNH, 6 (14%) had mild abdominal pain considered to be unrelated to the tumour (mean 
diameter, 4.7 cm; range, 3.0-5.6 cm) and 6 (14%) had nonspeciﬁc complaints of fatigue.
All patients with hepatocellular adenoma were asymptomatic. The mean greatest diameter 
of the tumour was 3.2 cm (range, 1.5-5.0 cm). Six (43%) of the 14 patients showed regression 
of the tumour after cessation of oral contraceptive use, and 2 of these tumours were not de-
tectable during last follow-up. Hepatitis B and C serologic tests were negative in all patients. 
There was no evidence of malignant transformation or bleeding during follow-up.
One patient with a haemangioma as an incidental ﬁnding showed growth of a large tumour 
(diameter 20 cm) without any complaints; during a follow-up of 4 years, the tumour diameter 
increased by 5 cm and, to date, this patient is being managed conservatively. Coagulation 
disorders or tumour-related mortality were not detected.
DISCUSSION
The results of our experience indicate that liver surgery for benign liver tumours may relieve 
complaints in a high percentage of symptomatic patients (80%). However, in many patients, 
symptoms persist after resection of the tumour and surgery-related complications might oc-
cur. Regarding the considerable long- and short-term morbidity and even mortality, careful 
patient selection is warranted, especially in view of the benign nature of these lesions.
The clinical presentation may be diﬀerent for FNH and haemangioma on the one hand and 
for hepatocellular adenoma on the other. Focal nodular hyperplasia and haemangioma are 
typically incidental ﬁndings since 50% to 90% of patients lack symptoms5,6,11,15-18. In the case 
of abdominal pain or discomfort, the clinician must decide whether this is caused by the 
Table 8. Clinical presentation in 134 patients with benign liver tumours, treated conservatively*
Focal Nodular Hyperplasia Hepatocellular Adenoma Haemangioma
Clinical presentation (n = 42) (n = 14) (n = 78)
Incidental 18 (43) 6 (43) 61 (78)
Abdominal pain 14 (33) 2 (14) 9 (12)
Nonspeciﬁc complaints 10 (24) 2 (14) 8 (11)
Bleeding 0 4 (29) 0
*Data are given as the number of patients.
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mass before considering speciﬁc treatment of the lesion17,19. Patients with a hepatocellular 
adenoma, however, have a higher prevalence of symptoms at ﬁrst presentation, probably 
caused by the rate of intra-tumoural or intra-abdominal haemorrhage (50%-65%)3,7,20.
Problems may arise in obtaining a deﬁnite diagnosis in the case of a solid hepatic tumour, 
and in diﬀerentiating between benign and malignant tumours. When clinical evidence of 
malignant disease is absent, serum α-fetoprotein levels are normal and hepatitis B and C 
serologic tests are negative, a benign lesion must be considered in the diﬀerential diagnosis. 
Because additional laboratory tests are not helpful during diagnostic work-up, the combina-
tion of US and contrast-enhanced CT can provide a diagnostic yield. Although not speciﬁc, 
ﬁndings of an avascular central scar or a feeding artery to the mass are highly supportive of 
FNH, and the presence of intralesional haemorrhage with necrosis is similarly supportive of 
hepatocellular adenoma (Figure 1). Although the use of more invasive imaging methods such 
as liver scintigraphy, cholescintigraphy, and angiography, is reported to be useful for diagno-
sis of benign lesions5,6, an additive value to preoperative imaging speciﬁcity was not shown 
in our study. The sensitivity rates of imaging methods in the surgically treated population 
are lower than those reported in the literature21-23. This may be caused by a selection bias of 
more atypical lesions in the group of operated on patients. Furthermore, diagnostic tools and 
experience have improved during the 20-year period of our study. Nowadays, familiarity with 
dynamic contrast-enhanced CT and MRI will allow a more accurate diagnosis. Increasingly, 
MRI is being used to improve the diagnostic accuracy in the case of a liver tumor21,22. Espe-
cially when the diﬀerential diagnosis includes haemangioma, MRI is a valuable tool, showing 
a speciﬁcity of 90% to 100% and sensitivity of about 90% (Figure 2)24.
Percutaneous liver biopsy is assumed to be of little value because of the possible lack of spe-
ciﬁc features in a small specimen and the risk of needle-induced bleeding in hypervascular 
Figure 1. Computed tomographic image of a hepatic tumour with intralesional haemorrhage and necrosis. Typical features of a hepatocellular 
adenoma. This tumour was resected because of its large diameter.
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tumors25,26. However, we perform a needle biopsy when doubt remains about the diagnosis 
and a conservative approach is being considered. The risk of serious haemorrhage during US- 
or CT-guided needle biopsy in benign liver tumours is reported to be low (0.03%-0.04%)27,28, 
and in our series there were no complications with the biopsies performed.
The strategy for management of benign hepatic tumours has ranged from routine resec-
tion7,29,30 to selective observation5,6,10,16,31-33. Indications for surgery have been the presence of 
symptoms, the development of complications, or the need to establish a deﬁnite diagnosis 
when radiological and histological studies were not conclusive. Yet the risk of signiﬁcant and 
sometimes uncontrollable intraoperative bleeding in addition to the common risks of any 
liver resection17,34,35 should be carefully balanced against the beneﬁt that might be expected 
from resection. Mortality rates of surgery, which may be underreported in the literature, must 
be considered as serious, especially taking into account the benign nature and prevalence 
of the tumour. Observation of the tumour can be used in most patients without risk of sig-
niﬁcant morbidity and with resolution of symptoms. There is no evidence that FNH lesions 
can bleed or undergo malignant transformation3,16, and the low potential for complications 
of a liver haemangioma (rupture, growth, mass eﬀect, Kasabach-Merritt syndrome) does not 
justify surgery for all detected lesions17,36,37. In contrast to FNH and haemangioma, resection 
of adenoma is advocated regardless of symptoms5,7,30,38-40.
In our clinic, we perform surgery for hepatocellular adenomas with a diameter greater 
than 5 cm, since lesion size may be an important indicator of malignancy and potential for 
rupture10,38,41. A conservative approach may be justiﬁed with smaller hepatocellular adeno-
mas, even in case of bleeding; patients have to be advised to stop steroid use and to avoid 
pregnancy. Large hepatocellular adenomas detected during pregnancy should be resected 
also, since there is an increased risk of bleeding due to high levels of endogenous steroid 
Figure 2. Magnetic resonance image of a conservatively treated patient, showing a typical lobulated hyperdense lesion on T2-weighted 
sequences, characteristic of a haemangioma.
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hormones and the increased vascularity of the liver42. Moreover, we advise surgery for any 
benign liver tumour which causes severe complaints and when there is an uncertain diagno-
sis (Figure 3). This may explain the fact that we did not ﬁnd a malignancy during follow-up of 
our conservatively managed patients.
When considering surgery, patients should be well informed that complaints may persist 
and that hepatic resection for benign lesions may still be related to serious morbidity and 
even mortality.
Figure 3. Algorithm for the management of solid liver tumors.
US indicates ultrasonography; CT, computed tomographic; MRI, magnetic resonance imaging; and FNH, focal nodular hyperplasia.
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Chapter 3
Hepatic haemangioma
3
Size of lesion is not a criterion for resection during management of giant liver haeman-
gioma.
T Terkivatan, WW Vrijland, PT den Hoed, RA de Man, SM Hussain, HW Tilanus, JNM IJzermans.
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SIZE OF LESION IS NOT A CRITERION FOR RESECTION DURING MANAGEMENT 
OF GIANT LIVER HAEMANGIOMA
ABSTRACT
Background: The unknown natural course and risk of complications of large haemangiomas 
may pose therapeutic dilemmas. The authors describe their experience with the manage-
ment of giant haemangiomas.
Methods: Patients with a giant haemangioma were identiﬁed by a survey of the hospital 
database. Forty-nine patients with a haemangioma of at least 4 cm in diameter presented 
between January 1990 to December 2000. Medical records were analysed retrospectively.
Results: Eleven patients had surgical treatment and 38 were managed conservatively. The 
median diameter of the tumours was 8.0 cm in surgically treated patients and 6.0 cm in the 
group managed by observation. Surgery-related morbidity occurred in three patients, and 
abdominal complaints persisted in three of ten patients with a symptomatic lesion. During a 
median follow-up of 52 months, 12 non-operated patients had mild abdominal complaints, 
considered to be unrelated to the lesion. In these patients symptoms either diminished or 
became minimal during follow-up. Complications did not occur.
Conclusion: Observation of giant haemangiomas can be performed safely. The authors ad-
vocate resection of cavernous liver haemangiomas only in patients with persistent severe 
complaints.
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INTRODUCTION
Cavernous haemangioma is the most common benign tumour of the liver, with an estimated 
prevalence of 5-7 per cent1. The incidental ﬁnding of liver haemangioma has increased con-
siderably as many patients undergo modern imaging techniques2,3. Although most of these 
lesions remain asymptomatic, they may be responsible for pain due to capsular stretch, par-
tial infarction or pressure on surrounding tissues. More rarely, haemangiomas may rupture, 
or be associated with a consumptive coagulopathy (Kasabach-Merritt syndrome) or abscess 
formation4-7. Strategies for the management of liver haemangioma have ranged from se-
lective observation to a variety of radiological and surgical interventions8-12. While there is 
general agreement that small asymptomatic lesions should be managed conservatively, the 
unknown natural history and the possibility of complications of larger, or giant, haemangio-
mas (4 cm or more) makes treatment selection diﬃcult3,9.
The management of large haemangiomas has become increasingly conservative with time. 
Because serious complications may occur during conservative management of liver haeman-
giomas, a retrospective review was undertaken to identify the magnitude of these risks.
METHODS
A survey of the hospital database was performed to identify all consecutive patients with 
a diagnosis of giant haemangioma (at least 4 cm in diameter) who presented at University 
Hospital Rotterdam-Dijkzigt between January 1990 and December 2000. Forty-nine patients 
were identiﬁed. The diameter of the tumour was 10 cm or more in eight patients. Liver hae-
mangiomas were solitary in 31 of the 49 patients. Bilaterally giant haemangiomas were found 
in 12 patients (Table 1).
Table 1. Tumour characteristics
Surgery (n = 11) Observation (n = 38)
Location
 Right
 Left 
 Bilateral
4
5
2
22
6
10
No. of tumours
 One
 Two
 Three or more
9
2
0
22
8
8
Diameter (cm)
 Mean
 Median
 Range
9.5
8.0
4.0-20.0
6.5
6.0
4.0-25.0
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There were 33 women (67 per cent) and 16 men, with a mean age of 55 (range 32-89) years. 
Eleven (22 per cent) of the 49 patients underwent operation and 38 (78 per cent) were man-
aged by observation. The medical records of all patients were reviewed to document clinical 
presentation, diagnostic strategies, treatment, complications, and follow-up.
Diagnostic investigation included ultrasonography, triphasic spiral computed tomography 
(CT) and magnetic resonance imaging (MRI). The current MRI protocol for haemangiomas 
includes T2-weighted images with short and long echo times, multiphasic dynamic contrast-
enhanced T1-weighted images, and delayed fat-saturated dynamic contrast-enhanced T1-
weighted images. In the ﬁrst part of this retrospective study, ultrasonographically guided 
needle cytology or biopsy was performed when there was still doubt regarding the diagnosis 
after the use of imaging modalities and a conservative approach was being considered. The 
histological diagnosis of cavernous liver haemangioma was retained if the biopsy specimen 
demonstrated endothelium-lined spaces containing either ﬁbrin thrombi or aggregates of 
red blood cells separated from one another by connective tissue septa. More recently, ﬁne-
needle aspiration cytology or biopsy has been performed only when MRI is not conclusive.
A variety of surgical procedures were employed (Table 2), designed to minimise the un-
necessary loss of normal liver tissue. When feasible enucleation was preferred. In patients 
with multiple haemangiomas, resection was performed for the tumour that was presumed to 
be causing symptoms, considering size and localisation.
Follow-up after either surgical or conservative treatment consisted of physical examination 
and ultrasonographic visualisation of the liver.
Table 2. Surgical procedures undertaken in 11 patients
n Diameter (cm)
Right hemihepatectomy 2 7.0, 12.0 (9.5)
Right extended hemihepatectomy 1 20.0
Left hemihepatectomy 2 9.0, 12.0 (10.5)
Segmental resection 3 4.0, 7.0, 9.0 (6.7)
Enucleation 3 5.0, 6.0, 7.0 (6.0)
Values in parentheses are mean.
RESULTS
In 27 (55 per cent) of the 49 patients, hepatic haemangioma was an incidental ﬁnding during 
abdominal imaging for unrelated pathology or during follow-up or staging of an extrahe-
patic malignancy (Table 3). Symptoms potentially related to haemangioma included upper 
abdominal pain, fullness and dyspepsia.
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Table 3. Clinical presentation of 49 patients with a giant haemangioma
Surgery
(n = 11)
Observation
(n = 38)
Total
(n = 49)
Abdominal complaints 10 12 22 (45)
Incidental ﬁnding 1 22 23 (47)
Suspected metastasis - 3 3 (6)
Raised γ-glutamyl transferase level - 1 1 (1)
Values in parentheses are percentages.
Liver function test results were abnormal in 25 patients (51 per cent) but did not contribute 
to the diagnosis. No patient had thrombocytopenia or anaemia.
Ultrasonography was performed in all 49 patients and demonstrated haemangioma in 30. 
Twenty-three patients had CT, which was conclusive in 21 patients. In some of the patients 
with a typical lesion, MRI was performed additionally to increase the level of conﬁdence and 
experience with this imaging technique; in eight of nine patients, MRI established the diag-
nosis unequivocally. When ﬁne-needle cytology or biopsy was employed, haemangioma was 
detected in ﬁve of ten and nine of eleven patients respectively.
Surgical treatment
In ten patients an operation was performed where abdominal symptoms were considered to 
be related to haemangioma (infarction, capsular stretch or pressure on surrounding tissues). 
One patient underwent operation for an asymptomatic giant haemangioma (diameter 12 
cm) with persistent growth (5 cm during radiological follow-up of 36 months). The mean 
greatest diameter of all resected tumours was 9.5 (median 8.0, range 4.0-20.0) cm (Table 1).
Post-operative complications occurred in three patients. One patient developed second-
ary bleeding that necessitated relaparotomy; one had a pleural eﬀusion and another had 
a subhepatic abscess, both of which required drainage. During postoperative follow-up of 
24.5 (range 13-110) months, abdominal symptoms persisted in three patients. Two of these 
symptomatic patients had bilaterally haemangiomas at the time of operation. They have 
been managed conservatively by radiological follow-up of the contralaterally lesions, which 
have been left in situ (6 and 7 cm). There was no surgery-related mortality.
Conservative management
Thirty-eight patients were managed conservatively. Twelve non-operated patients had mild 
abdominal pain or discomfort, considered to be unrelated to the lesion (Table 3). The mean 
greatest diameter of the tumour in these symptomatic patients (6.1 (median 6.0, range 4.0-
11.0) cm) was not signiﬁcantly diﬀerent from the symptomatic patients who underwent sur-
gery (mean 9.7 cm, median 8.5 cm) (P = 0.36).
During a mean follow-up of 59 (median 52, range 12-122) months, symptoms had either 
diminished or become minimal in all 12 patients with abdominal complaints. None of the 
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patients who were asymptomatic at the time of ﬁrst referral developed abdominal pain. In 
32 patients the tumour was followed by means of ultrasonography. An increased diameter 
was observed in only one patient with an asymptomatic haemangioma (5 cm growth over 
49 months). Coagulation disorders, other complications or tumour-related death has not oc-
curred.
DISCUSSION
In patients with benign liver tumours, surgery may relieve complaints in a large proportion 
of those with symptoms. In a substantial proportion of patients (15-30 per cent), however, 
symptoms persist after resection probably as a consequence of another misdiagnosed prob-
lem, such as irritable bowel syndrome, peptic ulcer or reﬂux disease8,13. It is essential to decide 
whether the mass is indeed the cause of the patient’s complaints, as simple observation of a 
benign liver lesion might be the best clinical approach without the risks of surgery and the 
potential for symptom resolution. In patients with a haemangioma, it may be even more 
diﬃcult to correlate symptoms with size and location. Indications for operation have tradi-
tionally been the presence of symptoms, the development of complications, and the need to 
establish a deﬁnite diagnosis when radiological and histological studies were inconclusive. 
Liver haemangiomas have also been resected because of a perceived risk of spontaneous 
or traumatic rupture, and the possibility of the Kasabach-Merritt syndrome, a consumption 
coagulopathy with low platelet counts and hypo-ﬁbrinogenaemia6,9,14,15. The potential for 
complications of a liver haemangioma is minimal4,16 and does not justify, per se, resection 
of all haemangiomas. The risk of signiﬁcant and sometimes uncontrollable intraoperative 
bleeding of hypervascular lesions, in addition to the common risks of any liver resection17-19, 
should be carefully balanced against the beneﬁt that might be expected from surgery. The 
reported mortality rate associated with elective liver resection of such tumours ranges from 
0 to 4 per cent8,13,20,21. The latter ﬁgure must be considered unacceptable, taking into account 
the benign nature and high prevalence of the tumour.
Speciﬁc features of cavernous liver haemangioma may be apparent with a variety of im-
aging techniques such as ultrasonography, dynamic contrast-enhanced CT and MRI. With 
ultrasonography, a typical haemangioma is characterised as a sharply marginated, lobulated, 
predominantly hyperechoic lesion22-24. Haemangiomas may be complicated by bleeding, scar 
tissue or calciﬁcation24. Such lesions have a variable appearance at ultrasonography. In addi-
tion, the ultrasonographic appearance of uncomplicated haemangiomas may overlap with 
those of primary or secondary malignant liver tumours. In patients with an unclear diagnosis 
and in those with a known (colorectal) malignancy or cirrhosis, the authors recommend MRI 
because of its high speciﬁcity in the diagnosis of haemangioma. At MRI, haemangiomas are 
typically very bright on T2-weighted images (Figure 1) and show peripheral nodular enhance-
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ment on dynamic contrast-enhanced T1-weighted images (Figure 2). Occasionally, small 
haemangiomas may show a homogeneous intense enhancement during early phases of the 
dynamic study, although haemangiomas, unlike malignant lesions, retain contrast material 
and stay hyperintense on delayed contrast-enhanced images22,24. The overall accuracy of MRI 
for the detection and characterisation of haemangioma has been reported to be high, with 
a speciﬁcity of 90-100 per cent and a sensitivity of about 90 per cent22-24, especially when 
T2-weighted images with short and long echo times are combined with multiphasic dynamic 
contrast-enhanced images, and delayed contrast-enhanced images. The results of MRI in the 
present study, although obtained in only a small number of patients with haemangioma, are 
in accordance with those reported previously22,24. The use of other invasive imaging meth-
ods, such as scintigraphy and technetium-99m-labelled red blood cell scanning, has been 
reported for the diagnosis of benign liver lesions and especially hemangiomas25,26.
The risk of needle-induced bleeding during ultrasonographically or CT-guided biopsy in be-
nign hypervascular tumours is reported to be low (0.03-0.04 per cent)27,28. In the present series 
there were no complications following biopsy. A tissue diagnosis is recommended when the 
radiological diagnosis remains unclear and conservative treatment is being considered.
Conservative management of liver haemangioma is preferred because of the minimal risk 
of complications. As supported by the present observation, mild symptoms often resolve 
Figure 1. T2-weighted magnetic resonance image with fat saturation 
showing a typical giant haemangioma (arrowhead) with a central scar 
(*) on the left side of the liver, and a small haemangioma in the right 
liver (black arrow). Both lesions are sharply marginated and very bright 
compared with surrounding liver.
Figure 2. T1-weighted image during the arterial phase of a dynamic 
study after intravenous injection of magnetic resonance imaging 
contrast medium (gadolinium-diethylenetriamine penta-acetate), 
showing typical peripheral nodular enhancement (black arrows) 
in both lesions (giant haemangioma indicated with white arrow). 
The presence of a combination of a bright lesion on a T2-weighted 
image and peripheral nodular enhancement is pathognomic for liver 
haemangioma.
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spontaneously during follow-up, and operation is not completely successful in terms of 
symptomatic relief. In addition, this series derives from a tertiary referral centre with a higher 
proportion of large tumours than is observed in the general population. The study clearly 
demonstrates that a conﬁdent diagnosis may be made using modern recent high-resolution 
radiological studies, and that conservative management can be undertaken safely. Based on 
the present experience, surgery for liver haemangioma is advocated only in patients with 
incapacitating symptoms. The size of the lesion is not a criterion for resection and some 
exceptional indications or complications which may necessitate liver surgery or even trans-
plantation12,13,29 conﬁrm the importance of this general guideline for the treatment of liver 
haemangioma: observe the lesion, unless the patient has severe symptoms.
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CHAPTER 4
Hepatocellular adenoma
4.1
Management of hepatocellular adenoma during pregnancy.
T Terkivatan, JHW de Wilt, RA de Man, JNM IJzermans.
Adapted from Liver 2000;20:186-187.
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MANAGEMENT OF HEPATOCELLULAR ADENOMA DURING PREGNANCY
Although the aetiology of hepatocellular adenoma is unknown, these benign tumours seem 
to be related to the use of oral contraceptives1,2. An association with pregnancy has also been 
described, probably due to increased levels of endogenous steroid hormones3,4. During preg-
nancy the risk of rupture of hepatocellular adenomas exists, and this is associated with high 
foetal and maternal mortality3,5-8. In non-pregnant women, surgical resection is often indi-
cated in larger hepatocellular adenomas because of a proven risk of rupture1,9,10 or malignant 
transformation11,12. Successful resection of malignant hepatic tumours during gestation has 
been reported13,14.
We report a case of 32-year-old pregnant woman with a hepatocellular adenoma, where 
surgical excision was performed. At 12 weeks’ gestation the patient complained of increas-
ing epigastric pain. She had been taking oral contraceptives for 15 years and did not use 
either alcohol or hepatotoxic medication. Except for an elevated alkaline phosphatase level 
of 273 (n. 25-75) IU/L and a γ-glutamyl transpeptidase level of 72 (n. 5-35) IU/L, all laboratory 
results were within normal limits (including alpha-fetoprotein) and actual or past infection 
with hepatitis B or C was excluded. Ultrasonography followed by computed tomography 
demonstrated a 7x9 cm tumour in the left hepatic lobe, consistent with either hepatocellular 
adenoma or focal nodular hyperplasia. Subsequent ultrasonography-guided percutaneous 
biopsy was consistent with hepatocellular adenoma, but a highly diﬀerentiated liver cell car-
cinoma could not be excluded. Radiological, laboratory, and histological ﬁndings, including 
the patient’s history of oral contraceptive use during 15 years, made the diagnosis of hepa-
tocellular adenoma most likely. Considering the risk of rupture in case of a hepatocellular 
adenoma, a resection of segment II and III was performed at 13 weeks’ gestation. Histological 
study of the tumour revealed free surgical margins of a hepatocellular adenoma in the left 
liver lobe. The postoperative recovery was unremarkable and the patient was discharged on 
the 7th postoperative day. There were no other problems during her pregnancy and the deliv-
ery was uneventful. Mother and child were in good condition 12 months after surgery.
In the last 40 years an increasing incidence of hepatocellular adenoma has been observed. 
In women who have never used oral contraceptives, hepatocellular adenoma develops at 
an annual rate of approximately 0.012 per 10.0001. On the other hand, the tumour even ap-
pears to be related to the drug exposure time. In women who have used oral contraceptives 
for more than 9 years, the risk of developing a hepatocellular adenoma is increased 25-fold. 
The use of oral contraceptives not only increases the risk of developing a hepatocellular ad-
enoma, but it also increases the risk of spontaneous rupture2,9. As a consequence, in patients 
who have been advised to discontinue oral contraceptives, regression of hepatocellular ad-
enoma has been described15. However, persistent growth of the tumour after cessation of 
oral contraception can occur as well16.
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Discussion about the right management of hepatocellular adenoma is still going on. Once 
the diagnosis of hepatocellular adenoma has been established, we advise patients to discon-
tinue oral contraception and to avoid pregnancy. Asymptomatic tumours with a diameter of 
less than 5 cm are treated conservatively, i.e. discontinuation of oral contraceptive use and 
ultrasonographic observation17,18. Primary surgical resection is performed in case of an initial 
diameter of 5 cm or more, or in patients with serious complaints.
It is unknown whether a hepatocellular adenoma found during pregnancy can regress after 
termination or completion of pregnancy. Stock et al. reported a case in which they performed 
a therapeutic abortion19. Abrupt necrosis occurred and the tumour did not regress in size.
High levels of sex steroids and increased vascularity of the liver during pregnancy increases 
the chances of liver rupture3. Elective resection of hepatocellular adenoma in non-pregnant 
women has a mortality rate of less than 1%, while the mortality with free rupture is 5% to 
10%1,2. Rupture of a hepatocellular adenoma during pregnancy carries a much higher mortal-
ity rate. In a review by Bis et al. comprising 91 cases, several cases of ruptured hepatocellular 
adenoma with intraperitoneal haemorrhage during gestation have been described, with a re-
ported 59% maternal and 62% foetal mortality8. The reason for this high mortality rate might 
be a serious delay in diagnosis because of confusion with other diseases, like preeclampsia or 
pulmonary embolism, which leads to a poor general condition prior to surgery3,6.
Successful resection of hepatic tumours during gestation has also been described by many 
other authors. Because of the unpredictable behaviour of hepatocellular adenomas and high 
maternal and foetal mortality rates in case of a rupture during pregnancy, we recommend 
resection once a large (≥5 cm) or a growing symptomatic hepatocellular adenoma is diag-
nosed. When a surgical procedure is performed during the second trimester, operative risks 
are minimal for both the mother and the foetus20.
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4.2
Treatment of ruptured hepatocellular adenoma.
T Terkivatan, JHW de Wilt, RA de Man, RR van Rijn, HW Tilanus, JNM IJzermans.
Adapted from British Journal of Surgery 2001;88:207-209.
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TREATMENT OF RUPTURED HEPATOCELLULAR ADENOMA
ABSTRACT
Background: Emergency resection is suggested as the treatment of choice in patients with 
ruptured hepatocellular adenoma. As the morbidity and mortality rates associated with 
emergency resection are high, the authors have favoured initial non-operative management 
in haemodynamically stable patients.
Methods: A retrospective study was performed to evaluate early management and treat-
ment of ruptured hepatocellular adenoma.
Results: Over a 21-year period, 12 patients presented with a ruptured hepatocellular ad-
enoma. Haemodynamic observation and support was the initial management in all 12 pa-
tients. Three underwent urgent laparotomy and gauze packing because of haemodynamic 
instability; no emergency liver resection was necessary. Eight patients had deﬁnitive surgery; 
three showed post-operative complications but none died. Regression of the tumour was 
observed in three of four patients treated conservatively.
Conclusion: The initial management of a ruptured hepatocellular adenoma should be hae-
modynamic stabilisation. Deﬁnitive resection is required for rebleeding or for tumours ex-
ceeding 5 cm in diameter. A conservative approach may well be justiﬁed in case of regression 
of an asymptomatic adenoma.
74
C
ha
pt
er
 4
.2
INTRODUCTION
Hepatocellular adenoma is a relatively uncommon liver tumour. Since the last 30 years the 
incidence of this benign lesion has clearly increased, which is partly a result of an increased 
awareness and improved diagnostic techniques. There also seems to be an association with 
the widespread use of oral contraceptives since the 1960s1-4. The use of oral contraceptives 
both increases the risk of developing hepatocellular adenoma, as well as the risk of serious 
complications from this lesion5,6. In addition, hepatocellular adenomas in oral contracep-
tive users tend to be larger, with higher rates of intratumoural and intraperitoneal haemor-
rhage5,7,8.
Emergency resection of a ruptured hepatocellular adenoma is associated with high morbid-
ity and mortality rates. While elective resection of a hepatocellular adenoma has a mortality 
rate of less than 1 per cent, this may increase to 5-10 per cent in those with intra-abdominal 
haemorrhage7-10.
In this study the management of 12 patients with a spontaneously ruptured hepatocellular 
adenoma was reviewed.
PATIENTS AND METHODS
A retrospective study was undertaken of 12 patients with a ruptured hepatocellular adenoma 
who were managed at University Hospital Rotterdam between 1978 and 1999. Medical re-
cords were reviewed with respect to the haemodynamic state on presentation, treatment 
and outcome. If operation was necessary, a distinction was made between emergency resec-
tion within 24 h of admission and (elective) resection after haemodynamic stabilisation.
Shock on admission was arbitrarily deﬁned as a pulse rate of more than 100 beats per min, 
a systolic blood pressure of less than 100 mm Hg and a decline or low haemoglobin level.
Follow-up was obtained by chart review, and all patients were invited to visit the outpa-
tient department, where an inquiry into complaints, physical examination and radiological 
investigation of the liver were performed.
There were ten women and two men, with a mean age of 35 (range 20-49) years. All the 
women had a history of oral contraceptive use with a mean duration of 10.5 (range 5-20) 
years. Both men had been using anabolic steroids, for 16 and 4 years, respectively.
In ten patients, bleeding was the ﬁrst presentation of the hepatocellular adenoma, and two 
patients were known to have a liver lesion. In one patient the liver lesion was misdiagnosed 
as a focal nodular hyperplasia 6 years before presentation, and one patient was known to 
have 3 hepatocellular adenomas.
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RESULTS
Five patients were in hypovolaemic shock on admission; the remainder were stable (Table 
1-2). Acute abdominal pain was the predominant complaint in all 12 patients. Four patients 
had lower chest pain, which referred to the right shoulder in combination with breathless-
ness; one of these patients was primarily misdiagnosed and treated as having a pulmonary 
embolism. Further radiological investigation revealed a bleeding liver tumour in this patient. 
Two patients had a history of abdominal pain before the onset of the acute moment.
Diagnostic work-up with ultrasonography (US) and computed tomographic (CT) scanning 
showed imaging characteristics of a hepatocellular adenoma with signs of haemorrhage and 
necrosis (ﬁgure 1a). The lesion was solitary in 10 patients. One patient had two lesions and 
one patient three. Bleeding was intra-abdominal in ﬁve patients, subcapsular in four and in-
trahepatic in three.
Laboratory tests demonstrated normal α-fetoprotein levels; hepatitis B and C serology 
(hepatitis B surface antigen, anti-hepatitis B core antigen, anti-hepatitis C virus) was negative 
in all patients.
Initial management included haemodynamic support. Urgent laparotomy and gauze pack-
ing was undertaken in three patients who had persistent bleeding. Eight patients had deﬁni-
tive surgery but no emergency resection was necessary (Table 1).
The median interval between presentation and deﬁnitive surgery was 10.5 (range 3-64) 
days. Resection involved right-sided hemihepatectomy (three patients), wedge resection 
(one patient), or segmental resection (four patients). Median intraoperative blood loss was 
1950 (range 750-5500) ml. There was no surgery-related mortality. Morbidity included a 
secondary haemorrhage that necessitated relaparotomy, thrombosis of the femoral and iliac 
vein, and a wound infection. Median hospital stay was 12.5 (range 5-22) days.
The median diameter of the resected tumour was 8 (range 4-20) cm; pathological investi-
gation conﬁrmed the diagnosis of hepatocellular adenoma in all patients.
The median duration of follow-up for the surgically treated patients was 13.5 (range 1-188) 
months. All patients were alive. Seven patients were asymptomatic; one had complaints of 
fatigue without any liver enzyme abnormalities. All patients stopped using oral contracep-
tives and US of the liver showed no recurrence of a hepatocellular adenoma.
Four patients were treated conservatively without resection; two of them were in hypo-
volaemic shock on initial admission (Table 2). The duration of follow-up ranged from 7 to 
15 months; steroids were not used. Three patients showed regression of the tumour and 
resorption of the haematoma on CT scanning. In two of these patients the tumour was not 
detectable at the last follow-up (Figure 1). One patient had no sign of regression, and resec-
tion was advised.
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DISCUSSION
Hepatocellular adenoma may present in various ways, including a mild abdominal pain or 
discomfort in the right upper quadrant, or as an incidental ﬁnding at abdominal imaging 
for unrelated pathology or at laparotomy. These tumours may also rupture and present with 
limited bleeding, causing acute abdominal pain in the right upper quadrant. On occasion, 
initial bleeding may be severe enough to produce haemorrhagic shock. Rupture is the mode 
of presentation in 50-65 per cent of individuals taking oral contraceptives who have a hepa-
tocellular adenoma2,11.
Size of a hepatocellular adenoma seems to be the predominant factor in determining 
whether bleeding will occur9,12. It has been suggested that the high rate of bleeding in case 
of a hepatocellular adenoma can be explained by their anatomical and pathological charac-
teristics; hepatocellular adenomas are highly vascular tumours containing multiple dilated, 
thin-walled sinusoids with a high pressure inside, which is caused by an extensive arterial 
blood supply to the lesion13,14. In addition, they lack connective tissue support that allows 
blood to spread diﬀusely throughout the tumour. Whether haemorrhage remains conﬁned 
to the tumour or produces haemoperitoneum depends principally on the distance separat-
ing the tumour from the liver surface and the thickness of the capsule.
Management of ruptured hepatocellular adenoma is of major concern. Many authors 
suggest that emergency resection is the preferred treatment for a ruptured hepatocellular 
adenoma12,15-18. However, high mortality rates and the serious morbidity after emergency 
resection7-10 argue for a more conservative approach. Alternative approaches include hepatic 
arterial embolization to control bleeding19-21. A primary, non-operative management with or 
without arterial embolization is currently the preferred treatment for blunt liver injury, as 
Figure 1. a. Computed tomogram at presentation showing a ruptured hepatocellular adenoma (asterisk) with subcapsular haematoma. The 
haematoma has displaced the right kidney (not seen in this ﬁgure) caudally and the falciform ligament (arrows) to the left. b. Computed 
tomogram at 15 months’ follow-up of the same patient, treated conservatively. No adenoma was detectable and total regression of the 
subcapsular haematoma was noted. The right kidney and falciform ligament have been replaced.
A B
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well22,23. Although spontaneous bleeding of a hepatocellular adenoma is an intrinsic process, 
the severity of liver injury may be equivalent to that sustained in major blunt trauma.
For this reason, a primary non-operative treatment with haemodynamic stabilisation and 
control of coagulation disorders is recommended. Even the possibility of malignancy is not 
an argument for acute resection, because intra-abdominal rupture of a carcinoma has to be 
considered as disseminated disease. In case of persistent or recurrent haemorrhage, lapa-
rotomy and abdominal packing is an option. In patients treated conservatively, subsequent 
management could include CT scanning at 3 and 6 months’ follow-up, stopping oral contra-
ceptives and avoiding pregnancy (Figure 2). Deﬁnitive resection should follow if the tumour 
diameter exceeds 5 cm after 6 months of follow-up or if rebleeding occurs. This distinction of 
5 cm as an indication for resection is in accordance with series described in the literature13,24, 
where data suggest that lesion size may be an important indicator of malignant transforma-
tion and rupture. If regression is noted, a conservative approach is justiﬁed in patients with 
an asymptomatic adenoma. One exception to these rules is when markers of chronic viral 
infection (hepatitis B or C) are positive or α-fetoprotein levels are high. In these patients it 
is virtually impossible for the pathologist to discriminate between adenoma and highly dif-
ferentiated hepatocellular carcinoma. If there is no regression or even growth of the lesion, 
resection has to be preferred to prevent rebleeding or malignant transformation.
Figure 2. Algorithm for the management of bleeding hepatocellular adenoma.
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WORK-UP OF FOCAL LIVER LESIONS: IS THERE STILL A PLACE FOR LIVER 
BIOPSY IN THE ERA OF CONTRAST MRI?
ABSTRACT
During diﬀerential diagnosis of a focal liver lesion most patients are subjected to an extensive 
work-up with diﬀerent radiological modalities and multiple needle biopsies of the tumour. 
While liver biopsy is considered to be the gold standard during diﬀerential diagnosis of focal 
liver lesions, it is questionable if it still has an additional value in the era of improved radio-
logical modalities, such as MR imaging.
We performed a review of the literature assisted by our own experience of three female 
patients who underwent surgery because of a focal liver lesion. In this report, we describe the 
diagnostic challenges that we encountered during diﬀerential diagnosis of these lesions and 
emphasise the improving role of the state-of-the art contrast MR imaging, which may equal 
or even exceed the value of needle biopsy.
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INTRODUCTION
Although histological examination by ﬁne needle biopsy is still considered to be the gold 
standard in the diagnosis of benign and malignant liver tumours1,2, the availability of highly 
advanced radiological techniques provides a non-invasive diagnostic tool that is frequently 
being used. It is remarkable that needle biopsy and radiological examination share almost 
the same accuracy rate, and in some studies even a higher accuracy has been reported for 
magnetic resonance imaging (MRI)3-6. The availability of MRI sequences that allow faster im-
aging of the entire liver with much thinner slices, and tissue speciﬁc magnetic resonance (MR) 
contrast media clearly improved the sensitivity and speciﬁcity of MRI, while needle biopsy of 
focal liver lesions does have its own diagnostic pitfalls7-9. The morphology and immunohis-
tochemical phenotype of liver tumours may overlap and sampling error can provide another 
diagnostic problem. In addition, precise histological criteria of liver cell dysplasia or atypia 
are not well described causing high interobserver variation and controversy concerning its 
diagnostic utility.
We report three cases of young female patients who underwent surgery for large liver le-
sions and the diﬃculty we encountered during the diﬀerential diagnosis of these tumours.
Case 1
A 29-year-old woman was referred to our hospital for evaluation of a hepatic mass, which was 
detected elsewhere. Her complaints consisted of diarrhoea without blood loss that started 
during her visit to a Latin American country. Intermittently, she experienced nausea and 
vomiting. Her complaints had been self-limiting at the time of ﬁrst presentation in another 
clinic. She denied fever, jaundice or a history of intravenous drugs or alcohol abuse. She had 
used an oral contraceptive for the last 10 years.
Physical examination revealed normal vital signs. The abdomen was soft and non-tender. 
There was no palpable mass, nor signs of liver insuﬃciency. The initial analysis consisted of 
viral serology tests (hepatitis B and C, cytomegalovirus and Epstein-Barr virus) and repeated 
stool microscopy for cysts or trophozoites; no infectious disease could be detected. Labo-
ratory values of aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline 
phosphatase, total bilirubin, γ-glutamyl transferase, and α-fetopotein were within the normal 
range.
Abdominal ultrasound (US) showed a large solid lesion in the liver, situated in the right 
lobe with only a subtle change in echogenecity compared to the surrounding normal liver 
parenchyma. A contrast-enhanced dynamic CT scan revealed a well-deﬁned lesion in seg-
ment V of the liver, which was hypodense to the surrounding liver on plain CT, and showed a 
very slight inhomogeneous increase in density after delivery of contrast. At MR imaging the 
lesion measured 7.8cm in largest diameter and had a well circumscribed, inhomogeneous 
appearance. On T1-weighted MR images, the tumour was composed of several nodules that 
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were surrounded by a low signal intensity tumour capsule. After intravenous administration 
of Gadolinium (a non-speciﬁc MR contrast agent), the lesion showed arterial enhancement of 
some nodules, with enhancement of the tumour capsule during the delayed images (Figure 
1). To assess the Kupﬀer cell activity of the lesion, an additional MRI after administration of a 
superparamagnetic iron oxide (SPIO) (a speciﬁc MR contrast medium) was performed; there 
was no change in signal intensity at all, indicating the absence of Kupﬀer cells. The multi-
nodularity of the lesion in combination with a diﬀerential enhancement of these nodules, 
the enhancement of a ﬁbrous capsule, and the absence of Kupﬀer cells were consistent with 
a malignant nature of the tumour.
An ultrasound-guided percutaneous ﬁne needle aspiration biopsy, which was performed 
before this patient presented in our clinic, showed foci of hepatocytes with a disturbed archi-
tecture within an irregular reticulin framework. Cytologically, the hepatocytes appeared uni-
form and normal. There were no mitotic ﬁgures, fatty change, or bile stasis. Multiple dilated, 
blood-ﬁlled spaces were observed. Portal tracts or ductular proliferation were not present. 
Based on these histological ﬁndings, a diﬀerential diagnosis of hepatocellular adenoma or 
focal nodular hyperplasia was made.
Considering the size of the tumour and the uncertain diagnosis, resection was recom-
mended. At the time of operation, there was a well-circumscribed, non-compressible liver 
mass in segment V, which was surrounded by a ﬁrm ﬁbrous capsule. The remainder of the 
liver was grossly normal. An enucleation of the tumour was performed.
The surgically enucleated tumour consisted of a 7.0 x 4.5 cm ﬁrmly encapsulated, well-cir-
cumscribed, solid tumour, which weighed 105 g (see Figure 1c). At microscopic examination, 
the tumour consisted of cells of hepatocellular origin that varied in size and were organised 
in groups, trabeculae and rosettes (see Figure 1d). The variation in nuclear and cellular size 
with hyperchromasia and prominent nucleoli was interpreted as mild to moderate atypia. No 
mitotic ﬁgures were present. Multiple arteries and veins were observed diﬀusely, but signs of 
vascular invasion were absent. A mildly to moderately increased mononuclear inﬁltrate was 
present in the tumour. Some connective tissue trabeculae with focal areas of haemorrhage 
and degeneration were seen. Portal zones with cholangioles, proliferating and reactive bile 
ductules were occasionally present. Because of the presence of areas with obvious atypia, 
the diﬃculty of diﬀerentiating between a hepatocellular adenoma, and a well-diﬀerentiated 
hepatocellular carcinoma persisted.
After a clinical and radiological follow-up of 28 months, no signs of tumour recurrence 
were detected in this patient.
Case 2
A 44-year-old woman was admitted to our hospital for the evaluation of multiple liver lesions 
that had been discovered by ultrasound elsewhere. The patient complained of an abdominal 
discomfort and had taken oral contraceptives continuously for 20 years until a few months 
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before admission. She denied alcohol or drugs abuse, and had no previous medical history. 
Physical examination revealed no abnormality, except obesity with a Body Mass Index of 28. 
Routine laboratory investigations and all tested tumour markers, e.g. alpha-fetoprotein (AFP), 
carcinoembryonic antigen (CEA), carbohydrate antigen (CA19-9), and cancer antigen 125 (CA 
125) were normal. Hepatitis serology tests were negative.
An abdominal US was performed, and showed multiple hyperechogeneous lesions scat-
tered throughout the liver. After having been transferred to our institution, MRI was per-
formed which illustrated a diﬀuse fatty liver (steatosis hepatis) with focal non-fatty areas. 
These areas were round or nodular in shape, creating “pseudotumours”, and appeared as 
heterogeneous and slightly hyperintense on fat-suppressed T2-weighted images. Two larger 
solid lesions (largest diameter 6.2 cm and 2.4 cm, respectively) were identiﬁed in segment 
VI and VII and appeared inhomogeneous and hyperintense on T2-weighted and isointense 
on T1-weighted images. On out-of-phase T1-weighted MR images these solid lesions had a 
high signal due to the absence of fat within the nodules. After intravenous administration of 
Gadolinium, all lesions showed an immediate, intense arterial blush; on delayed images they 
were isointense to the surrounding liver. During arterial phase, there were additional mul-
tiple small lesions that were not seen on plain series; in delayed phase images some of these 
lesions remained visible. An additional MRI with a SPIO-agent was performed; seventeen 
minutes after contrast administration most of the “pseudotumours” became isointense to the 
surrounding liver, while the two larger lesions in segment VI and VII remained somewhat 
inhomogeneous. The MR imaging ﬁndings were consistent with the diagnosis of multiple 
hepatocellular adenomas.
Fine needle biopsy of the largest lesion that was performed elsewhere and revised in our 
clinic conﬁrmed the outcome of MR imaging; normal hepatocytes with foci of double cell 
plates and steatosis were seen while there was an absence of bile ducts and portal triads. 
Using these morphologically diagnostic criteria, the lesion was diagnosed as a hepatocellular 
adenoma.
Because of the size of the largest adenoma, surgery was advised and the patient was oper-
ated on by an enucleation of the tumour.
The histopathologic examination of the resected specimen showed a normal background 
liver parenchyma with an extensive macrovacuolar pericellular steatosis. The lesion consisted 
of hepatocytes with normal nuclear/cytoplasmic ratios, and without mitotic ﬁgures. They were 
arranged in trabeculae of one or two cells thick. An irregular distribution of portal zones and 
dilated sinusoids were seen. No cholangioles or proliferating ductules were present, which 
has been conﬁrmed by cytoceratin 19 immunostaining. Occasionally, septae of connective 
tissue were present containing some inﬂammation and thin-walled vessels. Centrally within 
the lesion, areas of haemorrhage and necrosis were detected.
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Case 3
A 23-year old woman was referred to our clinic because of multiple liver lesions that were 
detected incidentally by an abdominal US, which was performed because of continuous left 
ﬂank pain. There was no nausea, fever, or jaundice. The patient denied the use cigarettes, 
alcohol, or drugs, and she had no past medical history. At admission she had already stopped 
using oral contraceptives, which she had taken for a few years.
During physical examination, her obesity was remarkable (Body Mass Index: 30). There 
were no palpable masses in the abdomen, nor signs of liver insuﬃciency. Routine laboratory 
tests were normal and viral serology tests negative.
In our clinic, MRI was performed, which showed four well circumscribed lesions in the 
right liver lobe; in segment VI and VII (largest diameter 8.0 cm), in segment V and VI (largest 
diameter 4.0 cm), in segment VII and VIII (largest diameter 2.6 cm), and the ﬁnal one in seg-
ment IVa (largest diameter 2.2 cm). All lesions had high signal intensity on T2- and low signal 
intensity on T1-weighted images, containing areas with low signal intensity on both T1- and 
T2-weighted sequences. There was no central scar. The post-Gadolinium images showed a 
moderate enhancement of all lesions with less enhancing areas in the largest lesion, which 
gained slight peripheral hyperintensity in the portal phase. On delayed images the lesions 
became isointense. On out-of-phase sequences the lesions showed a high signal on T1-
weighted images, which is characteristic for adenosis hepatis.
A ﬁne needle biopsy of the largest lesion was performed elsewhere and revised in our 
clinic. The lesion was of hepatocellular origin and contained some worrying morphological 
features, such as nuclear polymorphism and hyperchromasia, but no clear evidence for ma-
lignancy was found. Adenosis hepatis was considered in the diﬀerential diagnosis. Consider-
ing the uncertain diagnosis and the diameter of the largest lesion, a right hemihepatectomy 
was performed.
Histopathology showed a non-cirrhotic and remarkably steatotic background liver. The 
larger lesion with a maximum diameter of 8.0 cm consisted of a predominantly hepatocel-
lular tumour, which was in some places circumscribed from the adjacent liver tissue, but had 
a microscopically blending border in other areas. There was a heterogeneous intralesional 
appearance; in certain places there were thin trabeculae with normal hepatocytes, and else-
where there were foci of moderate pleomorphism with some areas of ballooned hepatocytes 
which contained usually small Mallory bodies. There was no mitosis or intralesional bile. In 
other places, often in the periphery of the lesion, there was more inﬂammation and ductular 
proliferation. Although the lesion had a merging border in places, neither deﬁnite invasion, 
nor vascular invasion was seen. An increase of solitary arterioles was present, but there were 
no abnormal vessels of the type that assist in the identiﬁcation of focal nodular hyperplasia. 
There also was intralesional haemorrhage in some places. The smaller lesion with a maximum 
diameter of 2.5 cm was less variegated and consisted almost entirely of a well-diﬀerentiated 
hepatocellular lesion with ductular proliferation and inﬂammatory cell inﬁltration resembling 
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the peripheral parts of the larger lesion. There was no loss of reticulin in either of the lesions, 
but the CD34 immunostaining pattern was diﬀuse and in some places corresponded to the 
more pleomorphic areas in the larger lesion. Regarding the above called histological features 
of both lesions, the smaller one was classiﬁed as a focal nodular hyperplasia, and the larger 
one as an “atypical adenoma”, indicating that histopathologically a relative benign prognosis 
was expected, but a careful clinical follow-up of the patient might be justiﬁed.
After a follow-up of 18 months, no tumour recurrence or extra-hepatic metastases were 
detected in this patient.
DISCUSSION
Fine needle biopsy is still accepted as the gold standard for diagnosing tumours in vari-
ous organs. In focal lesions of the liver the speciﬁcity and the positive predictive value is 
very high, however, the sensitivity of the procedure widely ranges between 67% to 93%6,10. 
Whereas the identiﬁcation of moderate and poorly diﬀerentiated hepatocellular carcinoma 
is easily achieved by histopathology, identiﬁcation of well-diﬀerentiated hepatocellular car-
cinoma is more diﬃcult. Distinction from hepatocellular adenoma, and in some cases from 
focal nodular hyperplasia remains a diagnostic challenge, particularly in small biopsies11,12. 
Besides, needle biopsy of hepatic tumours is associated with the known hazards of haemor-
rhage, needle-tract tumour seeding, sampling error, and misdiagnosis13. If liver cell dysplasia 
is diagnosed by liver biopsy, the question remains how to classify the degree of dysplasia 
because of lacking histological criteria of liver cell dysplasia. Another issue is the therapeutic 
implication of histological dysplasia. Is hepatocellular carcinoma preceded by liver cell dys-
plasia or should liver cell dysplasia be considered as a risk factor for development of hepato-
cellular carcinoma14,15? Another important subject is how much atypia is permissible within 
an adenoma before carcinomatous change should be considered. Modern cytopathological 
techniques such as cytophotometric analysis of DNA content underline the correlation of 
aneuploidy with the presence and grade of diﬀerentiation of hepatocellular carcinoma10. 
Other molecular genetic techniques, such as detection of loss of heterozygosity in hepatocel-
lular carcinoma may also provide a potential solution to problematic histological queries16. 
Comparative genomic hybridisation and ﬂuorescence in situ hybridisation revealed typical 
aberration patterns not only in moderate or poorly diﬀerentiated hepatocellular carcinoma 
but also in well-diﬀerentiated samples17-19. These aberrations were strikingly diﬀerent from 
the low number of aberrations detected in hepatocellular adenoma17. Although these tech-
niques may reduce the uncertainty of distinguishing benign lesions from well-diﬀerentiated 
carcinoma, they are based on an elaborate and time consuming procedures making it dif-
ﬁcult, and mostly impossible to apply in small biopsies in daily routine.
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During radiological investigation of a focal liver mass, MR imaging may be the most reli-
able way of diﬀerentiating malignant lesions from benign liver tumours4,7,8 (Figure 2a, 2b). 
The superiority of MR imaging is due to diﬀerences in techniques of data acquisition and 
contrast medium administration, in addition to inherently greater tissue contrast with MR im-
aging. Firstly, in most centres, dynamic gadolinium-enhanced MR imaging is performed with 
multislice two-dimensional or three-dimensional breath-hold and breathing-independent 
sequences that allow faster imaging of the liver with much thinner slices and have several 
intrinsic features that render them superior to CT20. Secondly, fast MR imaging sequences 
allow the use of timing bolus or automated contrast detection techniques to determine the 
contrast arrival time within the aorta. Finally, in MR imaging, a small amount of contrast me-
dium is injected. This allows a short injection time with a compact bolus. This facilitates the 
acquisition of truly distinct phases of dynamic contrast-enhanced MR imaging examination 
of the entire liver. The recent availability of tissue speciﬁc contrast media such as manganese 
chelates and reticuloendothelial agents, e.g. ferumoxides targeting either hepatocytes or 
Kupﬀer cells, provide new possibilities for lesion characterisation on the basis of its cellular 
composition and function rather than its vascularity and diﬀusion within its extracellular 
space21-23 (Figure 2c, 2d).
In all three cases presented in this report, a pre-operative needle biopsy was performed 
during work-up in another clinic before the patients were referred to our clinic. In case one, 
MR imaging could not exclude a malignant lesion, which should be reason to operate on a 
lesion at all times. The fact that needle biopsy showed benign morphological features did not 
change our decision for surgery. In the second and third case, MR imaging showed charac-
teristic features of adenosis hepatis. Apart from the outcome of pre-operative needle biopsy, 
surgery was decided upon the diameter of the lesions, since in our clinic, we follow an opera-
tive approach to large hepatocellular adenomas (>5 cm), due to the risk of haemorrhage and 
malignant degeneration.
By means of this report we would like to underline the improving role of radiology in the 
diagnosis of focal liver lesions. Although it is impossible to diﬀerentiate all focal liver lesions, 
the use of a state-of-the-art pattern recognition approach and the combination of various 
MR sequences and contrast enhancement techniques makes it possible to diagnose most 
hepatic tumours with conﬁdence7,24. This may have consequences for the role needle biopsy 
during work-up of a focal liver lesion. Considering the advantages and disadvantages of both 
diagnostic modalities, it may be questionable if radiology has equalled or even exceeded the 
value of needle biopsy as the gold standard. The accuracy rate of these modalities seems to 
be similar, and it should be questioned if an additional pre-operative needle biopsy will have 
therapeutic implications after having performed state of the art MR imaging of the liver.
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Figure 1. A 26-year-old woman (case 1) with a tumour of hepatocellular origin, with signs of malignancy at MR imaging and gross pathology, 
and predominantly adenoma-like histology. a. A T1-weighted MR image during the arterial phase after intravenous Gadolinium injection shows 
a tumour composed of several nodules with variable enhancement. One nodule enhances more (arrow) than the other (*). The nodules are 
surrounded by a dark capsule. These ﬁndings suggest malignancy. b. A T1-weighted MR image with fat-suppression during the delayed phase 
after the injection of Gadolinium shows the tumour (*) that is surrounded by a thick enhanced ﬁbrous tumour capsule (arrow), a classic sign of 
large hepatocellular carcinomas at MR imaging. c. Photograph of the resected specimen (*) conﬁrms the MR imaging ﬁndings of multi-nodularity 
and the thick ﬁbrous tumour capsule (arrow). Both ﬁndings are often seen in hepatocellular carcinoma. d. Photomicrograph (hematoxylin & eosin 
stain; 100x) through the periphery of the tumour shows the ﬁbrous tumour capsule (arrow) that contains cells of hepatocellular origin organised 
in groups, trabeculae and rosettes (*).
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Figure 2. A 30-year-old woman (not described in this manuscript) with a tumour that shows MR imaging ﬁndings of a typical hepatocellular 
adenoma. a. A T1-weighted MR image during the arterial phase after intravenous Gadolinium injection shows a tumour with homogeneous 
enhancement of the entire nodule (*). b. A T1-weighted MR image with fat-suppression during the delayed phase after the injection of 
Gadolinium shows the tumour (*) that has become almost isointense with the surrounding liver, without any evidence of a tumour capsule. 
c. A T2-weighted MR image with fat-suppression before the intravenous injection of superparamagnetic iron oxide (SPIO) contrast agent that is 
speciﬁcally taken up by the Kupﬀer cells. The tumour (*) is slightly brighter than the surrounding liver, a typical sign of a benign hepatocellular 
tumour like adenoma. d. A T2-weighted MR image with fat-suppression after the intravenous injection of superparamagnetic iron-oxide contrast 
agent. Note that the liver has become substantially darker compared to the image shown in c) due to the SPIO uptake. In addition, the tumour 
(*) also shows homogeneous decrease in signal intensity indicating that the tumour contains Kupﬀer cells with homogeneous distribution, 
suggesting the primary and benign nature of this lesion.
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Focal nodular hyperplasia
5.1
Focal nodular hyperplasia: Findings at state-of-the-art MR Imaging, US, CT, and patho-
logic analysis.
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FOCAL NODULAR HYPERPLASIA: FINDINGS AT STATE-OF-THE-ART MR 
IMAGING, US, CT, AND PATHOLOGIC ANALYSIS
ABSTRACT
Focal nodular hyperplasia (FNH) is the second most common benign liver tumor after 
hemangioma. FNH is classiﬁed into two types: classic (80% of cases) and nonclassic (20%). 
Distinction between FNH and other hypervascular liver lesions such as hepatocellular ad-
enoma, hepatocellular carcinoma, and hypervascular metastases is critical to ensure proper 
treatment. An asymptomatic patient with FNH does not require biopsy or surgery. Magnetic 
resonance (MR) imaging has higher sensitivity and speciﬁcity for FNH than does ultrasonog-
raphy or computed tomography. Typically, FNH is iso- or hypointense on T1weighted images, 
is slightly hyper- or isointense on T2-weighted images, and has a hyperintense central scar 
on T2-weighted images. FNH demonstrates intense homogeneous enhancement during the 
arterial phase of gadolinium-enhanced imaging and enhancement of the central scar dur-
ing later phases. Familiarity with the proper MR imaging technique and the spectrum of MR 
imaging ﬁndings is essential for correct diagnosis of FNH.
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INTRODUCTION
Edmondson1 introduced the term focal nodular hyperplasia (FNH) in 1958. In 1995, the 
International Working Party classiﬁed FNH with other regenerative lesions, in contrast to 
adenoma, which is known as a neoplastic lesion2. FNH is deﬁned as a nodule composed of 
benign-appearing hepatocytes occurring in a liver that is otherwise histologically normal or 
nearly normal2.
The pathogenesis of this lesion is not well understood3-7. Vascular malformation and vascu-
lar injury have been suggested as the underlying mechanism3. An association with steroids 
has been denied more recently5. FNH is the second most common benign liver tumor after 
hemangioma and has a reported prevalence of 0.9%6. The male-to-female ratio is 1:8, and the 
tumors occur in relatively young patients6. Approximately 20% of the patients have multiple 
FNH lesions6. The combination of multiple FNH lesions and hemangiomas is considered to be 
multiple FNH syndrome3,6.
FNH is often an incidental ﬁnding at imaging8-10. Distinction between FNH and other hyper-
vascular liver lesions such as hepatocellular adenoma, hepatocellular carcinoma (HCC), and 
hypervascular metastases is critical to ensure proper treatment. FNH is asymptomatic in most 
patients, and in such cases no treatment is necessary. In symptomatic or ambiguous cases, 
transarterial embolization or surgical resection may be considered.
Distinction of FNH from other hepatic abnormalities at ultrasonography (US) and comput-
ed tomography (CT) may be diﬃcult because these modalities, unlike magnetic resonance 
(MR) imaging, do not provide information concerning the tissue characteristics of the lesions. 
Currently, CT is increasingly being used for assessment of liver lesions. Therefore, it should be 
kept in mind that if triphasic CT is not performed or the timing of the arterial phase is incor-
rect, FNH can be misdiagnosed and many patients may be exposed to unnecessary biopsy 
or even surgery.
Based on our experience in more than 60 patients with FNH, this article describes the most 
recent concepts about the pathologic features of FNH including its angioarchitecture and 
demonstrates the full spectrum of ﬁndings in FNH at state-of-the-art MR imaging in compari-
son with US and CT.
CLASSIFICATION
Currently, FNH is divided into two types: classic and nonclassic. The nonclassic type contains 
three subtypes: (a) telangiectatic FNH, (b) FNH with cytologic atypia, and (c) mixed hyperplas-
tic and adenomatous FNH (Table)6.
Classic FNH is characterized by the presence of (a) abnormal nodular architecture, (b) 
malformed vessels, and (c) cholangiolar proliferation. Nonclassic FNH lesions lack one of the 
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following classic features - nodular abnormal architecture or malformed vessels - but always 
show bile ductular proliferation6.
Table 1. Current pathologic classiﬁcation of FNH
Type or Subtype Percentage of Cases
Classic FNH 80
Nonclassic FNH 20
Telangiectatic FNH 15
FNH with cytologic atypia 3
Mixed hyperplastic and adenomatous FNH 2
Figure 1. Gross pathologic and histologic features of classic FNH. a. Cross section of a resected specimen of classic FNH shows 
yellowish nodules of variable size (straight black arrows) surrounded by multiple septa (arrowhead) and a central scar (*). The
central scar contains large vessels (curved black arrow). Normal liver tissue (white arrow) surrounds the FNH. Note that there is no 
brous capsule at the interface of the lesion and the liver. b. Photomicrograph (original magnication, x40; hematoxylin-eosin [H-E] 
stain) shows the interface of the FNH (*), which contains multiple nodules and septa, and the surrounding normal hepatic 
parenchyma, which contains large vessels (straight arrow) and portal vein tracts with inammatory inltrates (curved arrow). c. 
Photomicrograph (original magnication, x40; H-E stain) shows a septum (arrow) dividing two neighboring nodules. The septum 
contains connective tissue and multiple arteries. d. Photomicrograph (original magnication, x100; H-E stain) shows a typical FNH 
nodule (*) surrounded by septa. At the interface of the nodule and the septa, ductular proliferation can be seen (arrows). 
Figure 1. Gross pathologic and histologic features of classic FNH. a. Cross section of a resected specimen of classic FNH shows yellowish nodules 
of variable size (straight black arrows) surrounded by multiple epta (arrowhead) and a central sc r *). The central scar contains arge vessels 
(curved black arrow). Normal liver tissue (white arrow) surrounds the FNH. Note that there is no ﬁbrous capsule at the interface of the lesion and 
the liver. b. Photomicrograph (original magniﬁcation, x40; hematoxylin-eosin [H-E] stain) shows the interface of the FNH (*), which contains 
multiple nodules and septa, and the surrounding normal hepatic parenchyma, which contains large vessels (straight arrow) and portal vein tracts 
with inﬂammatory inﬁltrates (curved arrow). c. Photomicrograph (original magniﬁcation, x40; H-E stain) shows a septum (arro ) dividing two 
neighboring nodules. The septum contains connective tissue and multiple arteries. d. Photomicrograph (original magniﬁcation, x100; H-E stain) 
shows a typical FNH nodule (*) surrounded by septa. At the interface of the nodule and the septa, ductular proliferation can be seen (arrows).
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GROSS PATHOLOGIC AND HISTOLOGIC FEATURES
The gross appearance of classic FNH consists of lobulated contours and parenchyma that is 
composed of nodules surrounded by radiating ﬁbrous septa originating from a central scar 
(Figure 1).
The central scar contains malformed vascular structures (Figure 2). Among classic FNH le-
sions, one or more macroscopic central scars are present in most cases. At histologic analysis, 
classic FNH shows nodular hyperplastic parenchyma. These nodules are completely or incom-
pletely surrounded by circular or short ﬁbrous septa. The hepatic plates may be moderately 
Figure 2. Vascularity of FNH. a. Drawing of part of an FNH lesion shows a septum that contains connective tissue, a large thick-
walled artery and numerous capillaries, and ductular proliferation with inammatory cells. The rich network of capillaries, which 
provides arterial blood to the hepatocytes and sinusoids, is responsible for the highly hypervascular nature of most FNH lesions at 
imaging. The sinusoids drain into veins. The malformed arteries of FNH arise from the hepatic artery, and the vein of FNH eventually 
drains into the hepatic vein. Note that FNH does not contain portal vessels. b. Photomicrograph (original magnication, x200; H-E 
stain) shows a brous septum (*) that contains a thick-walled artery (straight solid arrow). Note the ductular proliferation (curved 
arrow) at the interface of the septum and the parenchyma. The vein (open arrow) is located within the parenchyma. c. 
Photomicrograph (original magnication, x400; H-E stain) shows details of the end-artery (dashed line), which is divided into 
numerous small capillaries that are connected to the sinusoids (straight arrows). Curved arrow = ductular proliferation. d. 
Photomicrograph (original magnication, x400; H-E stain) shows details of the vein (open arrow). Note that numerous sinusoids 
(straight arrows) drain into a venule and eventually into the vein. 
The central scar contains malformed vascular structures (Figure 2). Among classic FNH lesions, one or 
more macroscopic central scars are present in most cases. At histologic analysis, classic FNH shows 
nodular hyperplastic parenchyma. These nodules are completely or incompletely surrounded by circular or 
short fibrous septa. The hepatic plates may be moderately thickened (two or three cells in thickness) with 
Figure 2. Vascularity of FNH. a. Drawing of part of an FNH lesion shows a septum that contains connective tissue, a large thick-walled artery 
and numerous capillaries, and ductular proliferation with inﬂammatory cells. The rich network of capillaries, which provides arterial blood to 
the hepatocytes and sinusoids, is responsible for the highly hypervascular nature of most FNH lesions at imaging. The sinusoids drain into v ins. 
The malformed arteries of FNH arise from the hepatic artery, and the vein of FNH eventually drains into the hepatic vein. Note that FNH does not 
contain portal vessels. b. Ph tomicrograph (original magniﬁcation, x200; H-E sta ) shows a ﬁbrous septum (*) tha  contains a thick-walled
artery (straight solid arrow). Note the ductular proliferation (curved arrow) at the interface of the septum and the parenchyma. The vein (open 
arrow) is located within the parenchym . c. Photomicrograph (original magniﬁcati n, x400; H-E stain) shows details of the end-artery (dashed 
line), which is divided into numerous small capillaries that are connected to the sinusoids (straight arrows). Curved arrow = ductular proliferation. 
d. Photomicrograph (original magniﬁcation, x400; H-E stain) shows details of the vein (open arrow). Note that numerous sinusoids (straight 
arrows) drain into a venule and eventually into the vein.
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thickened (two or three cells in thickness) with normal-appearing hepatocytes. The central 
scar contains ﬁbrous connective tissue, cholangiolar proliferation with surrounding inﬂam-
matory inﬁltrates, and malformed vessels of various caliber, including tortuous arteries with 
thickened walls, capillaries, vascular channels of undetermined type, and veins3,6. The aﬀer-
ent artery branches into the hierarchy of vessels, and the smallest arteries supply the mono-
nuclear nodules of approximately 1 mm in diameter3,6. The arterial blood in FNH, as opposed 
to that in adenomas, ﬂows centrifugally from the anomalous central arteries. Approximately 
50% of lesions show some degree of fatty inﬁltration, as opposed to the surrounding liver, 
which shows signs of steatosis in less than 20% of classic FNH lesions. Both the classic and 
nonclassic types contain variable amounts of Kupﬀer cells (Figure 3)3,6.
Figure 3. Important tissue components of FNH as shown with speciﬁc histologic stains. a. Photomicrograph (original magniﬁcation, x100; 
elastica van Gieson stain) of a biopsy specimen shows the ﬁbrous septa (straight arrow) and hepatocytes of FNH, which contain steatosis (curved 
arrow). b. Photomicrograph (original magniﬁcation, x200; CD 34 stain) shows the epithelium of the arteries (straight solid arrow) and capillaries 
(curved arrow) fading into the sinusoids of FNH (open arrow). c. Photomicrograph (original magniﬁcation, x200; keratine 19 stain) shows ductular 
proliferation within a short septum of FNH (arrow). d. Photomicrograph (original magniﬁcation, x200; CD 68 stain) shows numerous Kupﬀer cells 
lining the sinusoids of FNH (arrows).
normal-appearing hepatocytes. The central scar contains fibrous connective tissue, cholangiolar 
proliferation with surrounding inflammatory infiltrates, and malformed vessels of various caliber, including 
tortuous arteries with thickened walls, capillaries, vascular channels of undetermined type, and veins3,6.
The afferent artery branches into the hierarchy of vessels, and the smallest arteries supply the 
mononuclear nodules of approximately 1 mm in diameter3,6. The arterial blood in FNH, as opposed to that 
in adenomas, flows centrifugally from the anomalous central arteries. Approximately 50% of lesions show 
some degree of fatty infiltration, as opposed to the surrounding liver, which shows signs of steatosis in 
less than 20% of classic FNH lesions. Both the classic and nonclassic types contain variable amounts of 
Kupffer cells (Figure 3)3,6.
Figure 3. Important tissue components of FNH as shown with specic histologic stains. a. Photomicrograph (original magnication,
x100; elastica v n Gieson stain) of a biopsy specimen shows the brous septa (straight a row) and hepatocytes of FNH, which 
contain steatosis (curved arrow). b. Photomicrograph (original magnication, x200; CD 34 stain) shows the epithelium of the arteries 
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Figure 4. Gross pathologic and histologic features of nonclassic FNH. a. Cross section of a xed resected specimen shows a 
nonclassic FNH (*). The lesion contains neither prominent septa nor a central scar. Normal liver tissue surrounds the FNH without a 
brous capsule. b. Photomicrograph (original magnication, x200; H-E stain) of the FNH shows a short septum containing a small 
amount of connective tissue and ductular proliferation. (Figure 3c shows ductular proliferation in the same slide.) c. Photomicrograph 
(original magnication, x200; H-E stain) of a specimen from another patient shows a small area of FNH containing monotonous 
hepatocytes (*), an appearance that resembles that of adenoma and suggests a mixed type of FNH. d. Photomicrograph (original 
magnication, x200; H-E stain) of a specimen from another patient shows telangiectatic FNH, which is composed of a relatively short 
septum (straight arrow) and atrophic hepatocytes with wider sinusoids than those normally present in classic FNH (curved arrow).
IMAGING OF FNH 
At imaging studies, typical and atypical lesions can often be distinguished on the basis of morphology, the 
appearance of the lesion relative to the surrounding liver on unenhanced images, the vascularity of the 
lesion, and the presence of any diffuse parenchymal liver disease8-10. US may often be the initial imaging 
modality that indicates a focal liver lesion. Typical FNH can be diagnosed by confidence at CT or MR 
imaging. Atypical FNH may appear as a large lesion, which is sometimes multiple in location. The tumor 
may show less intense enhancement, unusual appearance or nonenhancement of the central scar, and 
Figure 4. Gross pathologic and histologic features of nonclassic FNH. a. Cross secti n of a ﬁxed resected specimen shows a nonclassic 
FNH (*). The lesion contains neither prominent septa nor a central scar. Normal liver tissue surrounds the FNH without a ﬁbrous capsule. 
b. Photomicrograph (original m gniﬁcation, x200; H-E stain) of the FNH s a short septum contai ing a small amount of connective tissue 
and ductular proliferation. (Figure 3c shows ductular proliferation in the same slide.) c. Photomicrograph (original magniﬁcation, x200; H-E stain) 
of a specimen from another patient shows a s all area of FNH containing monotonous hepatocytes (*), an appearance that resembles that of 
adenoma and suggests a mixed type of FNH. d. Photomicrograph (original magniﬁcation, x200; H-E stain) of a specimen from another patient 
shows telangiectatic FNH, which is composed of a relatively short septum (straight arrow) and atrophic hepatocytes with wider sinusoids than 
those normally present in classic FNH (curved arrow).
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The gross appearance of nonclassic FNH is heterogeneous and globally resembles that of 
adenomas in most cases, with vaguely lobulated contours and lack of a microscopic central 
scar in almost all cases. The histologic features of nonclassic FNH depend on the subtype. 
The telangiectatic type consists on hepatic plates that are one cell thick and frequently ap-
pear atrophic. The plates are separated by dilated sinusoids. A few ﬁbrous septa, which are 
shorter than in classic FNH, can be found in all cases of telangiectatic FNH. The telangiectatic 
type always contains some degree of bile ductular proliferation. The mixed hyperplastic and 
adenomatous form of FNH has two alternating aspects: one resembling the telangiectatic 
type, the other simulating adenomas. FNH with cytologic atypia contains areas of large cell 
dysplasia. Except for the dysplastic areas, most of these lesions have the gross and histologic 
features of classic FNH (Figure 4).
IMAGING OF FNH
At imaging studies, typical and atypical lesions can often be distinguished on the basis of 
morphology, the appearance of the lesion relative to the surrounding liver on unenhanced 
images, the vascularity of the lesion, and the presence of any diﬀuse parenchymal liver dis-
ease8-10. US may often be the initial imaging modality that indicates a focal liver lesion. Typical 
FNH can be diagnosed by conﬁdence at CT or MR imaging. Atypical FNH may appear as a 
large lesion, which is sometimes multiple in location. The tumor may show less intense en-
hancement, unusual appearance or nonenhancement of the central scar, and pseudocapsular 
enhancement on delayed images. In these cases, it may be diﬃcult to diﬀerentiate atypical 
FNH from benign and malignant lesions such as hepatocellular adenoma, HCC, ﬁbrolamellar 
carcinoma, and hypervascular hepatic metastases.
ULTRASONOGRAPHY
At US, typical FNH is often not well visualized. There may be only a subtle change in echo-
genicity compared with the surrounding normal liver parenchyma. The conspicuity of the 
lesions at US may improve with a relatively large or prominent central scar8. The lesions 
may be slightly hypo-echoic, isoechoic, or slightly hyperechoic. Some lesions may show a 
hypoechoic halo surrounding the lesion. This halo most likely represents compressed hepatic 
parenchyma or vessels surrounding the lesion. The halo may be more prominent around FNH 
with fatty inﬁltration that is located within a liver with steatosis as well. In such cases, the 
compressed liver parenchyma surrounding the lesion is devoid of fat and has relatively low 
echogenicity compared with the liver and the lesion. The outer contours of the lesions may 
be well deﬁned, although the internal structure of FNH, including the central scar, is often not 
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well visualized (Figure 5). Use of color and power Doppler US may add information concern-
ing the vascularity of the suspected FNH. In addition, use of US contrast media to character-
ize FNH has been reported7,8. Despite these possibilities, US is currently not considered the 
modality of choice for characterization of focal liver lesions.
Figure 5. US appearance of FNH. a. Sagittal US scan shows FNH that is slightly hypoechoic relative to the surrounding liver tissue (arrows) and 
causes slight distortion of the outer liver contour. b. Sagittal oblique US scan of another patient shows FNH that is well diﬀerentiated from the 
surrounding liver tissue (arrow). There is a suggestion of radiating septa within the lesion. c. Axial US scan of another patient shows FNH that is 
profoundly hypoechoic (arrow) due to diﬀuse fatty inﬁltration of the surrounding liver tissue.
Figure 5. US appearance of FNH. a. Sagittal US scan shows FNH that is slightly hypoechoic relative to the surrounding liver tissue 
(arrows) and causes slight distortion of the outer liver contour. b. Sagittal oblique US scan f another patient shows FNH that is well 
differentiated from the surrounding liver tissue (arrow). There is a suggestion of radiating septa within the lesion. c. Axial US scan of 
another patient shows FNH that is profoundly hypoechoic (arrow) due to diffuse fatty inltration of the surrounding liver tissue. 
Computed Tomography 
The broad availability of CT as well as the recent development and implementation of the faster multirow 
detector machines make this modality an excellent tool for detection and characterization of focal liver 
lesions, including FNH9,10. Currently, multirow detector CT does allow triphasic or even multiphasic 
dynamic contrast material–enhanced imaging in relatively shorter scanning times. The shorter scanning 
times allow the capture of distinct phases, including the unenhanced phase, arterial phase, portal phase, 
and venous phase. These phases provide important information concerning the enhancement patterns 
and hence offer the possibility of characterizing focal liver lesions. In clinical practice, the number of 
phases that are usually imaged with CT is limited and often kept to a minimum, mainly due to the radiation 
Figure 5. US appearance of FNH. a. Sagittal US scan shows FNH that is slightly hypoechoic relative to the surrounding liver tissue 
(arrows) and causes slight distortion of the outer liver contour. b. Sagittal oblique US scan of another patient shows FNH that is well 
differentiated from the surrounding liver tissue (arrow). There is a suggestion of radiating septa within the lesion. c. Axial US scan of 
another patient shows FNH that is profoundly hypoechoic (arrow) due to diffuse fatty inltration of the surrounding liver tissue. 
Computed Tomography 
The broad availability of CT as well as the recent development and implementation of the faster multirow 
detector machines make this modality an excellent tool f r detection and characterization of focal liver 
lesions, including FNH9,10. Currently, multirow d tector CT does allow tripha ic or even multiphasic 
dynamic contrast material–enhanced imaging in relatively shorter scanning times. The shorter scanning 
times allow the capture of distinct phases, including the unenhanced phase, arterial phase, portal phase, 
and venous phase. These phases provide important information concerning the enhancement patterns 
and hence offer the possibility of characterizing focal liver lesions. In clinical practice, the number of 
phases that are usually imaged with CT is limited and often kept to a minimum, mainly due to the radiation 
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COMPUTED TOMOGRAPHY
The broad availability of CT as well as the recent development and implementation of the 
faster multirow detector machines make this modality an excellent tool for detection and 
characterization of focal liver lesions, including FNH9,10. Currently, multirow detector CT 
does allow triphasic or even multiphasic dynamic contrast material–enhanced imaging in 
relatively shorter scanning times. The shorter scanning times allow the capture of distinct 
phases, including the unenhanced phase, arterial phase, portal phase, and venous phase. 
These phases provide important information concerning the enhancement patterns and 
hence oﬀer the possibility of characterizing focal liver lesions. In clinical practice, the number 
of phases that are usually imaged with CT is limited and often kept to a minimum, mainly 
due to the radiation hazard. The issue of radiation is even more important in relatively young 
and otherwise healthy patients with an incidental liver lesion that needs characterization or 
follow-up, such as FNH.
Typical FNH may have lobulated contours at CT8-10. At unenhanced CT, the lesions are ei-
ther hypoattenuating or isoattenuating to the surrounding liver. In the arterial phase, the 
lesions become hyperattenuating due to the homogeneous intense enhancement of the 
entire lesion, except the central scar. In the portal and later phases, the lesions become more 
isoattenuating with the surrounding liver and the central scar may show some enhancement 
(Figure 6).
MR IMAGING
MR imaging has higher sensitivity (70%) and speciﬁcity (98%) for FNH than US and CT10. The 
central scar was more often detected with MR imaging than with CT (78% and 60%, respec-
tively). The higher sensitivity and speciﬁcity of MR imaging may be due to the fact that state-
of-the-art MR imaging provides information concerning the soft-tissue characteristics as well 
as the vascularity of the lesions. In addition, on the basis of the physical principles, MR imaging 
provides a number of unique possibilities concerning the technique of data acquisition and 
contrast medium administration11-13. First, in most centers, dynamic gadolinium-enhanced MR 
imaging is currently performed with multisection two-dimensional (2D) or three-dimensional 
(3D) gradient-echo (GRE) sequences. With such sequences, the central k-space proﬁles, which 
determine the image contrast in all individual sections, are acquired in less than half the total 
duration of one breath-hold sequence (5 seconds). Second, fast MR imaging sequences allow 
use of a timing bolus, automated contrast detection techniques, and time-resolved scanning 
to determine the contrast material arrival time within the aorta. Finally, in MR imaging, a small 
amount of contrast medium (15-20 mL of gadolinium contrast material) is injected. This al-
lows a short injection time with a compact bolus. This facilitates the imaging of truly distinct 
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hazard. The issue of radiation is even more important in relatively young and otherwise healthy patients 
with an incidental liver lesion that needs characterization or follow-up, such as FNH. 
Typical FNH may have lobulated contours at CT8-10. At unenhanced CT, the lesions are either 
hypoattenuating or isoattenuating to the surrounding liver. In the arterial phase, the lesions become 
hyperattenuating due to the homogeneous intense enhancement of the entire lesion, except the central 
scar. In the portal and later phases, the lesions become more isoattenuating with the surrounding liver and 
the central scar may show some enhancement (Figure 6). 
Figure 6. CT appearance of typical FNH with pathologic correlation. a. Precontrast CT image shows a large lesion (straight arrow) 
that is only slightly hypoattenuating relative to the surrounding liver tissue. Within the lesion, a central scar (curved arrow) can be 
seen. b. Contrast-enhanced CT image obtained during the arterial phase shows intense homogeneous enhancement of the lesion 
(straight arrow), except for the central scar (curved arrow). c. Contrast-enhanced CT image obtained during the portal phase shows 
that the lesion (straight arrow) has become isoattenuating relative to the liver. The central scar (curved arrow) has not yet fully 
Figure 6. CT appearance of typical FNH with pathologic correlation. a. Precontrast CT image shows a large lesion (straight arrow) that is only 
slightly hypoattenuating relative to the surrounding liver tissue. Within the lesion, a central scar (curved arrow) can be seen. b. Contrast-enhanced 
CT image obtained during the arterial phase shows intense homogeneous enhancement of the lesion (straight arrow), except for the central scar 
(curved arrow). c. Contrast-enhanced CT image obtained during the portal phase shows that the lesion (straight arrow) has become isoattenuating 
relative to the liver. The central scar (curved arrow) has not yet fully enhanced. d. Photomicrograph (original magniﬁcation, x200; H-E stain) 
of a biopsy specimen shows classic FNH composed of nodules (*) surrounded by septa (straight arrow), which contain ductular proliferation, 
inﬂammatory inﬁltrates, connective tissue, and large vessels (curved arrow).
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phases in dynamic contrast-enhanced MR imaging of the entire liver. Lack of radiation allows 
multiphasic gadolinium-enhanced MR imaging in combination with multiple other sequences 
that facilitate detection and characterization of diﬀuse and focal liver lesions.
Typically, FNH is iso-or hypointense on T1-weighted images (94%–100%), is slightly hyper- or 
isointense on T2-weighted images (94%–100%), and has a hyperintense central scar on T2-
weighted images (84%)10. FNH shows intense homogeneous enhancement in the arterial phase 
and enhancement of the central scar in the later phases of gadolinium-enhanced imaging (Fig-
ure 7). Hepatocellular adenomas show less intense enhancement and lack a central scar.
Figure 7. MR imaging appearance of typical FNH. a. Axial T2-weighted single-shot fast spin-echo (SE) image shows a large FNH 
lesion (straight arrow) that is isointense relative to the surrounding liver parenchyma. The central scar (curved arrow) has slightly 
higher signal intensity than the lesion. b. Axial gadolinium-enhanced 2D T1-weighted GRE image obtained during the arterial phase 
shows intense homogeneous enhancement of the entire lesion (straight arrow), except for the central scar (curved arrow). c. Axial 
gadolinium-enhanced 2D T1-weighted GRE image obtained during the portal phase shows that the lesion (straight arrow) has 
become isointense relative to the surrounding liver parenchyma, and the central scar (curved arrow) has enhanced. 
Specic contrast media such as superparamagnetic iron oxide–based (eg, ferucarbotran [Resovist; 
Schering, Berlin, Germany]) and manganese-based (ie, mangafodipir trisodium [Tesla-scan; Nycomed 
Amersham, Oslo, Norway]) media are targeted at the Kupffer cells and hepatocytes, respectively12-15.
These contrast media can be used to demonstrate the hepatocellular origin of the lesions. The Kupffer 
cells show uptake of ferucarbotran and lower the signal intensity of the lesions as well as the surrounding 
liver on T2- and T2*-weighted images (Figure 8). 
Figure 7. MR imaging appearance of typical FNH. a. Axial T2-weighted sin le-shot fast spin-echo (SE) mage shows a large FNH lesion (st aight 
arrow) that is isointense relative to the surrounding liver parenchyma. The central scar (curved arrow) has slightly higher signal intensity than the 
lesi n. b. Axial gad linium- nhanced 2D T1-w ighted GRE image obtained during the arterial phase shows intense homogeneous enhancement 
of the entire lesion (straight arrow), except for the central scar (curved arrow). c. Axial gadolinium-enhanced 2D T1-weighted GRE image obtained 
during the portal phase shows that the lesion (straight arrow) has become isointense relative to the surrounding liver parenchyma, and the 
central scar (curved arrow) has enhanced.
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Speciﬁc contrast media such as superparamagnetic iron oxide–based (eg, ferucarbotran 
[Resovist; Schering, Berlin, Germany]) and manganese-based (ie, mangafodipir trisodium 
[Tesla-scan; Nycomed Amersham, Oslo, Norway]) media are targeted at the Kupﬀer cells and 
hepatocytes, respectively12-15. These contrast media can be used to demonstrate the hepato-
cellular origin of the lesions. The Kupﬀer cells show uptake of ferucarbotran and lower the 
signal intensity of the lesions as well as the surrounding liver on T2- and T2*-weighted images 
(Figure 8).
Figure 8. Appearance of typical FNH at superparamagnetic iron oxide (ferucarbotran)–enhanced MR imaging. a. Axial unenhanced 
T2-weighted fast SE image shows a large FNH lesion (straight arrow) that is isointense relative to the surrounding liver parenchyma. 
The central scar (curved arrow) has slightly higher signal intensity than the lesion. b. Axial contrast-enhanced fast SE image shows 
that the lesion (straight arrow) as well as the liver and spleen have decreased signal intensity due to the uptake of ferucarbotran into 
Kupffer cells. The central scar (curved arrow) does not contain Kupffer cells and has relatively increased signal intensity. 
Figure 9. MR imaging appearance of multiple FNH lesions. a. Axial gadolinium-enhanced fat-saturated 3D fast GRE image obtained 
during the arterial phase shows intense homogeneous enhancement of two lesions (arrows). This nding is compatible with FNH. b.
Photomicrograph (original magnication, x200; H-E stain) of a biopsy specimen from one of the lesions shows classic FNH 
composed of nodules (*) with fatty inltration (open arrow). Septa (curved arrow) surround the nodules and contain ductular 
proliferation, inammatory inltrates, connective tissue, and vessels. 
Multiple FNH lesions occur in approximately 20%–25% of patients with FNH (Figure 9)6. Multiple FNH 
lesions are more often of the non-classic type and may contain atypical features at imaging. In addition, 
multiple FNH lesions can be associated with other benign lesions, such as cysts, hemangiomas, and 
adenomas. Distinction from multiple adenomas and multifocal HCC, particularly in noncirrhotic livers, may 
be challenging (Figure 10)12,13,16.
Figure 8. Appearance of typical FNH at superparamagnetic iron oxide (ferucarbotran)–enhanced MR imaging. a. Axial unenhanced T2-weighted 
fast SE image shows a large FNH lesion (straight arrow) that is isointense relative to t e surrou ding liver pare chyma. T e central scar (curved 
arrow) has slightly higher signal intensity than the lesion. b. Axial contrast-enhanced fast SE image shows that the lesion (straight arrow) as well 
as the liver and spleen have decreased signal intensity due to the uptake of ferucarbotran into Kupﬀer cells. The central scar (curved arrow) does 
not contain Kupﬀer cells and has relatively increased signal intensity.
Figure 8. Appearance of typical FNH at superparamagnetic iron oxide (ferucarbotran)–enhanced MR imaging. a. Axial unenhanced 
T2-weighted fast SE image shows a large FNH lesion (straight arrow) that is isointense relative to the surrounding liver parenchyma. 
The central scar (curved arrow) has slightly higher signal intensity than the lesion. b. Axial contrast-enhanced fast SE image shows 
that the lesion (straight arrow) as well as the liver and spleen have decreased signal intensity due to the uptake of ferucarbotran into 
Kupffer cells. The central scar (curved arrow) does not contain Kupffer cells and has relatively increased signal intensity. 
Figure 9. MR im ging appearance of multiple FNH l sions. a. Axial gadolinium-enha ced fat-saturated 3D fast GRE im ge obtained 
during the arterial phase shows intense homogeneous enhancement of two lesions (arrows). This nding is compatible with FNH. b.
Photomicrograph (original magnication, x200; H-E stain) of a biopsy specimen from one of the lesions shows classic FNH 
composed of nodules (*) with fatty inltration (open arrow). Septa (curved arrow) surround the nodules and contain ductular 
proliferation, inammatory inltrates, connective tissue, and vessels. 
Multiple FNH lesions occur in approximately 20%–25% of patients with FNH (Figure 9)6. Multiple FNH 
lesions are more often of the non-classic type and may contain atypical features at imaging. In addition, 
ultiple  lesions can be associated with other benign lesions, such as cysts, hemangiomas, and 
. istinction from multiple adenomas and multifocal HCC, particularly in no cirrhotic livers, may
ll ing (Figure 10)12,13,16.
Figure 9. MR imaging ppearance of multiple FNH lesi ns. a. Axial gadolinium-enhanced fat-saturated 3D fast GRE image obtained during 
the arterial phase shows intense homogeneous enhancement of two lesions (arrows). This ﬁnding is compatible with FNH. b. Photomicrograph 
(o ig nal magn ﬁc tion, x200; H-E stain) of a biopsy specimen from on  of the lesions shows classic FNH composed of nodules (*) with fatty 
inﬁltration (open arrow). Septa (curved arrow) surround the nodules and contain ductular proliferation, inﬂammatory inﬁltrates, connective 
tissue, and vessels.
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Figure 10. MR imaging appearance of multiple HCCs in a noncirrhotic liver. a. Axial gadolinium-enhanced fat-saturated 3D GRE 
image obtained during the arterial phase showes heterogeneous enhancement of two lesions (arrows). b. Photomicrograph (original 
magnification, x 100; H-E stain) of a resected specimen from the larger lesion shows an HCC (*) surrounded by a fibrous tumor 
capsule (arrow). 
FNH does not have a tumor capsule, although the pseudocapsule surrounding some FNH lesions may be 
quite prominent. The pseudocapsule of FNH results from compression of the surrounding liver 
parenchyma by the FNH, perilesion vessels, and inammatory reaction (Figures 1b, 4a). The 
pseudocapsule is usually a few millimeters thick and typically shows high signal intensity on T2-weighted 
images. The pseudocapsule may show enhancement on delayed contrast-enhanced images (Figure 11). 
A tumor capsule is a characteristic sign of HCC and is present in 60%–80% of cases12. This capsule 
mainly consists of brosis and has low signal intensity on both T1- and T2-weighted images; it shows 
persistent enhancement on delayed contrast-enhanced images (Figure 12). 
Figur  10. MR imaging app arance of multiple HCCs in a noncirrhotic liver. a. Axial gadolinium-enhanced fat-saturated 3D GRE ma e obtained 
during the arterial phase showes heterogeneous enhancement of two lesions (arrows). b. Photomicrograph (original magniﬁcation, x 100; H-E 
stain) of a resected specimen from the larger lesion shows an HCC (*) surrounded by a ﬁbrous tumor capsule (arrow).
Figure 11. MR imaging appearance of an FNH lesion with a prominent pseudocapsule. a. Axial fat-saturated T2-weighted fast SE image shows 
a medium-sized FNH lesion (arrow) with a central scar, a pseudocapsule, and septa, all of which are prominent and have high signal intensity. b. 
Axial gadolinium-enhanced 3D GRE image obtained during the arterial phase shows intense homogeneous enhancement of the lesion (arrow), 
except for the central scar and septa. c. Axial gadolinium-enhanced 3D GRE image obtained during the delayed phase shows enhancement of the 
central scar as well as the pseudocapsule (arrow).
Figure 11. MR imaging appearance of an FNH lesion with a prominent pseudocapsule. a. Axial fat-saturated T2-weighted fast SE 
image shows a medium-sized FNH lesion (arrow) with a central scar, a pseudocapsule, and septa, all of which are prominent and 
have high signal intensity. b. Axial gadolinium-enhanced 3D GRE image obtained during the arterial phase shows intense 
homogeneo s en ment of the lesion (arrow), except for the central scar and septa. c. Axial gadoli ium-enhanced 3D GRE 
image obtained during the delayed phase shows enhancement of the central scar as well as the pseudocapsule (arrow). 
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Multiple FNH lesions occur in approximately 20%–25% of patients with FNH (Figure 9)6. Mul-
tiple FNH lesions are more often of the non-classic type and may contain atypical features at 
imaging. In addition, multiple FNH lesions can be associated with other benign lesions, such 
as cysts, hemangiomas, and adenomas. Distinction from multiple adenomas and multifocal 
HCC, particularly in noncirrhotic livers, may be challenging (Figure 10)12,13,16.
FNH does not have a tumor capsule, although the pseudocapsule surrounding some FNH 
lesions may be quite prominent. The pseudocapsule of FNH results from compression of the 
surrounding liver parenchyma by the FNH, perilesion vessels, and inﬂammatory reaction 
(Figures 1b, 4a). The pseudocapsule is usually a few millimeters thick and typically shows 
high signal intensity on T2-weighted images. The pseudocapsule may show enhancement 
on delayed contrast-enhanced images (Figure 11). A tumor capsule is a characteristic sign 
of HCC and is present in 60%–80% of cases12. This capsule mainly consists of ﬁbrosis and has 
low signal intensity on both T1- and T2-weighted images; it shows persistent enhancement 
on delayed contrast-enhanced images (Figure 12).
Figure 12. MR imaging appearance of an HCC with a tumor capsule in a noncirrhotic liver. a. Axial fat-saturated T2-weighted fast SE image shows 
an HCC with predominantly high signal intensity (arrow). Owing to its ﬁbrotic nature, the tumor capsule has low signal intensity on T2-weighted 
images and therefore is not visible. b. Axial gadolinium-enhanced 3D GRE image obtained during the arterial phase shows intense, nearly 
homogeneous enhancement of the lesion (arrow). This appearance may simulate FNH. c. Axial gadolinium-enhanced 3D GRE image obtained 
during the delayed phase shows enhancement of the tumor capsule surrounding the lesion (arrow), which demonstrates complete washout.
Figure 12. MR imaging appearance of an HCC with a tumor capsule in a noncirrhotic liver. a. Axial fat-saturated T2-weighted fast SE 
image shows an HCC with predominantly high signal intensity (arrow). Owing to its brotic nature, the tumor capsule has low signal 
i tensity on T2-weighted images a d therefore is not visible. . Axi l gadolini -enhanced 3D GRE image obtained during the 
arterial phase shows intense, nearly homogeneous enhancement of the lesion (arrow). This appearance may simulate FNH. c. Axial 
gadolinium-enhanced 3D GRE image obtained during the delayed phase shows enhancement of the tumor capsule surrounding the 
lesion (arrow), which d monstrat  complete washout. 
A central scar is present at imaging in most patients with FNH10,13. The amount of scar tissue within FNH 
and the size of the central scar may vary. The central scar is typically high in signal intensity on T2-
weighted images and low in signal intensity on T1-weighted images. It shows visible enhancement on 
delayed contrast-enhanced images (Figure 13). High signal intensity of the central scar may be caused by 
the inammatory reaction round the ductular proliferation as wel  as the vessels within the septa and 
central scar. The central scar is not a specic nding of FNH and can be seen in a variety of other focal 
liver lesions such as giant hemangiomas (Figure 14) and HCCs (Figure 15). The central scar in giant 
hemangiomas is typically larger and brighter on T2-weighted images. In addition, the lesions have 
homogeneous high signal intensity on T2-weighted images and show peripheral odular enhancement in 
most cases. Some HCCs may contain a central scar. Owing to the presence of scar tissue, calcications, 
or necrosis, the central scar in HCC shows low signal intensity on T2- and T1-weighted images and does 
not enhance much on contrast-enhanced images. Although HCCs occur in noncirrhotic livers, the lesions 
show quit  a different type of enhancem nt than FNH (Figure 15). 
Figure 11. MR imaging appearance of an FNH lesion with a prominent pseudocapsule. a. Axial fat-saturated T2-weighted fast SE 
image shows a medium-sized FNH lesion (arrow) with a central scar, a pseudocapsule, and septa, all of which are prominent and 
have high signal intensity. b. Axial gadolinium-enhanced 3D GRE image obtained during the arterial phase shows intense 
homogeneous enhancement of the lesion (arrow), except for the central scar and septa. c. Axial gadolinium-enhanced 3D GRE 
image obtained during the delayed phase shows enhancement of the central scar as well as the pseudocapsule (arrow). 
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A central scar is present at imaging in most patients with FNH10,13. The amount of scar tis-
sue within FNH and the size of the central scar may vary. The central scar is typically high in 
signal intensity on T2-weighted images and low in signal intensity on T1-weighted images. 
It shows visible enhancement on delayed contrast-enhanced images (Figure 13). High signal 
intensity of the central scar may be caused by the inﬂammatory reaction around the ductular 
proliferation as well as the vessels within the septa and central scar. The central scar is not a 
speciﬁc ﬁnding of FNH and can be seen in a variety of other focal liver lesions such as giant 
hemangiomas (Figure 14) and HCCs (Figure 15). The central scar in giant hemangiomas is 
typically larger and brighter on T2-weighted images. In addition, the lesions have homoge-
neous high signal intensity on T2-weighted images and show peripheral nodular enhance-
ment in most cases. Some HCCs may contain a central scar. Owing to the presence of scar 
tissue, calciﬁcations, or necrosis, the central scar in HCC shows low signal intensity on T2- and 
T1-weighted images and does not enhance much on contrast-enhanced images. Although 
HCCs occur in noncirrhotic livers, the lesions show quite a diﬀerent type of enhancement 
than FNH (Figure 15).
Rarely, FNH may show more than one atypical feature at MR imaging and cause diﬃculty in 
diagnosis. Such lesions may have exceptionally high signal intensity on T2-weighted images 
with a suggestion of lamellae, a central scar with low signal intensity on T2-weighted images, 
a prominent pseudocapsule, and incomplete intense enhancement of the lesion (Figure 
16). In such cases, application of a speciﬁc type of contrast medium, such as ferucarbotran 
or mangafodipir trisodium, may demonstrate the hepatocellular origin of the lesion. When 
there is homogeneous uptake of such an agent in combination with a normal α-fetoprotein 
level and normal results at viral serologic analysis, the patient may be safely followed up with 
imaging. If any doubt remains, one or more biopsies should be performed within the lesion 
as well as the surrounding liver to exclude malignancies, such as ﬁbrolamellar carcinoma and 
HCC in a noncirrhotic liver12-18.
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Figure 13. MR imaging appearance of an FNH lesion with a prominent central scar. a. Axial fat-saturated T2-weighted fast SE image 
shows a large FNH lesion with a prominent central scar (arrow), which has high signal intensity. A pseudocapsule is not visible. b.
Axial gadolinium-enhanced fat-saturated 2D T1-weighted GRE image obtained during the delayed phase shows that the lesion has 
become isointense relative to the liver and the central scar has enhanced (arrow). 
Figure 14. MR imaging of a giant hemangioma with a prominent central scar. a. Axial fat-saturated T2-weighted fast SE image 
shows a high-signal-intensity giant hemangioma (straight arrow) with a prominent central scar (curved arrow), which has even higher
signal intensity than the lesion. Note the smaller hemangioma without a central scar. b. On an axial gadolinium-enhanced fat-
saturated 3D GRE image obtained during the delayed phase, the smaller lesion (arrow) has completely filled in, whereas the central 
scar within the larger lesion has not enhanced. 
Figure 13. MR imaging appearance of an FNH lesion with a prominent central scar. a. Axial fat-saturated T2-weighted fast SE image shows 
a large FNH lesion with a prominent central scar (arrow), which has high signal intensity. A pseudocapsule is not visible. b. Axial gadolinium-
enhanced fat-saturated 2D T1-weighted GRE image obtained during the delayed phase shows that the lesion has become isointense relative to 
the liver and the central scar has enhanced (arrow).
Figure 14. MR imaging of a giant hemangioma with a prominent central scar. a. Axial fat-saturated T2-weighted fast SE image shows a high-
signal-intensity giant hemangioma (straight arrow) with a promi ent central scar (curved a row), which has eve  higher signa  i tensity than the
lesion. Note the smaller hemangioma without a central scar. b. On an axial gadolinium-enhanced fat-saturated 3D GRE image obtained during 
the delayed phase, the smaller lesion (arrow) has completely ﬁlled in, whereas the central scar within the larger lesion has not enhanced.
Figure 15. MR imaging appearance of an HCC with a central scar in a patient who was not cirrhotic but who had extremely high levels of 
α-fetoprotein. a. Axial fat-saturated T2-weighted fast SE image shows a predominantly high-signal-intensity lesion (arrow) with a low-signal-
intensity central scar. b. Axial gadolinium-enhanced fat-saturated 2D T1-weighted GRE image obtained during the delayed phase shows washout 
of contrast material in most of the lesion and an enhanced tumor capsule (arrow). The central scar remains mainly unenhanced.
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Figure 16. MR imaging appearance of an FNH lesion with a low-signal-intensity scar and a pseudocapsule. a. Axial fat-saturated T2-weighted 
fast SE image shows a predominantly high-signal-intensity FNH lesion with a spinning wheel appearance due to the presence of radiating septa 
and a pseudocapsule (arrow). b. Axial gadolinium-enhanced fat-saturated 3D GRE image obtained during the arterial phase shows intense 
enhancement of most of the central part of the lesion (arrow). c. Axial gadolinium-enhanced fat-saturated 3D GRE image obtained during 
the portal phase shows nearly homogeneous enhancement of the lesion, including the pseudocapsule (arrow). The lesion has becomes nearly 
isointense relative to the surrounding liver tissue. d. Axial T2-weighted fast SE image and corresponding photograph of an orange show a striking 
similarity to the FNH lesion.
Figure 16. MR imaging appearance of an FNH lesion with a low-signal-intensity scar and a pseudocapsule. a. Axial fat-saturated T2-
weighted fast SE image shows a predominantly high-signal-intensity FNH lesion with a spinning wheel appearance due to the 
presence of radiating septa and a pseudocapsule (arrow). b. Axial gadoli ium- nhanc d fat-s turated 3D GRE image obtained 
during the arterial phase shows intense enhancement of most of the central part of the lesion (arrow). c. Axial gadolinium-enhanced 
fat-saturated 3D GRE image obtained during the portal phase shows nearly homogeneous enhancement of the lesion, including the 
pseudocapsule (arrow). The lesion has becomes nearly isointense relative to the surrounding liver tissue. d. Axial T2-weighted fast 
SE im ge and correspondin  photogr ph of an orange show a s riking similarity to the FNH lesion. 
DISCUSSION AND CONCLUSIONS 
This article presents the most recent pathologic classification of FNH, its gross appearance, and its 
histologic features. Currently, FNH is divided into two types, classic (80%) and nonclassic (20%)6. Classic 
FNH contains all of the components, including an abnormal nodular architecture, malformed vessels, and 
cholangiolar proliferation. The nonclassic type contains two of the three components but always shows 
bile ductular proliferation6.
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DISCUSSION AND CONCLUSIONS
This article presents the most recent pathologic classiﬁcation of FNH, its gross appearance, 
and its histologic features. Currently, FNH is divided into two types, classic (80%) and non-
classic (20%)6. Classic FNH contains all of the components, including an abnormal nodular 
architecture, malformed vessels, and cholangiolar proliferation. The nonclassic type contains 
two of the three components but always shows bile ductular proliferation6.
In addition, the results of recent studies reveal a typical angioarchitecture for FNH. Typi-
cally, FNH contains one or more thick-walled, large arteries that run within the ﬁbrous septa 
and divide into numerous capillaries that are connected to the sinusoids. Relatively large 
veins drain blood from the sinusoids toward the hepatic vein. FNH does not contain portal 
veins. The delayed enhancement of the central scar at CT and MR imaging relates to increased 
interstitial space and ﬂuid content with slow diﬀusion of contrast material into this space.
The imaging modalities, particularly CT and MR imaging, make use of the abundant vascu-
larity of FNH. On the basis of the vascularity as well as the tissue characteristics, MR imaging 
allows reliable distinction of FNH from other focal liver lesions in most cases. In fact, since the 
introduction of state-of-the-art MR imaging at our hospital in 1999, FNH has been diagnosed 
noninvasively. Diagnoses of typical FNH are conﬁrmed with at least one follow-up MR imag-
ing examination at 6–12 months. Atypical cases undergo additional imaging with speciﬁc 
contrast media to rule out malignancy. Before 1999, most patients underwent US-guided 
biopsies of focal liver lesions, including FNH, at our institution. US was often used for guid-
ance of the biopsy and not for noninvasive diagnostic imaging.
MR imaging is an ideal imaging modality for work-up of lesions in relatively young women 
suspected of having FNH because radiation and iodine-based contrast media are not used. 
Based on our experience, this article demonstrates the full spectrum of ﬁndings of FNH at 
state-of-the-art MR imaging.
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Focal nodular hyperplasia: Lesion characteristics at state-of-the-art MR imaging in-
cluding dynamic gadolinium-enhanced and superparamagnetic iron-oxide-uptake 
sequences in a prospective cohort study.
T Terkivatan, IC van den Bos, SM Hussain, PA Wielopolski, RA de Man, JNM IJzermans.
Accepted for publication in Journal of Magnetic Resonance Imaging.
Focal nodular hyperplasia 115
FOCAL NODULAR HYPERPLASIA: LESION CHARACTERISTICS AT STATE-
OF-THE-ART MAGNETIC RESONANCE IMAGING INCLUDING DYNAMIC 
GADOLINIUM-ENHANCED AND SUPERPARAMAGNETIC IRON-OXIDE-UPTAKE 
SEQUENCES IN A PROSPECTIVE COHORT STUDY
ABSTRACT
Purpose: To image a cohort of patients with pathology-proven focal nodular hyperplasia 
(FNH) in order to assess which of the characteristics on state-of-the-art magnetic resonance 
(MR) imaging of the liver are most useful for improved detection and characterization of 
FNH.
Materials and Methods: In fourteen patients, pathology-proven FNH (n=33) were prospec-
tively examined with the state-of-the-art MR imaging using Gadolinium (Gd) and superpara-
magnetic iron-oxide (SPIO) contrast media. All lesions were evaluated for signal intensity, 
fatty inﬁltration, central scar, mode of enhancement with Gadolinium and uptake of SPIO. 
Percentages of dynamic contrast-enhancement in arterial, portal and delayed phases were 
assessed. Contrast-to-noise ratio (CNR) before and after administration of SPIO contrast was 
calculated.
Results: Signal intensity of the lesions was intermediate to isointense on T2-weighted and 
low to isointense on T1-weighted imaging. Fatty inﬁltration of the lesion was present in 6%. 
Percentage of enhancement in liver and lesion respectively were 110, 115 and 95% and 151, 
182 and 160% (p<0.0001). All lesions showed uptake of SPIO with improved conspicuity of 
central scar and septa. The CNR values pre-contrast and post-Gd/SPIO were signiﬁcantly dif-
ferent for T1 in- and opposed-phase black-blood echo planar imaging.
Conclusion: Combination of dynamic Gd-enhanced imaging with T1- and T2-weighted se-
quences after administration of SPIO facilitates comprehensive evaluation of FNH.
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INTRODUCTION
Although focal nodular hyperplasia (FNH) of the liver is a well-described lesion in literature, 
considerable diagnostic problems regarding this lesion still remain. Given the fact that FNH 
is the second most common benign liver tumor after hemangioma and has a reported preva-
lence of approximately 1%1, deﬁnitive distinction between this benign liver lesion and other 
benign and malignant hepatic masses is a common dilemma. Since FNH is usually observed 
in young to middle-aged women and most often is asymptomatic, the main goal of imaging 
in these patients is to ﬁrmly establish the diagnosis in order to avoid unnecessary biopsy or 
surgical resection and to suggest a conservative approach to therapy2,3.
Since morphology and radiological enhancement patterns of a FNH is strongly determined 
by its histological composition, it is important to realize that this lesion is divided into two 
types: classic and non-classic1. According to one large pathology study, the non-classic type 
contains three subtypes (a) teleangiectatic FNH, (b) FNH with cytologic atypia, and (c) mixed 
hyperplastic and adenomatous FNH. More recently, a study based on DNA micro-array analy-
sis suggested that teleangiectatic FNH had more similarities with hepatocellular adenomas 
than with FNH4. Classic FNH is characterized by the presence of (a) abnormal nodular archi-
tecture, (b) malformed vessels, and (c) cholangiolar proliferation. Nonclassic FNH lack one of 
the following classic features – nodular abnormal architecture or malformed vessels – but 
always show bile duct proliferation.
Typical magnetic resonance (MR) imaging features of FNH – that is iso- or hypointensity on 
T1-weighted images, slight hyper- or isointensity on T2-weighted images, and a hyperintense 
central scar on T2-weighted images – are seen in up to 84-100% of these lesions (Figure 1)5,6. 
However, in our experience these imaging features alone are not diagnostic for FNH and have 
been observed in a number of benign and malignant lesions7,8.
Dynamic Gadolinium (Gd)-enhanced MR imaging enables evaluation of the hemokinetics 
of contrast distribution during the ﬁrst few minutes after injection. Related to the hyper-
vascularity of the tumor, during the arterial phase of hepatic enhancement, FNH typically 
shows an immediate and intense enhancement, with the exception of the central scar, which 
has delayed enhancement caused by the presence of abundant ﬁbrous stroma (Figure 1)9,10. 
During portal or delayed venous phases the hyperintensity of the tumor fades, which results 
in an isointense lesion with gradual diﬀusion of the contrast material into the ﬁbrous central 
scar. On delayed phase imaging, the central scar shows high signal intensity because of the 
accumulation of contrast material.
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Figure 1. State-of-the-art MR imaging of classical FNH; signal intensity, enhancement patterns and uptake of SPIO. A. Fat-suppressed T2-
weighted fast spin-echo (FSE): large, well circumscribed FNH in the left liver lobe, just slightly hyperintense to the liver, with a faint hyperintense 
septa. B. Black-blood T2-weighted echo planar imaging (BBEPI): hyperintense signal intensity, with hyperintensity of central scar and septa. 
C. Single-shot T2-weighted fast spin-echo (SSFSE): the lesion is isointense with the liver. D. Opposed-phase T1-weighted gradient echo (GRE): 
the lesion is isointense, with hypointense central scar, septa and pseudocapsule composed of compressed vessels. E. Arterial phase Gadolinium 
(Gd)-enhanced T1-weighted GRE: immediate, homogeneous enhancement with sparing of central scar and septa. F. Delayed phase Gd-enhanced 
3D T1-weighted GRE: the signal intensity has faded to isointensity with the liver, with faint delayed enhancement of central scar, septa and 
pseudocapsule. G. Post-SPIO fat-suppressed T2-weighted fast spin-echo (FSE): the liver and spleen have dropped in signal intensity after SPIO. The 
lesion is hyperintense, with slightly improved conspicuity of central scar and septa. H. Post-SPIO diﬀusion T2-weighted black-blood echo planar 
imaging (BBEPI): better conspicuity of central scar and septa, with high signal intensity. I. Post-SPIO opposed-phase T1-weighted gradient echo 
(GRE): high signal of central scar and septa, especially when compared to delayed phase 3D dynamic Gd-enhanced imaging (F).
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Atypically, FNH may present as large lesions, sometimes with multiple localization5. Rare im-
aging features include nonvisualization or nonenhancement of the central scar, and pseudo-
capsular enhancement on delayed images9. In these cases it may be diﬃcult to diﬀerentiate 
an atypical FNH from other benign and malignant hypervascular liver lesions such as hepato-
cellular adenoma (HCA), hepatocellular carcinoma (HCC) and hypervascular metastases11-13.
Previous studies have described imaging features of FNH using both non-speciﬁc and 
speciﬁc contrast agents such as manganodipir14 and superparamagnetic iron-oxide (SPIO) 
particles. In a few studies, uptake of SPIO and imaging characteristics of FNH were assessed 
using conventional MR sequences15-19. To our knowledge, none of the previous studies have 
evaluated lesion characteristics of pathology-proved FNH using both dynamic Gd-enhanced 
imaging and multiple T1- and T2-weighted sequences after Gd/SPIO.
At our institute, we apply a state-of-the-art comprehensive MR imaging, which provides 
information concerning the soft tissue characteristics of the lesion besides the vascularity 
of the lesion at Gd-enhanced multi-phasic dynamic imaging. In addition, in selected cases 
speciﬁc MR imaging contrast agents such as SPIO particles can provide information concern-
ing the primary nature of the lesion20,21.
The purpose of our prospective study was to image a cohort of patients with pathology-
proven FNH in order to assess which of the characteristics derived from the state-of-the-
art comprehensive MR imaging of the liver (including T1-weighted imaging, T2-weighted 
imaging with short and long TE-values, dynamic Gd-enhanced, multi-phasic imaging, and 
imaging after SPIO-uptake) would be most useful in the future for improved detection and 
characterization of FNH.
MATERIALS AND METHODS
Patients
The study was performed in a tertiary referral center with a large experience in hepatobiliary 
surgery and transplantation. Liver pathology reports of percutaneous needle biopsies that 
were performed between 1990 and 2003 were reviewed for the diagnosis of FNH. These data 
were matched with the hospital database to retrieve patients who were managed conserva-
tively by observation of the lesion. Fifty-one patients had been evaluated for therapy by a 
hepatobiliary surgeon. In none of these patients a surgical treatment was indicated because 
of the absence of complaints. All of these 51 patients were contacted to take part in this 
prospective cohort study with the state-of-the-art MR imaging. Of those patients, 14 replied 
and provided informed consent. Approval for the study was granted by the local ethics com-
mittee.
A total of 33 lesions were detected in 14 patients. All patients were women with a mean 
age of 45 years (range, 30-68 years). Analysis of data was based on evaluation of each lesion 
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individually. The mean size of all lesions was 2.6 cm (range, 0.6-10.0 cm). Twenty-two lesions 
were located in the right lobe and 11 in the left lobe. A single lesion was depicted in 7 pa-
tients, and multiple lesions were present in the other 7 patients (two lesions in two patients, 
three in three patients, four in one patient, and nine in one patient).
Histologic proof of FNH was obtained in 14 of the 33 lesions (14 patients). In case of multiple 
lesions, a percutaneous needle biopsy was performed in the largest one. Nine-teen lesions 
not conﬁrmed at histology were identical at (follow-up) MR imaging to the biopsy-proved 
FNH. This is a common clinical practice, and it would have been unnecessary and unethical to 
biopsy all those lesions. The appearance of the lesions without biopsy remained unchanged 
at imaging for a period of at least 12-months.
MR imaging technique
The MR examinations were performed using a 1.5-T unit (Philips Medical Systems, Best, The 
Netherlands). Scan sequences included single-shot fast spin-echo (SSFSE) with varying TE 
values (short and long TE), fat-suppressed T2-weighted fast spin echo (FSE), diﬀusion T2-
weighted black-blood echo planar imaging (BBEPI) and T1-weighted in- and opposed-phase 
gradient echo (GRE) sequences. After administration of an intravenous bolus of 30cc of non-
liver speciﬁc Gadolinium chelate (Magnevist [gadopentetate dimeglumine], Schering, Berlin, 
Germany), dynamic imaging with 2D or 3D T1-weighted sequences in at least 4 phases (pre-
contrast, arterial, portal and delayed phases) was performed. In each patient, a timing bolus 
technique was used to capture the arterial phase after the administration of Gadolinium. The 
portal phase was acquired 45 seconds, and delayed at least 120 seconds, after the acquisition 
of the arterial phase.
After completion of the Gd-enhanced imaging, a SPIO contrast agent (Ferrocarbutan, 
Schering AG, Berlin, Germany) was administered intravenously as a bolus of 1.4cc (>60 kg 
body weight). Ten minutes after the administration of SPIO imaging was performed using fat-
suppressed T2-weighted FSE, BBEPI, and T1-weighted in- and opposed-phase GRE sequences 
were performed. No adverse reactions were reported during the study.
The MR scan sequences, including SSFSE with short and long TE values, fat-suppressed 
T2-weighted FSE, diﬀusion T2-weighted BBEPI and T1-weighted in- and opposed-phase GRE 
sequences were complete for at least 29 lesions. In the following sequences, a few lesions 
were too small to visualize: 2 lesions on SSFSE sequences with short and long TE values 
(n=31) and 2 lesions on T1-weighted in- and opposed-phase GRE sequences (n=31). Because 
of technical problems with data acquisition, the following lesions were excluded for the fol-
lowing sequences: SSFSE with long TE values in one patient (2 lesions, n=29), fat-suppressed 
T2-weighted FSE sequence in 1 patient (3 lesions, n=30) and diﬀusion T2-weighted BBEPI in 
2 patients (with 1 and 2 lesions, respectively; n=30). The dynamic series were available for 28 
of 33 lesions after contrast enhancement with Gadolinium and for 30 lesions after enhance-
ment with a SPIO contrast agent. For post-enhancement evaluation of signal intensities of 
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both the liver and the lesion, analysis was based on 30 lesions for T1-weighted in- and op-
posed-phase GRE sequences, 27 lesions for fat-suppressed T2-weighted FSE, and 23 lesions 
for BBEPI sequences.
Image Analysis
All MR imaging exams were transported digitally to a viewing station, using a picture ar-
chiving and communication system. The analysis of all liver lesions was performed by two 
radiologists in consensus and with the knowledge of the diagnosis of FNH.
The following MR items were assessed qualitatively and/or quantitative: 1) liver surround-
ing the focal lesions (presence or absence of normal parenchyma, 2) diﬀuse and focal fatty 
inﬁltration, 3) focal non-steatosis, 4) iron deposition); 5) lesion localization according to the 
hepatic segment numbering system of Couinaud; 6) number and diameter of lesions; 7) 
signal intensity of lesions compared with normal parenchyma before and after intravenous 
administration of Gadolinium and SPIO at T1- and T2-weighted images; 8) signal intensity 
characteristics of the lesions at unenhanced and contrast-enhanced T1-weighted images 
with regard to the surrounding liver parenchyma; 9) homogeneous or heterogeneous ap-
pearance; 10) presence of fatty inﬁltration within the lesion (in and opposed phase); 11) pres-
ence of a central scar, 12) presence of a pseudocapsule; 13) the uptake of SPIO, and 14) the 
conspicuity of the central scar and septa after the uptake of SPIO.
For quantitative image analysis, the signal intensity of the lesion and liver parenchyma 
were measured using operator-deﬁned regions of interest (ROI). For the lesions, the largest 
possible region of interest in the lesion that excluded ﬁbrotic areas was selected for measure-
ment of signal intensity. For the liver, a region of interest that excluded vessels and artifacts 
was used to measure the signal intensity of the liver adjacent to the tumor. The ROI’s were 
placed identically for both the unenhanced and contrast-enhanced images.
In dynamic Gd-enhanced imaging, enhancement patterns in arterial, portal en delayed 
phase imaging were subjectively evaluated. The lesion-to-liver contrast-to-noise ratio (CNR) 
was calculated as the diﬀerence in signal intensity between the lesion and the liver scaled 
to the standard deviation of background noise. The percentage of contrast enhancement 
was calculated for Gadolinium chelates and the SPIO agent as follows:[(SIenhanced - SIunenhanced) / 
SIunenhanced] x 100, where SI is signal intensity.
Statistical analysis
Statistical parameters (mean, median, standard deviation, and range) are calculated using 
the Statistical Package for the Social Sciences (SPSS) program. Signiﬁcance levels were de-
termined by two-tailed Mann-Whitney test analysis. The unit of measure in our statistical 
analysis was number of lesions, rather than number of patients.
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RESULTS
Signal intensity of the lesions
At T1-weighted imaging, signal intensity of the lesions compared to the surrounding liver pa-
renchyma was slightly lower to isointense at both in-phase T1-weighted GRE (30 of 31 lesions 
(96.8%)) and opposed-phase T1-weighted GRE (21 of 31 lesions (67.8%)) images. The lesions 
appeared relatively brighter to much brighter to the liver at opposed-phase T1-weighted GRE 
in 24.5% (8 of 31 lesions). This was caused fatty inﬁltration of the liver parenchyma in those 
cases.
At T2-weighted imaging, the lesions showed an isointense to slightly higher signal inten-
sity of the lesions at SSFSE T2-weighted images with short and long TE respectively (18 of 31 
lesions (90.4%) and 26 of 29 lesions (89.6%). This implied that the lesion and the liver behaved 
very similar on both sequences, most likely because of the solid nature as well as comparable 
tissue composition.
At fat-suppressed T2-weighted FSE and diﬀusion T2-weighted BBEPI, the lesions showed 
a slightly higher to much higher signal intensity in 28 of 30 patients (93.3%) and 30 of 30 
lesions (100%), respectively. In FSE, fat-suppression and fewer numbers of refocusing pulses 
per TR than SSFSE, most likely improved the liver-to-lesion contrast. In BBEPI, several fac-
tors improved the liver-to-lesion contrast, including 1) fat-suppression; 2) less magnetization 
transfer contrast eﬀect than in FSE and SSFSE images due to the lack of refocusing pulses; 3) 
black-blood imaging based on the low diﬀusion-weighted gradient that dephased the signal 
from intrahepatic vessels; and 4) the application of the diﬀusion gradients was applied in all 
three orthogonal directions, and the composite image was a sum of three individual images. 
This improved the signal-to-noise ratio (SNR) of BBEPI.
Enhancement after Gadolinium
In arterial phase imaging after the administration of Gadolinium, an intense enhancement 
was observed in 27 of 28 lesions (95%). The enhancement was either completely homoge-
neous in 15 of 28 lesions (53.6%) or intensely homogeneous with sparing of septa and the 
central scar in 12 of 28 lesions (42.8%).
In the portal phase, most lesions remained higher or slightly higher in signal intensity com-
pared to the surrounding liver parenchyma (18 of 28 lesions (64.2%)). The remaining lesions 
became almost isointense in 9 of 28 lesions (32.1%).
In the delayed phase, 11 of 28 (39.3%) lesions remained higher in signal intensity, whilst 
14 of 28 (50%) lesions now showed an almost isointense signal intensity compared to the 
surrounding liver parenchyma. Enhancement of central scar and septa was noted in delayed 
phase imaging.
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A quantitative analysis of the enhancement in the diﬀerent phases showed a percentage 
increase of enhancement in liver parenchyma in arterial, portal and venous phases respec-
tively of 110, 115 and 95%, and in the lesion this was 151, 182 and 160% (p<0.0001) (Figure 
2). This shows that the lesions are typically hypervascular in the arterial phase, but behave in 
a similar pattern as the surrounding liver parenchyma in the portal and delayed phase.
Figure 2. Percentage of enhancement of liver parenchyma and the lesion in arterial, portal and venous phases (p<0.0001).
t0; pre-contrast phase, t1; arterial phase, t2; portal phase, t3; venous phase.
Signal intensity after SPIO-uptake
After administration of SPIO marked decrease in the signal intensity of the liver and spleen 
was observed at T2-weighted sequences, which indicated the accumulation of iron particles 
in the Kupﬀer cells. When compared to the same sequence before and after SPIO-uptake, all 
lesions showed loss of signal intensity. This ﬁnding, in fact, revealed the presence of Kupﬀer 
cells within the lesions, and hence their hepatocellular origin.
The lesions showed a marked uptake in 17 of 30 lesions (56.7%) and slight, but certainly 
present uptake in 13 of 30 lesions (43.3%). Conspicuity of speciﬁc lesion characteristics such 
as presence of a central scar and septa had improved in 90% (27 of 29) of the lesions.
A qualitative, subjective evaluation of signal intensity of the lesion compared to the sur-
rounding liver parenchyma was repeated.
At T1-weighted imaging, signal intensity was slightly higher to isointense at in-phase 
T1-weighted GRE (23 of 30 lesions (76.7%)) and now slightly higher to much higher at op-
posed-phase T1-weighted GRE (30 lesions, 100%). This can be explained by intense lowering 
of signal intensity of the surrounding liver parenchyma both by shorter TE value at opposed 
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phase imaging combined with T2* eﬀects caused by accumulation of SPIO in reticuloendo-
thelial cells.
At T2-weighted imaging, signal intensity of the lesions was slightly to much higher at both 
fat-suppressed T2-weighted FSE and diﬀusion T2-weighted BBEPI (26 of 27 lesions (96.3%) 
and 22 of 23 lesions (95.7%)).
Contrast-to-noise ratio before and after SPIO-uptake
Based on the measurements of signal intensity of lesion and surrounding liver parenchyma, 
CNR values of the lesions before and after SPIO-uptake were calculated. These values were as 
follows: T1 in-phase -2.8 and 6.95 (p<0.0005), T1 opposed-phase -0.44 and 1.65 (p<0.0005), 
fat-suppressed T2-weighted FSE 6.45 and 16.4 (p<0.9) and BBEPI 5.64 and 9.25 (p<0.05) 
(Figure 3). The values for T1 in- and opposed-phase and BBEPI were signiﬁcantly diﬀerent. 
High CNR values in BBEPI demonstrated a more pronounced uptake in the liver parenchyma 
compared to the lesion, with sensitive detection through susceptibility (T2*) eﬀects of iron 
particles in SPIO.
Figure 3. Contrast-to-noise ratio (CNR) before and after Gadolinium (Gd) and superparamagnetic iron-oxide (SPIO)-uptake. A. in in-phase 
T1-weighted GRE, showing a signiﬁcant increase after contrast enhancement (p<0.0005). B. in opposed-phase T1-weighted GRE, showing a 
signiﬁcant increase after contrast enhancement (p<0.0005). C. in fat-suppressed T2-weighted FSE (FSE fatsat), showing a non-signiﬁcant 
increase after contrast enhancement (p=0.9). D. in diﬀusion-weighted black-blood echo planar imaging (BBEPI), showing a signiﬁcant increase 
after contrast enhancement (p<0.05).
A. B.
C. D.
124
C
ha
pt
er
 5
.2
Miscellaneous ﬁndings
The liver parenchyma surrounding the lesions was normal in magnitude, shape and contour 
in 12 out of 14 cases (85.7%). Diﬀuse fatty inﬁltration of the liver was present in 3 out of 14 
cases (21.4%), and focal fatty inﬁltration in 4 out of 14 cases (28.6%). Focal non-steatosis was 
seen in 2 of 14 cases (14.3%). No iron deposition was reported. Fatty inﬁltration within the 
lesion was noted in 2 of 33 lesions (6.1%). Visibility of a central scar and pseudocapsule varied 
between 3 and 15% of the lesions for diﬀerent sequences, but was best in post-Gd sequences. 
Low detection rate of these characteristics can be explained by the relatively large amount 
of small lesions in this study.
DISCUSSION
In this study, a cohort of patients with pathology-proven FNH were examined to assess which 
of the characteristics derived from the state-of-the-art MR imaging of the liver are most use-
ful for improved detection and characterization of FNH. The results of our study indicated 
that 1) the signal intensity of FNH was only slightly diﬀerent from the surrounding liver on 
pre-contrast T1- and T2-weighted images; 2) chemical shift imaging showed fatty inﬁltra-
tion in a minority of FNH (6%) whereas the surrounding liver shows focal or diﬀuse fatty 
inﬁltration in up to 50% of the cases; 3) Almost all lesions showed intense homogeneous 
enhancement (with or without intra-tumoral septal sparing) in the arterial phase after the ad-
ministration of Gadolinium; 4) the lesions faded almost to isointensity on the delayed phase; 
5) the central scar and septa were visible only in a minority of patients; 6) all lesions showed 
uptake of SPIO with improved conspicuity of the central scar and septa; 7) most sensitive 
sequences to detect the SPIO-uptake were in- and opposed-phase T1-weighted GRE and dif-
fusion T2-weighted BBEPI. The results of our study indicate that the following characteristics 
are signiﬁcant for the diagnosis of FNH.
Firstly, the similarity of the signal intensity with the surrounding (non-cirrhotic) liver should 
be considered as a strong indicator that the lesion is most likely of hepatocellular origin.
Secondly, the presence of fatty inﬁltration in a relatively small number of lesions as well as 
in the surrounding liver is important. In our study, the lesions demonstrated fatty contents in 
only 6% of all lesions, conﬁrming the fact that accumulation of fat inside FNH does occur but 
is an uncommon ﬁnding. Other primary liver lesions that contain fat include HCA, and HCC. 
HCA may have fatty contents in up to 35-77% and HCC in 35%22.
Thirdly, the enhancement pattern at dynamic Gd-enhanced imaging is essential in the 
work-up of focal liver lesions. As shown in this study, in the case of FNH, lesions show intense 
enhancement in the early arterial phase, but show almost similar enhancement in the later 
phases; the lesions remain slightly more enhanced than the surrounding liver. This enhance-
ment pattern is typical for primary solid liver lesions, such as FNH, HCA, and HCC. Particularly, 
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in HCA early arterial enhancement is often observed23, but is often less intense compared to 
enhancement patterns observed in FNH24. As in FNH, HCA fades to near isointensity with the 
surrounding liver parenchyma in delayed phase imaging23,24. HCA, however, do not show any 
enhancing central scar and septa. In FNH, central scar and septa show high signal intensity at 
T2-weighted imaging, with enhancement in delayed phase imaging. Enhancement patterns 
in small HCC may show almost homogeneous enhancement in the arterial phase, but will 
often become heterogeneous (partial washout) or even homogeneously lower than the liver 
(complete washout). In addition, HCC often show enhanced tumor capsule in the delayed 
phase, and occur in livers with parenchymal disease such as ﬁbrosis and cirrhotic livers. HCC 
in non-cirrhotic liver are often single lesions with a large size and strong heterogeneous 
enhancement in the arterial phase. Other lesions such as hemangiomas and metastases 
have quite diﬀerent signal intensities and enhancement patterns24. Hemangiomas typically 
enhance in a peripheral nodular fashion, with slow centripetal enhancement over time, to be-
come and remain isointense with the liver in delayed phase imaging. Enhancement patterns 
in metastases may vary according to the origin of the malignancy. Colorectal metastases typi-
cally demonstrate ring-like arterial enhancement, with ﬁlling of the central areas of the lesion 
over time and washout of contrast material in the active peripheral border of the lesion24.
Fourthly, after administration of SPIO, all lesions showed uptake of contrast which caused 
signal loss in the lesion, the liver, and spleen on sequences with T2*-weighting, such as T2-
weighted FSE, SSFSE, and BBEPI, and T1-weighted GRE sequences. The signal loss in the liver 
was most pronounced, followed by the spleen and the lesions. It should be noticed that rela-
tively more signal loss in the normal liver rendered FNH lesions brighter to the liver, which 
may improve the detection rate of FNH. The intratumoral signal loss was mainly present in 
areas with hepatocytes that were mostly arranged in small nodules. The septa and the central 
scar surrounding the intralesional nodules therefore appeared brighter with improved con-
spicuity (Figure 4). This ﬁnding may improve the characterization of FNH, and may facilitate 
distinction from HCA. In our study, the most sensitive sequences in SPIO-enhanced imaging 
were BBEPI and T1-weighted GRE sequences. As demonstrated in the calculated CNR, T1-
weighted sequences may be useful in analysis of lesions after Gd/SPIO. In particular, the op-
posed-phase T1-weighted sequence is useful, because of its shorter TE in combination with 
T2* eﬀects of the administered SPIO. Although T1-weighted sequences are not commonly 
used in evaluation after Gd/SPIO, the ability of detection of intrinsic details and less artifacts 
in combination with high resolution compared to T2-weighted sequences make it a useful 
additional sequence, as has been demonstrated before18,25. In addition, high SNR and CNR in 
these sequences may allow a smaller amount of SPIO, which may facilitate further reduction 
of side eﬀects.
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Figure 4. Improved conspicuity of central scar and septa after SPIO. A. Axial pre-contrast fat-suppressed T2-weighted FSE, in which a slightly 
hyperintense lesion is demonstrated. B. Axial pre-contrast diﬀusion T2-weighted black-blood echo planar imaging (BBEPI): higher signal intensity 
of the lesion. C. Axial post-SPIO fat-suppressed T2-weighted FSE, in which lower signal intensity of the liver is observed, due to absorption 
of contrast agent in the Kuppfer cells. Central scar and septa have a slightly higher signal intensity compared to pre-contrast sequences. 
D. Axial post-SPIO diﬀusion T2-weighted BBEPI: high signal intensity of central scar and septa with better conspicuity compared to pre-contrast 
sequences. Note that conspicuity is better in the BBEPI sequence compared to the T2-FSE sequence (C).
The results of our study indicate that FNH may show complete homogeneous enhancement 
(without any septal sparing), especially in smaller lesions. It may also be diﬃcult to assess the 
intensity of enhancement for diﬀerentiation from HCA. In such cases, T2-weighted images 
and Gd-enhanced T1-weighted images in the delayed phase should be carefully assessed for 
the presence of central scar and septa. In addition, SPIO-uptake may reveal the presence of 
central scar and septa, making the distinction between FNH and HCA. Also, in a recent study 
it has been suggested that delayed imaging, 1-3 hours after administration of non-speciﬁc 
contrast material, may be helpful in diﬀerentiation between FNH and HCA26.
Distinction between FNH and HCA is very important: 1. for follow up in pregnancy or use 
of oral anticonceptive medication; 2. because of the risk for hemorrhage and malignancy in 
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the case of a HCA; and 3. for assessment of the need for surgical or endovascular emboliza-
tion treatment. At our institution, an asymptomatic single HCA of less than 5 cm in diameter 
or multiple HCA with variable diameters are subject to intensive follow-up with imaging 
and laboratory tests because of the risk of hemorrhage and malignancy. Whereas a single 
HCA larger than 5 cm or HCA with signs of malignancy at imaging (increasing size, changing 
density of signal intensity, changing enhancement, washout of contrast, enhancing ﬁbrous 
tumor capsule) will often need surgical removal or at least biopsy. It is also important to 
know that HCA can present with intrahepatic or intraperitoneal hemorrhage that can be life 
threatening and may need intervention, including surgery or embolization.
Several studies have described imaging characteristics of focal liver lesions after adminis-
tration of both speciﬁc and non-speciﬁc liver contrast agents. As has been described by Kim 
et al18, Ba-Ssalamah17 and Precetti et al15, use of ferumoxide contrast agents may aid in better 
delineation of central scar and septa in FNH. Also, Paley et al16 have shown a signiﬁcant up-
take of SPIO in pathology-proven FNH at T2-weighted imaging compared to other focal liver 
lesions. Recently, Scharitzer et al14 have described the improved accuracy for diﬀerentiation 
between surgical and non-surgical liver lesions with mangafodipir-enhanced imaging. Few 
studies have evaluated the combined use of both Gd- and SPIO-enhanced imaging for focal 
liver lesions17,19. Ba-Ssalamah et al describe the imaging results of several focal liver lesions 
in separate imaging sessions for speciﬁc and non-speciﬁc contrast agents17. In addition to 
this study, we combine the use of dynamic Gd-enhanced imaging with T1- and T2-weighted 
imaging after administration of SPIO in one imaging session, to illustrate imaging ﬁndings of 
FNH using modern state-of-the-art MR sequences.
Our study has a limitation because of the relatively small cohort of patients. Only patients 
with a FNH lesion that was conﬁrmed by percutaneous needle biopsy were included because 
histological proof is still considered to be the gold standard for diagnosis. However, since the 
introduction of state-of-the-art MR imaging at our department in 1999, FNH has been diag-
nosed non-invasively. Diagnosis of FNH is conﬁrmed with at least one follow-up MR imaging 
examination at 6-12 months. Consequently, the small amount of patients that are included 
in this cohort were diagnosed with a needle biopsy before the availability of MR imaging or 
during analysis elsewhere before being admitted to our clinic.
In conclusion, our study indicates that combination of dynamic Gd-enhanced imaging 
with T1- and T2-weighted imaging after administration of SPIO facilitates detection and char-
acterization of FNH. It is shown that: 1. signal intensity of FNH prior to contrast diﬀers only 
slightly from the surrounding liver; 2. accumulation of fat is present in a minority of FNH; 3. 
enhancement of FNH is intense homogeneous in arterial phase imaging with fading to near 
isointensity in delayed phase imaging; 4. uptake of SPIO in FNH is pronounced with improved 
conspicuity of the central scar and septa. Most sensitive sequences to detect the SPIO-uptake 
are in- and opposed-phase T1-weighted GRE and diﬀusion T2-weighted BBEPI.
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5.3
Transcatheter arterial embolization as a safe and eﬀective treatment for focal nodular 
hyperplasia of the liver.
T Terkivatan, SM Hussain, JS Lameris, JNM IJzermans.
Cardiovascular and Interventional Radiology 2002;25:450-453.
Focal nodular hyperplasia 131
TRANSCATHETER ARTERIAL EMBOLIZATION AS A SAFE AND EFFECTIVE 
TREATMENT FOR FOCAL NODULAR HYPERPLASIA OF THE LIVER
ABSTRACT
When a surgical treatment is being considered for focal nodular hyperplasia, the risk of liver 
surgery must be carefully balanced against the beneﬁt of resection, especially in the case of a 
large or centrally located lesion. However, when resection is contraindicated or even impos-
sible, transcatheter arterial embolization should be considered as a safe and less invasive 
alternative treatment.
We describe two cases of young women who presented with abdominal pain and a hyper-
vascular enhancing mass with the radiologic features of focal nodular hyperplasia. Arterial 
embolization was the therapy selected due to the risk of surgery. In both cases the procedure 
was successful, and the lesion showed shrinkage during follow-up.
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INTRODUCTION
Focal nodular hyperplasia (FNH) is a benign liver tumour predominantly detected in young 
healthy women1-3. Although considered as a rare neoplasm, FNH is the second most common 
benign liver tumour after hemangioma4,5. Since most cases are incidental ﬁndings during ab-
dominal imaging performed for other reasons, management of this solid liver lesion requires a 
systematic approach. A conservative approach for asymptomatic lesions is well established be-
cause there is no predisposition to haemorrhage or malignant transformation and symptoms 
may resolve during follow-up1-3,6. Nevertheless, large lesions (>4 cm) may be responsible for 
abdominal complaints due to pressure on surrounding tissues or the liver capsule, and surgery 
might be indicated3,7. In order to aﬀord the best clinical approach, it is essential to evaluate 
whether symptoms are indeed related to the tumour or are caused by extrahepatic pathology.
On the basis of our experience with nonsurgical treatment of solid benign liver tumours, 
we treated two patients by arterial embolization. In this report, we describe this technique 
and the results of treatment in these female patients with abdominal complaints attributed 
to FNH in the liver.
CASE REPORTS
Case 1
A 29-year-old woman was admitted elsewhere for evaluation of a mild persistent right sub-
costal pain. Intermittently, she was nauseous and vomited. The patient had lost 3 kg in weight 
during the preceding 3 months when she had a decreased appetite. She denied fever, jaun-
dice or a history of intravenous drugs or alcohol abuse. She had used an oral contraceptive in 
the past for 10 years but did not use steroids at presentation.
Physical examination revealed normal vital signs. There was slight tenderness in the right 
upper quadrant without clinical signs of hepatosplenomegaly or ascites.
Laboratory values of AST, ALT, alkaline phosphatase, total bilirubin, γ-glutamyl transferase, 
and α-fetopotein were within the normal limits. Serologic tests for HBsAg, anti-HBc, and anti-
HCV were all negative.
Abdominal ultrasonographic examination showed a slightly hyperechoic lesion with a 
diameter of 4 cm, which was well circumscribed and lobulated. The remainder of the liver, 
intrahepatic and extrahepatic bile ducts, the gallbladder, and the urinary tract were normal 
without signs of stone disease. A spiral CT scan was performed and revealed a hypodense 
lesion with a strong homogeneous increase in density immediately after delivery of con-
trast. The lesion was centrally located and involved liver segments V, VI, VII, and VIII (Figure 
1). Nonenhancing central areas suggested a central scar, characteristic for FNH. Other intra-
abdominal organs appeared normal.
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An additional needle biopsy, which was performed elsewhere and reviewed in our hospital, 
was conﬁrmatory for the histological diagnosis of FNH, and showed nodules of hyperplastic 
parenchyma completely surrounded by irregular ﬁbrous septa and containing areas of dense 
ductular proliferation. The inﬂammatory inﬁltrate consisted mainly of mononuclear cells, and 
there was a lack of portal tracts and “native” bile ducts.
Given the location and relatively small size of the lesion, a gastroduodenoscopy was per-
formed to exclude extrahepatic pathology that might have been causing the patient’s com-
plaints. There were no abnormalities in the gastroduodenal tract. Realising the risk of surgery 
for a centrally located liver lesion, a transcatheter arterial embolization was performed. Dur-
ing the angiographic procedure the right hepatic artery was catheterised selectively using a 
4 Fr catheter. Then an angiographic series was performed to obtain an overview of the vascu-
lar anatomy and the feeding arteries of the FNH (Figure 2a). After all the feeding arteries had 
Figure 1. Case 1. Hyperdense lesion after delivery of contrast with nonenhancing central areas suggestive for a central scar, and a feeding 
branch from the right hepatic artery to the tumour.
Figure 2. Case 1. A. Celiac angiography shows a hypervascular 
lesion with a central feeding artery radiating in a spoke-wheel 
manner into the lesion.
B. Disappearance of the vascularity to the tumour after  
transcatheter arterial embolization.
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been identiﬁed, an infusion microcatheter (Fastracker-18MX; diameter 0.533 mm; Boston Sci-
entiﬁc) with its hydrophilic guidewire (FasDasher-14; diameter 0.3556 mm; Boston Scientiﬁc) 
were introduced superselectively through the 4 Fr catheter into the feeding arteries, which 
were embolised using embolisation particles (Contour; diameter 150-250 μm; Boston Scien-
tiﬁc). At the end of the embolization procedure another angiographic series was performed 
using the 4 Fr catheter to evaluate the eﬀect of the therapy (Figure 2b). During the procedure 
there was no need for a sedative or analgesic. Antibiotic prophylaxis was not used.
The results of treatment were followed up by CT scan, which showed an ischaemic area at 
the site of the previous lesion (Figure 3). No major treatment-related complications occurred 
during the hospital stay after embolization. The patient developed a temperature up to 38.3 
°C with a minimal increase in serum transaminase levels (< 3x the upper limit of normal). 
These parameters returned to normal and the patient was discharged within 10 days post-
embolization.
After 1 year of follow-up at the outpatient department, imaging methods showed shrinkage 
of the tumour and the lesion could no longer be visualised (Figure 4). At present, the patient 
is being treated for irritable bowel syndrome, and does not have complaints that might be 
related to the embolization procedure.
Case 2.
A 19-year-old woman was referred to our hospital for evaluation of a hepatic mass, which 
was detected elsewhere. The patient complained of persistent right upper abdominal pain 
radiating to the back, and fatigue. She had lost 10 kg in weight during a period of 6 months. 
She denied nausea, vomiting, diarrhoea, constipation, and changes in appetite. There was no 
previous history of jaundice, intravenous drugs or alcohol abuse. She had started to take an 
oral contraceptive during the month before admission.
On examination the patient was slim and appeared well. The abdomen was soft and non-
tender. There was no palpable mass, or signs of liver insuﬃciency.
Figure 3. Case 1. CT scan performed 3 days after embolization shows 
an ischaemic area at the site of the previous lesion.
Figure 4. Case 1. CT scan after 1 year of follow-up, without signs of 
the tumour.
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Routine liver tests and α-fetopotein were within the normal range, and serology tests for 
viral hepatitis were negative.
Abdominal ultrasound showed a solid liver lesion of 7 cm in the lobus caudatus with only a 
subtle change in echogenicity as compared with the surrounding normal liver parenchyma. 
Other intra-abdominal organs and structures appeared normal. An additional MRI exami-
nation, performed elsewhere, revealed typical features of FNH: homogeneous hyperdense 
enhancement on early phases with a rapid washout (Figure 5). The presence of a central scar, 
which showed enhancement only on delayed phases, made the diagnosis conclusive, and a 
needle biopsy was therefore unnecessary.
Figure 5. Case 2. A dynamic contrast-enhanced T1-weighted MR image during the arterial phase shows a tumour (large
arrow) with intense homogeneous enhancement. The central scar (small arrows) shows less enhancement during this
phase. Note that a pulsation artefact (asterisk), caused by the aorta, is obscuring part of the lesion.
Figure 5. Case 2. A dynamic contrast-enhanced T1-weighted MR image during the arterial phase shows a tumour (large arrow) with intense 
homogeneous enhancement. The central scar (small arrows) shows less enhancement during this phase. Note that a pulsation artefact 
(asterisk), caused by the aorta, is obscuring part of the lesion.
Figure 6. Case 2.
A. Celiac angiography shows a hypervascular lesion with a microcatheter 
placed in the left hepatic artery, which supplied the tumour.
B. Angiographic image after the embolization procedure. Note that only 
a small part of the lesion remains (arrow).
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Considering the risk of surgery for this symptomatic lesion in segment I of the liver, an arterial 
embolization via the left hepatic artery was performed (Figure 6a). A small part of the lesion, 
which was supplied by the right hepatic artery, could not be embolised during the same 
session (Figure 6b). However, the embolization procedure was considered to be successful 
after a post-intervention angiography. And the procedure was ended. CT imaging showed an 
ischaemic area at the site of the lesion, and during a radiological follow-up of 6 months the 
tumour showed signiﬁcant shrinkage (> 90%). The patient was free of symptoms.
DISCUSSION
Although the natural history of FNH is not precisely known, certain clinical and pathologic 
aspects of its behaviour are well known and form the basis for current clinical management. 
FNH is typically a benign, usually asymptomatic liver tumour (50-90%) with a strong pre-
dominance for young women1,2,4. While there is a clear association with the use of oral contra-
ceptives and hepatic adenomas, the association of FNH with steroids has been denied8.
During evaluation of a solid hepatic tumour, a benign lesion must be considered when 
clinical evidence of malignant disease is absent, serum α-fetoprotein levels are normal and 
hepatitis B and C serology tests are negative. Familiarity with dynamic contrast-enhanced CT 
and MRI allows an accurate diagnosis in most cases (sensitivity of 90-100%). Most FNHs are 
isodense or slightly hypodense to the liver on unenhanced CT. The typical contrast enhance-
ment pattern of FNH is diﬀuse immediate homogeneous hyperdense enhancement on early 
phases (arterial and early portal venous) with rapid washout of contrast material, becoming 
isodense to the liver on late portal venous and delayed images. In particular the presence 
of a hypodense central scar on unenhanced images, showing a gradual ﬁlling-in on portal 
venous and delayed images, or a feeding artery radiating in a spoke-wheel pattern from the 
periphery to the centre of the tumour, is highly supportive of a diagnosis of FNH4,9. At MRI, 
FNH shows a similar enhancement pattern. However, MRI has a better speciﬁcity than CT 
because of its soft tissue signal characteristics on various T1- and T2-weighted images, better 
conspicuity of the central scar on T2-weighted and delayed contrast-enhanced images, and 
the availability of tissue-speciﬁc MR contrast media targeting either the Kupﬀer cells or he-
patocytes10. The increasing use of these highly improved, fast scanning techniques will avoid 
the need for needle biopsies or aspirations in the near future.
A conservative approach to asymptomatic FNH lesions is justiﬁed due to the absence of 
risks for haemorrhage, necrosis and malignant degeneration1-3,6,11. In the case of a symp-
tomatic lesion, surgical intervention can be considered although it is essential to determine 
whether the symptoms are caused by the tumour. The risk of signiﬁcant and sometimes un-
controllable intraoperative bleeding during surgery for a hypervascular lesion, in addition to 
the common risks of any liver resection12, should be carefully balanced against the beneﬁt 
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that might be expected from resection. Mortality rates of surgery must be considered as seri-
ous and unacceptable in the management of a benign disease in young patients.
Transcatheter arterial embolization has been increasingly useful as a less invasive percu-
taneous tumour ablation technique in a variety of liver lesions and hemorrhage13-16. As it has 
been suggested that FNH is a hyperplastic response of hepatic parenchyma to a congenital 
arterial malformation, embolization appears to be a logical treatment option1,17. Besides, a 
central feeding artery is detected radiologically in 50-60% of cases, which makes this method 
more feasible18. Complications such as abscess formation and infections have been reported 
in the literature19,20. However, most of these, and some other complications, including major 
infarctions, tumour lysis syndromes and death, occurred in patients with serious underlying 
liver disease, or haemorrhagic shock from hepatic arterial or gastroduodenal bleeding19,21. In 
addition, the use of microcatheters will permit a more precise deposition of the embolization 
particles in the small feeding arteries, without occluding major arterial branches.
In the two patients described in this report, the technique of superselective transcatheter 
arterial embolization was performed successfully, conﬁrming the experience of others1,22. We 
conclude that arterial embolization should be considered as a safe and eﬀective alternative 
to surgical treatment of symptomatic cases of FNH, especially those with a considerable risk 
of surgery because of the location of the tumour.
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Summary and implications of the thesis
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SUMMARY AND CONCLUSIONS
In part 1.1 a historical overview lines out the beginning of understanding the aetiology and 
pathogenesis of hepatocellular adenoma as a milestone in diagnosis and treatment of be-
nign liver tumours, followed by an outline of the thesis in part 1.2.
In part 2.1 an extensive review of the literature is presented in order to describe epide-
miology, aetiology, pathogenesis, histology, and radiologic features of the most common 
benign liver tumours. The role of improved imaging modalities versus the role of liver biopsy 
in diagnosis of benign liver tumours is discussed and treatment options are pointed out. This 
review shows that the state-of-the-art MR imaging has a high accuracy in diagnosing benign 
liver lesions and should be part of the diagnostic work-up of focal liver lesions. Knowledge of 
these imaging features will avoid the need for liver biopsy that has it own diagnostic diﬃcul-
ties and pitfalls. Treatment options that are described in the literature vary from observation 
to surgery or other invasive interventional techniques. Reviewing the indications for treat-
ment of benign liver tumours, it seems to be rarely indicated to perform surgery for a benign 
liver lesion, as most of these are asymptomatic and have an uncomplicated natural course.
The authors’ own experience with the diagnosis and treatment of benign liver tumours is 
reported in part 2.2. In a large series of 208 patients who presented with hepatocellular ad-
enoma, focal nodular hyperplasia, and cavernous haemangioma in a 20-year period, indica-
tions and long-term outcome after either a conservative or surgical treatment are reported. 
In the surgically treated population the liver lesion was an incidental ﬁnding in 36 per cent of 
patients. Operative morbidity and mortality was 27 and 3 per cent, respectively. Twenty-two 
per cent of patients with an incidentaloma, developed complaints of abdominal pain after 
hepatic surgery. During observation of the tumour in the conservatively managed group, 
87 per cent of patients who presented with complaints were asymptomatic during a mean 
follow-up of 45 months. These results clearly justify a conservative approach to benign liver 
lesions as focal nodular hyperplasia and haemangioma. Surgery for liver lesions should be 
advised when there is an inability to exclude malignancy, e.g. due to a high a priori chance 
for malignancy as in metabolic or viral liver disease, or in case of severe complaints related 
to the tumour. Data from literature indicate that resection is always advocated for a large he-
patocellular adenoma to reduce the risk of rupture and malignant degeneration. This study 
emphasises that it is important to inform patients about complaints that may persist after 
surgery, and that hepatic resection for benign lesions is still related to serious morbidity and 
even mortality.
Part 3 presents the results of a retrospective study, which has been performed to investi-
gate the safety of a conservative management of giant haemangiomas. The medical records 
of 49 patients with a haemangioma of at least 4 cm in diameter were reviewed to document 
clinical presentation, diagnostic strategies, treatment, complications, and follow-up. This 
study showed that symptoms often resolved spontaneously during a mean follow-up of 52 
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months, and operation was not completely successful in terms of symptomatic relief. Liver 
haemangiomas have been resected because of a perceived risk of spontaneous or traumatic 
rupture, abscess formation, and the possibility of the Kasabach-Merritt syndrome. However, 
the potential for complications of a liver haemangioma is minimal and does not justify resec-
tion of all haemangiomas. As supported by the present observation, it can be concluded that 
observation of giant haemangiomas can be performed safely. Surgery for liver haemangioma 
is advocated only in patients with incapacitating symptoms, and size of the lesion is not a 
criterion for resection.
In part 4.1 special attention is paid to the management of hepatocellular adenoma de-
tected during pregnancy. High levels of endogenous steroid hormones and increased liver 
bloodﬂow during pregnancy increases the chances of liver rupture. Rupture of a hepatocellu-
lar adenoma during pregnancy carries a much higher mortality rate, as there may be a serious 
delay in diagnosis because of confusion with other pregnancy-related diseases. Supported 
by data from literature a successful resection of a hepatocellular adenoma was performed in 
a 32-year-old pregnant woman, which is reported in this chapter. Because of the unpredict-
able behaviour of hepatocellular adenomas and high maternal and foetal mortality rates in 
case of a rupture during pregnancy and partus, resection is recommended once a large (more 
than 5 cm) or a growing hepatocellular adenoma is diagnosed.
In part 4.2 a study is presented which has been performed to evaluate early management 
and treatment of ruptured hepatocellular adenoma. In this study 12 patients with a ruptured 
hepatocellular adenoma are reported. As the morbidity and mortality rates associated with 
emergency resection are high, the initial management of a ruptured hepatocellular adenoma 
should be non-surgical by haemodynamic stabilisation. Deﬁnitive resection is required for 
rebleeding or for tumours exceeding 5 cm in diameter, and a conservative approach may well 
be justiﬁed in the case of regression of an asymptomatic hepatocellular adenoma.
In part 4.3 special emphasis is made on the diagnostic challenges that may be encoun-
tered during diﬀerential diagnosis of a focal liver lesion. A review of the literature is per-
formed assisted by the authors’ own experience of three female patients who underwent 
surgery because of a focal liver lesion with an uncertain diagnosis despite of an extensive 
work-up. Although histological examination by ﬁne needle biopsy is still considered to be 
the gold standard in the diagnosis of benign and malignant liver tumours, the availability 
of highly advanced radiological techniques provides a non-invasive diagnostic tool that is 
being used frequently. The use of a state-of-the-art pattern recognition approach, the com-
bination of various MR sequences and tissue speciﬁc MR contrast media makes it possible to 
diagnose most hepatic tumours with conﬁdence. This imaging modality may have equalled 
or even exceeded the value of needle biopsy as the gold standard. The accuracy rate of these 
modalities seems to be similar, and it should be questioned if an additional pre-operative 
needle biopsy will have therapeutic implications after having performed state-of-the-art MR 
imaging of the liver.
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In part 5.1 the pathologic spectrum of focal nodular hyperplasia is described with an em-
phasis on the pathologic classiﬁcation that divides focal nodular hyperplasia into classic and 
nonclassic forms. The most recent concepts about the pathologic features of focal nodular 
hyperplasia including its angioarchitecture are described. This report also demonstrates the 
full spectrum of ﬁndings in focal nodular hyperplasia at state-of-the-art MR imaging in com-
parison with ultrasonography and CT scanning.
In part 5.2 a prospective study is presented in which a cohort of patients with focal nodular 
hyperplasia has been imaged in order to assess which of the characteristics on state-of-the-
art MR imaging of the liver are most useful for improved detection and characterization of 
this lesion. Pathology-proven focal nodular hyperplasias were prospectively examined with 
the state-of-the-art MR imaging using Gadolinium and superparamagnetic iron-oxide (SPIO) 
contrast media. This study indicates that combination of dynamic Gadolinium-enhanced 
imaging with T1- and T2-weighted imaging after administration of SPIO facilitates detection 
and characterization of FNH. It is shown that signal intensity of focal nodular hyperplasia 
prior to contrast diﬀers only slightly from the surrounding liver; accumulation of fat is pres-
ent in a minority of focal nodular hyperplasia; enhancement of focal nodular hyperplasia is 
intense homogeneous in arterial phase imaging with fading to near isointensity in delayed 
phase imaging; and uptake of SPIO in focal nodular hyperplasia is pronounced with improved 
conspicuity of the central scar and septa. Most sensitive sequences to detect the SPIO-uptake 
are in- and opposed-phase T1-weighted GRE and diﬀusion T2-weighted BBEPI.
In part 5.3 superselective transcatheter arterial embolisation is described as an alternative 
treatment for focal nodular hyperplasia. As it has been suggested that focal nodular hyper-
plasia is a hyperplastic response of hepatic parenchyma to a congenital arterial malforma-
tion, embolisation appears to be a logical treatment option. Besides, a central feeding artery 
is detected radiologically in 50-60% of cases, which makes this method more feasible. When 
a surgical treatment is being considered for focal nodular hyperplasia, the risk of liver surgery 
must be carefully balanced against the beneﬁt of resection, especially in the case of a large 
or centrally located lesion. Transcatheter arterial embolisation should be considered as a safe 
and less invasive percutaneous tumour ablation technique, and as an eﬀective alternative to 
surgical treatment of symptomatic cases of focal nodular hyperplasia, especially those with a 
considerable risk of surgery because of the location of the tumour.
CONCLUSION
From history till now, at least some things have changed in diagnosis and treatment of focal 
liver lesions. Diﬀerent radiological and nuclear tools have been used to obtain an accurate 
diagnosis and most importantly to diﬀerentiate benign from malignant lesions, each of them 
with a less or more invasive nature, or radiation hazard. Nowadays, state-of-the-art MR imag-
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ing and the use of tissue speciﬁc contrast media, will permit lesion characterisation based 
on its cellular composition, enhancement pattern and morphological features. The use of 
this highly advanced imaging modality during diﬀerential diagnosis of a focal liver lesion 
will prevent unnecessary liver biopsy or surgery. The accuracy rate of the state-of-the-art 
MR imaging and needle biopsy as the gold standard seems to be similar, and it should be 
questioned if an additional pre-operative needle biopsy will have therapeutic implications 
after having performed MR imaging of the liver.
Concerning therapeutic options for benign liver lesions, it should be realised these le-
sions, except for hepatocellular adenoma and cystadenoma, are often incidentalomas and 
possess a benign natural course with a minimal risk of complications that does not justify a 
primary surgical treatment. Even when the patient is symptomatic, it is essential to evaluate 
if complaints are related to the lesion as they may persist after surgery, and more importantly, 
asymptomatic patients may develop symptoms while being exposed to a treatment with a 
considerable risk of morbidity and mortality.
In the case of a bleeding hepatocellular adenoma, a primary non-surgical management 
might aﬀord the best clinical approach with a minimal risk for complications. However, 
surgery might well be necessary for a large or growing hepatocellular adenoma, or a cyst-
adenoma. Transcatheter arterial embolisation should be considered as a safe and eﬀective 
alternative treatment of vascularised lesions when there is a considerable risk for surgery.
The treatment of benign liver lesions can thus be summarised with the statement “conser-
vative, unless…”
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SAMENVATTING EN CONCLUSIES
In hoofdstuk 1.1 wordt in een korte historische inleiding aandacht besteed aan de ontwik-
keling van ideeën over de etiologie en pathogenese van het hepatocellulair adenoom als 
mijlpaal in de diagnose en behandeling van benigne levertumoren, gevolgd door de opzet 
van het proefschrift in hoofdstuk 1.2.
In hoofdstuk 2.1 wordt een uitgebreid literatuuronderzoek gepresenteerd met als doel 
een overzicht te bieden van de epidemiologie, etiologie, pathogenese, histologische en ra-
diologische aspecten van de meest voorkomende benigne lever tumoren. In dit hoofdstuk 
wordt de rol van nieuwe diagnostische modaliteiten versus de rol van het histologisch naald-
biopt tijdens de diﬀerentiaaal diagnose van benigne lever tumoren besproken en worden 
de behandelingsopties voor deze tumoren uiteen gezet. Dit literatuuroverzicht laat zien dat 
de huidige moderne MRI scan met geavanceerde en geoptimaliseerde sequenties een hoge 
accuratesse heeft in het diagnostiseren van benigne lever tumoren en dat deze onderdeel 
moet zijn van de work-up van focale lever afwijkingen. Een exacte kennis van alle radiolo-
gische kenmerken van deze tumoren zal in de praktijk vaak de behoefte aan een leverbiopt 
en de diagnostische dilemma’s die inherent zijn hieraan, voorkomen. De verschillende be-
handelingsopties die in de literatuur beschreven worden, variëren van een conservatieve, 
niet chirurgische behandeling tot resectie van de tumor of andere invasieve interventie tech-
nieken. Naar aanleiding van dit literatuuronderzoek naar de behandeling van benigne lever 
tumoren, wordt geconcludeerd dat er steeds minder vaak plaats is voor een chirurgische 
behandeling van benigne lever tumoren aangezien deze lesies vaak asymptomatisch zijn en 
een ongecompliceerd naturlijk beloop hebben.
Hoofdstuk 2.2 beschrijft een retrospectief onderzoek dat verricht is met het doel een in-
ventarisatie te verrichten naar eigen ervaringen met de diagnostiek en behandeling van be-
nigne lever tumoren. In een grote serie van 208 patiënten die zich in een periode van 20 jaar 
presenteerden met een hepatocellulair adenoom, focale nodulaire hyperplasie of een caver-
neus hemangioom worden de indicaties en lange termijn resultaten van een conservatieve of 
chirurgische behandeling geanalyseerd. In de chirurgisch behandelde groep was de lesie een 
toevalsbevinding in 36% van de patiënten. De chirurgische morbiditeit en mortaliteit bed-
roegen respectievelijk, 27% en 3%. Van de patiënten waarbij de tumor een toevalsbevinding 
was ontwikkelde 22% klachten van buikpijn na de chirurgische behandeling. In de groep die 
conservatief benaderd werd, verdwenen daarentegen de klachten bij 87% van de patiënten 
gedurende een mediane follow-up van 45 maanden. Deze studieresultaten rechtvaardigen 
een conservatieve benadering van benigne lever tumoren zoals het hemangioom en focale 
nodulaire hyperplasie. Een resectie is aangewezen indien een maligniteit niet uit te sluiten is 
of indien er een hoge a priori kans bestaat op maligniteit, zoals het geval is bij metabole of 
virale leveraandoeningen. Een primair chirurgische behandeling is eveneens geïndiceerd in 
geval van een groot hepatocellulair adenoom in verband met het risico op bloedingen of ma-
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ligne degenaratie. In alle gevallen dient men de voordelen van een chirurgische behandeling 
af te wegen tegen de eventuele complicaties en risico’s van leverchirurgie.
In hoofdstuk 3 wordt een retrospectieve studie gepresenteerd dat verricht is met het doel 
om de conservatieve benadering van giant hemangiomen en de veiligheid van een dergelijk 
beleid te evalueren. In deze studie worden data bestudeerd van 49 patiënten met een hema-
gioom van minstens 4 cm in diameter met speciale aandacht voor de klinische presentatie, 
het diagnostische traject, de behandeling, complicaties en periode van follow-up. Deze 
studie toont aan dat de meeste patiënten die niet geopereerd zijn, symptoomvrij waren na 
een mediane follow-up duur van 52 maanden en dat klachten kunnen persisteren na een 
chirurgische behandeling. Hemangiomen van de lever worden vaak chirurgisch behandeld 
in verband met het vermeende risico op een spontane of traumatische ruptuur, abcesvorm-
ing en de mogelijkheid op het Kasabach-Merritt syndroom. Echter, de kans op complicaties 
bij een hemangioom van de lever is minimaal en rechtvaardigt niet een resectie van alle 
hemangiomen. Geconcludeerd wordt dat observatie van giant hemangiomen veilig is en 
dat een chirurgische behandeling van hemangiomen overwogen kan worden in geval van 
invaliderende klachten.
In hoofdstuk 4.1 wordt ingegaan op de behandeling van het hepatocellulair adenoom 
tijdens zwangerschap. Hoge hormoon spiegels en een toegenomen doorbloeding van de 
lever tijdens de zwangerschap verhoogt het risico op een ruptuur van het hepatocellulair 
adenoom. De mortaliteit van een geruptureerd hepatocellulair adenoom gedurende een 
zwangerschap is hoog in verband met de kans op verwarring met zwangerschap gerelateerde 
pathologie en de daarmee samenhangende delay in behandeling. Ondersteund door deze 
literatuurgegevens werd er een resectie verricht van een hepatocellulair adenoom bij een 
32 jarige zwangere vrouw, hetgeen beschreven wordt in dit hoofdstuk. In verband met het 
onvoorspelbare beloop van een hepatocellulair adenoom en de hoge mortaliteit van zowel 
de moeder als het kind in geval van een ruptuur, is het aan te raden een groot adenoom 
(diameter groter dan 5 cm) dat ontdekt is tijdens de zwangerschap te reseceren.
In hoofdstuk 4.2 wordt een studie beschreven, waarin het beleid bij een geruptureerd 
hepatocellulair adenoom wordt geëvalueerd. In verband met de hoge morbiditeit en mor-
taliteit die geassocieerd is met een acute leverresctie, wordt in deze studie geconcludeerd 
dat het beleid bij een geruptureerd hepatocellulair adenoom primair een niet-chirurgische 
benadering moet zijn waarbij hemodynamische stabilisatie op de voorgrond staat. Een elec-
tieve resectie dient verricht te worden in geval van een herbloeding of een tumor diameter 
groter dan 5 cm en een conservatieve benadering is gerechtvaardigd indien er sprake is van 
regressie van een asymptomatisch hepatocellulair adenoom.
In hoofdstuk 4.3 wordt nader ingegaan op de diagnostische dilemmas die kunnen ont-
staan tijdens de diﬀerentiaal diagnose van een focale lever tumor. Aan de hand van drie 
patiënten die een resectie ondergingen van een focale lever afwijking die ondanks een uit-
gebreide analyse niet nader gakarakteriseerd kon worden, wordt een overzicht gegeven van 
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de meest recente literatuur betreﬀende de diagnostiek van focale lever afwijkingen. Ondanks 
de beschikbaarheid en het gebruik van de meest ontwikkelde radiologische technieken die 
een niet-invasief middel vormen voor de diagnostiek van benigne en maligne lever tumoren, 
wordt het histologisch naaldbiopt heden ten dage nog steeds beschouwd als de “gouden 
standaard”. Het gebruik van de meest geavanceerde MRI scan met de mogelijkheid om ver-
schillende moderne sequenties te combineren en de beschikbaarheid van weefsel-speciﬁek 
contrast maakt het mogelijk de meeste lever tumoren met een hoge accuratesse te diag-
nostiseren. De waarde van de MRI scan lijkt derhalve de rol van het histologisch naaldbiopt 
als de “gouden standaard” te evenaren of soms zelfs te overstijgen. De accuratesse van deze 
twee modaliteiten zijn overlappend en de vraag reist of een pre-operatief naaldbiopt van de 
tumor therapeutische implicaties zal hebben nadat er een MRI scan van de lever is verricht.
Hoofdstuk 5.1 bevat een overzicht van het pathologische spectrum van focale nodulaire 
hyperplasie met een nadruk op de histologische classiﬁcatie die onderscheid aanbrengt in de 
klassieke en niet-klassieke vorm. Hierin worden de meest recente concepten wat betreft de 
histologische kenmerken van focale nodulaire hyperplasie, inclusief de vasculaire opbouw, 
beschreven. Ook wordt in dit artikel het volledige radiologische spectrum van focale nodu-
laire hyperplasie op een geavanceerde MRI scan met de meest optimale scan sequenties 
uiteengezet en vergeleken met de bevindingen op een echo en CT scan.
In hoofdstuk 5.2 wordt een prospectief cohort onderzoek uiteengezet waarin patiënten 
met een focale nodulaire hyperplasie zijn geïncludeerd. Het doel van deze studie was het 
bestuderen van karakteristieken van deze benigne lesie op geavanceerde MRI scan sequen-
ties, waarbij gebruik wordt gemaakt van geoptimaliseerde, moderne scan parameters. In 
deze studie werd gebruik gemaakt van Gadolinium en SPIO (superparamagnetic iron-oxide) 
contrast. Dit onderzoek illustreert dat de combinatie van een dynamisch MRI onderzoek met 
Gadolinium en een T1- en T2-gewogen opname na toediening van SPIO contrast de detectie 
en diﬀerentiatie van focale nodulaire hyperplasie bevordert. De signaal intensiteit van focale 
nodulaire hyperplasie op blanco T1- en T2-gewogen sequenties verschilt slechts marginaal 
van de signaal intensiteit van de lever. Een klein percentage van de lesies bevat vet deposi-
ties. Het aankleuringspatroon na contrasttoediening is intens homogeen in de arteriële fase 
en er is sprake van een versterkte opname van SPIO contrast in de lesie waarbij het centrale 
bindweefselschot en de verschillende septa goed te visualiseren zijn. Daarnaast zijn de meest 
sensitieve sequenties om SPIO-opname te detecteren de in- en uit-fase T1-gewogen gradient 
echo sequentie en diﬀusie T2-gewogen BBEPI sequentie.
In hoofdstuk 5.3 wordt de superselectieve arteriële embolisatie beschreven als een alter-
natieve behandeling voor focale nodulaire hyperplasie. Aangezien een van de etiologische 
concepten suggereert dat focale nodulaire hyperplasie een hyperplastische respons is van 
het leverparenchym op een congenitale arteriële malformatie, lijkt embolisatie een vanzelf-
sprekende behandeling. Bovendien is een centraal voedend vat radiologisch aantoonbaar 
in 50-60% van de gevallen, hetgeen deze methode toepasbaar maakt. Wanneer een chirur-
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gische behandeling overwogen wordt voor focale nodulaire hyperplasie, dienen de risico’s 
van leverchirurgie, zoals in geval van een grote of centraal in de lever gelocaliseerde tumor, 
nauwkeurig afgewogen te worden tegen het voordeel van een resectie. Arteriële embolisatie 
is een veilige en minimaal invasieve percutane techniek voor een ablatieve behandeling van 
benigne levertumoren. Het lijkt dan ook een eﬀectief alternatief te zijn voor een chirurgische 
behandeling van symptomatische patiënten met een focale nodulaire hyperplasie, in het bi-
jzonder bij een verhoogd risico op complicaties ten gevolge van de localisatie van de tumor.
CONCLUSIE
In de diagnostiek van focale levertumoren zijn er gedurende de afgelopen jaren verschil-
lende radiologische en nucleaire technieken toegepast om te kunnen diﬀerentiëren tussen 
benigne en maligne lesies en om een accurate diagnose te stellen. MRI onderzoek biedt 
hierin de meest optimale afbeeldingsmogelijkheden zonder enige stralingsbelasting. In het 
bijzonder is de beschikbaarheid van weefsel-speciﬁeke contrastmiddelen een mogelijkheid 
bij uitstek om lesies te karakteriseren op basis van cellulaire compositie, contrast opname en 
morfologische eigenschappen. Het gebruik van deze geavanceerde modaliteit gedurende 
de diﬀerentiaal diagnose van een focale levertumor zal onnodige invasieve ingrepen zoals 
een leverbiopsie of chirurgie tot een minimum beperken. De waarde van de MRI scan lijkt 
derhalve de rol van het histologisch naaldbiopt als de “gouden standaard” op zijn minst te 
evenaren. De accuratesse van deze twee modaliteiten zijn overlappend en de vraag is of een 
pre-operatief naaldbiopt van de tumor therapeutische implicaties zal hebben nadat er een 
MRI scan van de lever is verricht.
Wat betreft de therapeutische mogelijkheden in geval van een benigne levertumor, is het 
van belang om te realiseren dat het vaak een toevalsbevinding betreft. Met uitzondering van 
het hepatocellulair adenoom en het cystadenoom, beschikken deze tumoren over een be-
nigne aard en een naturlijk verloop met een zeer gering risico op complicaties, hetgeen een 
primair chirurgische behandeling niet rechtvaardigt. Zelfs indien er sprake is van symptom-
en, is het essentieel om te evalueren of de klachten gerelateerd zijn aan de tumor, aangezien 
deze kunnen persisteren na een chirurgische behandeling. Van groter belang is het feit dat 
asymptomatische patiënten klachten kunnen ontwikkelen na een resectie terwijl zij onder-
worpen zijn aan een behandeling met een aanzienlijk risico op morbiditiet en mortaliteit.
In geval van een geruptureerd hepatocellulair adenoom, verdient een primair niet-chirur-
gische behandeling als de meest aangewezen benadering met een minimaal risico op 
complicaties, de voorkeur. Een chirurgische behandeling dient in ieder geval toegepast te 
worden in geval van een groot of groeiend hepatocellulair adenoom of in geval van een 
cystadenoom. Daarnaast vormt arteriële embolisatie een veilige en eﬀectieve behandeling 
van goed gevasculariseerde lesies als alternatief voor risicovolle leverchirurgie.
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De behandeling van benigne levertumoren kan dan ook worden samengevat met de stel-
ling “conservatief, tenzij…”.
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